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ABSTRACT
Several studies have identified Rho family GTPases (i.e. Rho, Rac, Cdc42) as
mediators of diverse critical cellular processes, such as actin cytoskeleton remodeling,
gene transcription, cell-cell adhesion, and cell cycle progression. However, more recent
data highlight an essential role for Rho GTPases as regulators of neuronal morphology
and neuronal survival. In particular, Rac GTPase generally induces neurite outgrowth and
promotes neuronal survival while Rho GTPase typically provokes neurite retraction and
induces neuronal apoptosis.

However, the precise signaling pathways that regulate

neuronal survival downstream of Rho GTPases and the potential involvement of
dysregulated activity of Rho GTPases as a causative factor in the progression of
neurodegenerative diseases remains to be elucidated.
Consistent with a pro-survival function for Rac in neurons, inhibition of Rac with
Clostridium difficle toxin B (ToxB) or expression of a dominant negative Rac1 mutant
significantly induces activation of the “death executioner” caspase-3 and subsequent
apoptosis in primary cerebellar granule neuron (CGN) cultures. We have previously
shown that Rac inhibition evokes apoptosis via inactivation of a pro-survival mitogen
activated protein kinase kinase (MEK)1/2/ extracellular signal regulated-kinase (ERK)1/2
cascade which functions in healthy CGNs to promote the degradation of the pro-apoptotic
Bcl-2 homology-3 domain (BH3)-only protein Bim while also repressing a pro-apoptotic
Janus kinase (JAK)/Signal transducer and activator of transcription (STAT) signaling
ii

cascade.

Here, we reveal that ToxB induces the JAK-dependent phosphorylation

(activation) of STAT5, which is sufficient to induce apoptosis through transcriptional
repression of pro-survival Bcl-xL. Collectively, these data implicate Rac GTPase as a
critical mediator of CGN survival.
Given that ToxB inhibits Rho, Rac, and Cdc42, we aimed to elucidate the effects
of more targeted Rac inhibition in CGNs. NSC23766 specifically inhibits Rac GTPase
activation by the Rac-specific GEFs Tiam1 and Trio. Targeted inhibition of Rac GTPase
via NSC23766 treatment in CGNs evoked apoptosis via repression of unique
MEK5/ERK5, p90Rsk, and Akt-dependent pro-survival pathways.

Furthermore,

selective inactivation of Rac induced the activation and translocation of the pro-apoptotic
BH3-only protein Bad to the mitochondria, where it has been demonstrated to induce
apoptosis. Intriguingly, adenoviral expression of a constitutively active MEK5 protected
CGNs from apoptosis induced by NSC23766, but not ToxB. These data demonstrate that
selective inhibition of Rac GTPase with NSC23766 versus global inhibition of Rho
GTPases with ToxB induces cell death via repression of distinct MAP kinase signaling
pathways.
We also report that treatment with either ToxB or Clostridium sordelli lethal
toxin, which also inhibits Rac GTPase, induces caspase-dependent downregulation of the
pro-survival transcriptional corepressor, C-terminal binding proteins (CtBPs), in CGNs.
Interestingly, we demonstrate that downregulation of CtBPs undergoing apoptosis does
not appear to occur via enhanced degradation or reduced transcription. Instead, our data
suggest that caspases indirectly regulate the expression of CtBPs in CGNs undergoing
apoptosis in a manner that occurs post-transcriptionally and is dependent on intact
iii

miRNA machinery. Finally, inhibition of CtBPs with 4-methylthio-2-oxobutyric acid
(MTOB) provoked CGN apoptosis that was associated with induction of the CtBP target
Noxa. These data indicate a novel function for CtBPs in regulating survival of primary
CGNs.
Finally, we examined the involvement of Rho GTPases in regulating the survival
of motor neurons derived from embryonic stem cells (ESCs) as selective degeneration of
motor neurons in the spinal cord and motor cortex underlies the pathology of
amyotrophic lateral sclerosis (ALS). Consistent with our previous findings in CGNs,
inhibition of Rac GTPase via NSC23766 treatment resulted in apoptotic cell death of
ESC-derived motor neurons that was coincident with deactivation of pro-survival ERK5
and Akt signaling pathways. Surprisingly, we report that the BH3-only protein Bad
localized exclusively to the nucleus in ESC-derived motor neurons treated with the Rac
inhibitor. In agreement with an antagonistic relationship exerted between Rac GTPase
and Rho GTPase as a determinant of neuronal survival, we also report that constitutive
activation of Rho GTPase via CN03 treatment induced Rho kinase (ROCK)-dependent
apoptosis of ESC-derived motor neurons. Next, we investigated Rac and Rho GTPase
activitity and localization in motor neurons in vivo. In the G93A mutant Cu, Zn
superoxide dismutase (mSOD1) transgenic mouse model of ALS, we demonstrate that
active Rac1-GTP is reduced within spinal cord motor neurons when compared to agematched wild type (WT) littermates. Furthermore, we report that total RhoB is expressed
in the soma and nucleus of WT motor neurons; however, RhoB shows a marked
redistribution to neuronal processes in end-stage mice harboring the G93A SOD1
mutation. These data underscore the importance of Rho family GTPases in maintaining
iv

motor neuronal survival and suggest that diminished Rac GTPase activity or enhanced
Rho GTPase activity may each contribute to selective loss of motor neurons during the
progression of ALS.

v
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CHAPTER ONE: INTRODUCTION
Rho family GTPases (i.e. RhoA, Rac1, Cdc42) are best known for their role in
regulating actin cytoskeleton dynamics. In neurons, Rho GTPases have an important and
conserved function in guiding dendritic arborization, growth cone development, and axon
guidance. In addition, more recent efforts have underscored an important function for
Rho GTPases in regulating neuronal survival and death. In the regulation of both
neuronal cytoskeletal dynamics and neuronal survival, Rho GTPase and Rac GTPase
typically exhibit antagonistic functions. For example, Rho GTPase generally stimulates
axonal retraction and neuronal death while Rac GTPase typically promotes axonal
growth and neuronal survival. In addition to in vitro and in vivo animal models of
neurodegenerative disease, recent studies in humans implicate that dysregulation of Rho
family GTPases may potentially underscore the etiology of some forms of
neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). Nonetheless, the
precise signaling pathways that are disrupted in neurons exposed to dysregulated Rho
family GTPase activity remain incompletely understood. Thus, given the potential role
of Rho GTPases in regulating neuronal development and survival, a major focus of this
thesis is to elucidate the pro-survival and pro-apoptotic signals transmitted by members
of the Rho GTPase family in models of neuronal demise.

1

1.1 Apoptosis as a mechanism of neuronal death
Although neuronal cell death can occur through many diverse mechanisms,
accumulating evidence suggests that neuronal apoptosis appears to be a major
contributing factor common to several devastating neurodegenerative diseases and acute
neuronal injury. Apoptosis is a conserved process of programmed cell death that is
crucial to the proper development of organisms. While inadequate apoptosis within an
organism can lead to cancer, excessive apoptosis can underlie the progression of
neurodegenerative diseases. In healthy cells, members of the B cell lymphoma (Bcl)-2
family of proteins tightly regulate the two principal pathways that transmit apoptotic
signals in neuronal cells, the intrinsic (mitochondrial) pathway and the extrinsic (death
receptor) pathway (Fig. 1.2).
1.1.1

Overview of the Bcl-2 family members as regulators of apoptosis

Abundant evidence demonstrates that signals of cell survival and cell death are
critically regulated by the Bcl-2 family of proteins (Fig. 1.1). This family is classified
into three functionally and structurally distinct categories. The first subfamily includes
the pro-survival family members, most notable Bcl-2, Bcl-xL, and Mcl-1. These proteins
are critical constituents of the cell, functioning to negatively regulate pro-apoptotic
proteins. The second subfamily includes multi-domain pro-apoptotic Bax and Bak which,
when activated, act at the mitochondria to induce permeabilization of the outer
mitochondrial membrane and release of apoptogenic molecules (e.g. cytochrome C). The
final subgroup of the Bcl-2 family comprises the Bcl-2 homology-3 domain (BH3)-only
pro-apoptotic proteins. This family includes Bid, Bim, Bad, and Puma, amongst several
others. Numerous reports have demonstrated that the balance between pro-survival and
2

pro-apoptotic Bcl-2 family members represents a vital checkpoint in whether or not a cell
commits to apoptosis (Danial and Korsmeyer, 2004; Youle and Strasser, 2008).
1.1.2 Extrinsic apoptotic pathway
The extrinsic apoptotic pathway is aptly named as it requires an extracellular
signal to induce apoptosis (Fig. 1.2). This cascade is activated when a death ligand (e.g.
Fas ligand) binds to a transmembrane death receptor (e.g. Fas) and leads to receptor
oligomerization and recruitment of the Fas-associated death domain (FADD) adaptor
protein. The death domain of the adaptor protein recruits pro-caspase-8 and forms the
death inducing signaling complex (DISC). DISC formation triggers proteolysis of procaspase-8 to its active form, caspase-8, which then cleaves and activates two critical
executioners of apoptosis, pro-caspase-3 and pro-caspase-7. An alternate function of
caspase-8 is cleavage of the BH3-only protein Bid to an active form termed truncated Bid
(tBid). Truncated Bid translocates to the mitochondria and initiates the intrinsic apoptotic
pathway by inducing the oligomerization of Bax and Bak, discussed below. Thus, tBid is
an important link between the extrinsic and intrinsic apoptotic cascades (Li et al., 1998;
Yin, 2006).
1.1.3 Intrinsic apoptotic cascade
Central to the intrinsic apoptotic pathway is the mitochondria whose outer
membrane’s permeabilization is a critical determinant in executing the death program
(Fig. 1.2). The permeability of the mitochondria is tightly regulated by the balance of
pro-survival and pro-apoptotic Bcl-2 family members. Under normal conditions, prosurvival proteins such as Bcl-2 and Bcl-xL function to neutralize the inherent pro-death
activity of multi-domain pro-apoptotic family members. Intrinsic apoptosis is provoked
3

by apoptotic signals that originate within the cell, such as DNA damage or oxidative
stress. Following apoptotic stimulation, BH3-only proteins respond by either inactivating
pro-survival Bcl-2 members or by directly activating Bax and Bak to form homo- or
hetero-oligomeric pores in the outer mitochondrial membrane (Kuwana et al., 2005; Kim
et al., 2006). This allows subsequent release of apoptogenic factors such as cytochrome
C (cytC) and Smac/Diablo. CytC binds monomeric apoptotic protease-activating factor-1
(APAF-1), inducing a conformational change that permits heptamerization and
recruitment of pro-caspase-9 into a large complex known as the apoptosome (Zou et al.,
1999). Once activated, pro-caspase-9 activates the death executioners caspase-3 and
caspase-7 (Hakem et al., 1998).
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Figure 1.1 Members
rs of Bcl
Bcl-2 family. A. Pro-survival
survival members of the Bcl-2
Bcl family. B.
Multi-domain, pro-apoptotic
apoptotic members of the Bcl
Bcl-2 family. C. BH3-only,
only, pro-apoptotic
pro
members of the Bcl-22 family.
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Figure 1.2 Overview of apoptotic pathways. The extrinsic pathway is activated when a
death ligand (e.g. Fas ligand) binds to a transmembran
transmembranee receptor (e.g. Fas) to induce
recruitment of the Fas-associated
associated death domain (FADD) adaptor protein. Pro-caspase-8 is
recruited and forms the death inducing signaling complex (DISC), which triggers the
activation of caspase-88 and the subsequent activatio
activation of pro-caspase-3
3 and pro-caspase-7.
pro
An additional function of caspase
caspase-8
8 is the cleavage of Bid to its active form, truncated
Bid (tBid). tBid translocates to the mitochondria and initiates the intrinsic apoptotic
pathway by inducing the oligomerization ooff Bax and Bak. Bak and Bak form homohomo or
hetero-oligomeric
ligomeric pores in tthe
he outer mitochondrial membrane, allowing for the release of
apoptogenicc factors such as cytochrome C
C.. CytC binds monomeric apoptotic proteaseprotease
activating factor-11 (APAF
(APAF-1), inducing a conformation
formation change that permits
heptadimerization
tion and recruitment of pro
pro-caspase-9
9 into a large complex known as the
apoptosome. Once activated, pro
pro-caspase-9 activates pro-caspase-3 and pro-caspase-7.
pro
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1.1.4 Evidence supporting a role for apoptosis as a contributing factor to the etiology of
human neurodegenerative disorders
Although neuronal cell death can occur through many diverse mechanisms,
accumulating evidence suggests that neuronal apoptosis appears to be a major
contributing factor common to several devastating neurodegenerative diseases. For
example, Alzheimer’s disease (AD) is the most common form of dementia and is
characterized by extensive loss of neurons in the hippocampus. Although the involvement
of apoptosis in the progression of AD remains controversial, increased DNA
fragmentation consistent with apoptotic cell death has been reported in AD brain tissue
samples when compared to aged control brains (Su et al., 1994; Troncoso et al., 1996). In
further agreement with apoptotic cell death, Masliah et al. (1998) reported that AD
patient brain samples demonstrated increased immunoreactivity of the death executioner
of apoptosis, caspase-3.
In addition to AD, Huntington’s disease (HD) is a fatal autosomal dominant
disorder characterized by loss of cells in the striatum and cortex, resulting in involuntary
body movements (chorea). Early studies identified that DNA fragmentation consistent
with apoptotic cell death may occur in HD striatal sections as Tdt-mediated dUTP–biotin
nick end labeling (TUNEL) staining was increased when compared to neurologically
normal postmortem brain tissue (Dragunow et al., 1995; Thomas et al., 1995; Butterworth
et al., 1998). In addition, mitochondrial dysfunction has been reported in HD brains and
studies examining lymphoblasts from HD patients revealed increased stress-induced
apoptosis and enhanced activation of caspase-3 (Sawa et al., 1999). Furthermore, both
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activation of caspase-1 and caspase-8 was observed in HD patient brain samples when
compared to neurologically unaffected controls (Ona et al., 1999; Sánchez et al., 1999).
As a final example, amyotrophic lateral sclerosis (ALS) is a progressive and fatal
neurodegenerative disorder characterized by loss of motor neurons from the motor cortex,
brain stem, and upper and lower spinal cord, resulting in loss of motor function and
eventually death due to respiratory failure. Increased DNA fragmentation consistent with
apoptotic cell death has been reported in the motor cortex, brain stem, cervical cord,
thoracic cord, and lumbar cord of ALS patients when compared to neurologically normal
control samples (Ekegren et al., 1999; Martin, 1999). Furthermore, an analysis of mRNA
expression in spinal motor neurons from postmortem ALS tissue revealed decreased
expression of pro-survival Bcl-2 mRNA and enhanced expression of pro-apoptotic Bax
mRNA (Mu et al., 1996). In agreement with disruption of the balance of Bcl-2 family
members as a causative factor underlying mitochondrial-dependent neuronal apoptosis,
Bcl-2 protein expression is diminished and Bax and Bak expression is enhanced in
mitochondrial fractions from ALS patients when compared to age-matched controls
(Ekegren et al., 1999; Martin, 1999). Collectively, these studies highlight the potential
involvement of apoptotic cell death as a common factor underlying the etiology of
several diverse neurodegenerative diseases.
1.2 Introduction to C-terminal Binding Proteins (CtBPs)
CtBPs were initially identified as binding partners for the E1A transforming
proteins (Schaeper et al., 1995). Although the invertebrate genome encodes one CtBP
protein, two CtBPs (CtBP1 and CtBP2) are encoded by the vertebrate genome and
perform both unique and duplicative functions (Chinnadurai, 2002). CtBP1 and CtBP2
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are closely related and act as transcriptional corepressors when activated by nicotinamide
adenine dinucleotide (NADH) binding to their dehydrogenase domains (Kumar et al.,
2002). Binding of NADH induces a conformational change within CtBPs that promotes
association with DNA-binding transcriptional repressors, such as the E-box repressor
ZEB (Postigo and Dean, 1999). Experimental evidence suggests that the majority of
DNA-binding transcriptional repressors appear to recruit CtBPs through a PxDLS
sequence (Chinnadurai, 2002). More recent studies have demonstrated that CtBPs exert
transcriptional repression primarily via recruitment of a corepressor complex to DNA that
consists of histone deactylases and histone methyltransferases (Shi et al., 2003).
Nonetheless, CtBPs can also repress transcription through an HDAC-independent
mechanism (Meloni et al., 1999; Koipally et al., 2000).
More recent studies have demonstrated a critical function for CtBPs in the
transcriptional repression of pro-apoptotic genes. For instance, murine embryonic
fibroblasts (MEFs) deficient in CtBP1 and CtBP2 demonstrated enhanced sensitivity to
apoptosis and showed increased expression of the pro-apoptotic proteins Bax, Puma, and
Noxa (Grooteclaes et al., 2003; Bergman and Blaydes, 2006). Furthermore, human
colorectal cancer HCT116 cells deficient in CtBP2 demonstrated increased expression of
the BH3-only pro-apoptotic protein Bik (Kovi et al., 2010). In addition to a critical role
for CtBPs in transcriptional co-repression of pro-apoptotic genes, a recent study by
Paliwal et al. (2012) demonstrated that CtBP2 can also bind to the promoter region and
enhance the transcriptional activation of Tiam1 to promote a pro-oncogenic function of
CtBP2 in cancer cell migration. Nonetheless, while recent efforts have characterized the
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involvement of CtBPs in promoting cellular survival in non-neuronal cell types, the
involvement of CtBPs in regulation of neuronal survival remains to be elucidated.
1.3 Introduction to Rho Family GTPases
The Rho family of GTPases belongs to the Ras superfamily of GTPases of low
molecular weight (~21 kDa) guanine nucleotide binding proteins. Although the Rho
GTPase family is further divided into seven subfamilies (Rho, Rac, Cdc42, Rnd, RhoD,
RhoBTB, and RhoH), the most extensively studied members are RhoA, Rac1, and
Cdc42. In the last few decades, studies have demonstrated that Rho family GTPases are
important regulatory molecules that link surface receptors to the organization of the actin
cytoskeleton. However, the involvement of Rho GTPases in maintaining other essential
cellular functions has also been described, such as gene transcription (Hill et al., 1995),
cell cycle progression (Olson et al., 1995), and regulation of cellular survival and death
(Heasman and Ridley, 2008; Linseman and Loucks, 2008).
Rho family GTPases are molecular switches that are activated by a variety of cellsurface receptors, including tyrosine kinase and adhesion receptors, cytokine receptors,
and G-protein coupled receptors (Kjoller and Hall, 1999; Sah et al., 2000). While the Nterminal domain of Rho GTPases is highly conserved, the C-terminal domain contains
more variation and may confer diverse functions for members of the Rho GTPase family
(Didsbury et al., 1990).

Rho GTPases contain both nucleotide-and Mg2+-binding

pockets. While nucleotide (GDP or GTP)-binding pockets within Rho GTPases regulate
the conformation of the switch regions, Mg2+ is important for high-affinity binding of
guanine nucleotides (Rossman et al., 2005). In addition, Rho family GTPases also contain
a ~200 residue Dbl homology (DH) domain and an adjacent, C-terminal, Pleckstrin
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homology (PH) domain. The DH domains of Rho GTPases facilitate the exchange of
GDP for GTP while the PH domains bind phosphoinositides to localize Rho GTPases to
plasma membranes (Rossman et al., 2005).
Similar to Ras family GTPases, activation of Rho GTPases is regulated by cycling
between an inactive GDP-bound state and an active GTP-bound state (Fig. 1.3). The
binding of GTP elicits a conformational change within Rho GTPases which promotes
their interaction with various downstream effectors. Rho family GTPase activation is
facilitated by guanine nucleotide exchange factors (GEFs) that catalyze the conversion of
GDP to GTP while inactivation of Rho GTPases is induced by GTPase activating
proteins (GAPs) that stimulate the intrinsic ability of Rho GTPases to hydrolyze GTP to
GDP.

The third class of molecules that regulate Rho GTPase activity, guanine

dissociation inhibitors (GDIs), sequester Rho GTPases in a GDP-bound state in the
cytosol and the dissociation of GDIs is required for membrane localization and
subsequent activation of Rho family GTPases.
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Figure 1.3 Activation of Rho family GTPases. Guanine nucleotide exchange factors
(GEFs) catalyze the conversion of GDP to GTP to enhance Rho GTPase activation.
GTPase activating proteins (GAPs) inactivate Rho GTPases by stimulating the ability of
Rho GTPases to hydrolyze GTP to GDP. Finally, guanine dissociation inhibitors (GDI)
regulate Rho GTPase activation by sequestering Rho GTPases in a GDP-bound state in
the cytosol.
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1.4 Functions of Rho GTPases in regulating cytoskeletal dynamics
1.4.1 Functions of Rho family GTPases in regulating the actin cytoskeleton
Classic studies in serum-starved Swiss 3T3 fibroblasts underscored a crucial
function for Rho family GTPases in regulating actin cytoskeletal dynamics (Hall, 1998).
For example, addition of the Rho GTPase-activator lysophosphatidic acid (LPA) led to
the formation of stress fibers and focal adhesion complexes while microinjection of a
constitutively active mutant of Rac induced the formation of lamellipodia and the
associated adhesion complexes. Finally, microinjection of a GEF for Cdc42 enhanced
the formation of filopodia and the associated adhesion complexes (Hall, 1998). More
recent efforts have identified the key signaling pathways that link Rho GTPases to
modulation of the actin cytoskeleton (Fig. 1.4).
The p21-activated kinase 1-6 (PAK1-6) family of serine/threonine kinases can be
activated by both Rac and Cdc42 via the Cdc42/Rac-interactive binding (CRIB) motif.
Although six isoforms of PAK have been identified, PAK1-3 are the most extensively
characterized and it has been demonstrated that their kinase activity is stimulated upon
interaction with Rac or Cdc42 (Wells and Jones, 2010). When the crystal structure of
PAK1 was revealed by Lei et al. (2000), it became apparent that an autoinhibitory switch
domain within the N-terminus of PAK1 prevents the activation of the C-terminal kinase
domain. Binding of Rac or Cdc42 stimulates activation of PAK via an
autophosphorylation event which disrupts the interaction between the autoinhibitory
domain and the kinase domain (Buchwald et al., 2001). Once activated, PAKs can
directly phosphorylate and inhibit the activity of myosin light chain kinase (MLCK),
effectively reducing the phosphorylation of the downstream effector myosin II regulatory
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chain (MLC) and ultimately leading to the formation of lamellipodia while promoting the
disassembly of stress fibers (Sanders et al., 1999; Bokoch, 2003; Watanabe et al., 2007).
In addition to regulation of MLCK, PAK activity has also been shown to positively
regulate LIM kinase via phosphorylation. Phosphorylation of LIM kinase stimulates its
ability to phosphorylate and inhibit the actin capping protein, cofilin (Yang et al., 1998;
Edwards and Gill, 1999; Dan et al., 2001). Cofilin functions as a destabilizing factor for
actin filaments; therefore its inhibition enhances the actin polymerization that is
necessary for the Rac-dependent formation of lamellipodia and membrane ruffles (Yang
et al., 1998; Bamburg, 1999). Finally, recent studies suggest that Rac and Cdc42 transmit
signals to the actin cytoskeleton via Wiskott-Aldrich-syndrome (WASP) family of
proteins. In particular, activated Cdc42 directly binds both WASP and neuronal WASP
(NWASP), inducing the activation of actin related protein 2/3 (Arp2/3) to promote the
formation of new actin filaments (Machesky and Gould, 1999; Kim et al., 2000).
Conversely, Rac indirectly activates Arp2/3 via an interaction with additional members of
the WASP family, WAVE1-3 (Eden et al. 2002; Kunda et al., 2003; Schenck et al.,
2003). Thus, Rac and Cdc42 signal through many diverse pathways to induce
cytoskeletal rearrangements.
Research has identified two major downstream effectors that are involved in Rho
GTPase-mediated cytoskeletal rearrangements, Rho Kinase I and II (ROCKI/II) and the
Diaphanous formin subfamily (Dia). Experimental evidence has established that
Rho/ROCK signaling can directly oppose Rac/PAK signaling to influence cytoskeletal
dynamics. For instance, while activation of Rac/PAK reduces the phosphorylation of
MLC via inhibition of MLCK, activation of Rho/ROCK leads to the inhibition of myosin
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light chain phosphatase (MLCPPase), increasing the phosphorylation and activation of
MLC to induce the subsequent formation of actin stress fibers (Kimura et al., 1996).
Nonetheless, Rho/ROCK signaling can also act in a manner parallel to Rac to induce
cytoskeletal rearrangements. For example, Rho-dependent activation of ROCK can
increase the phosphorylation and activation of LIMK, ultimately resulting in inhibition of
the downstream effector cofilin to promote actin polymerization (Maekawa et al., 1999;
Ohashi et al., 2000). In addition to ROCK activation, Rho GTPase can also disrupt an
autoinhibitory interaction between the N- and C-terminal domain of Dia proteins,
stimulating their regulation of actin and microtubule cytoskeleton dynamics (Alberts,
2001). Thus, Rho GTPase regulates the actin cytoskeleton through activation of ROCK or
Dia.
The antagonistic relationship established between Rac/Pak and Rho/ROCK
signaling underscores the importance of maintaining a delicate balance between Rho
family GTPase signaling in order to properly regulate actin cytoskeletal dynamics.
Furthermore, the potential functions and importance of Rho GTPases in maintaining
neuronal morphology are underscored by their crucial regulation of actin cytoskeletal
dynamics.
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Figure 1.4 Rho GTPase signaling pathways regulating actin cytoskeletal dynamics.
Rho activates its downstream effector ROCK to increase MLC and cofilin
phosphorylation and induce the subsequent formation of actin stress fibers. Rac signals to
PAK to decrease MLC phosphorylation, leading to the generation of lamellipodia. Rac
and Cdc42 both activate Arp2/3 to induce actin polymerization and the formation of
filopodia.
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1.4.2

Functions of Rho family GTPases in regulating of neuronal morphology

In accordance with a conserved function in regulation of actin cytoskeleton
dynamics, Rho family GTPases have been highlighted as key modulators of neuronal
morphology. Similar to regulation of the actin cytoskeleton, Rho and Rac/Cdc42 exhibit
an antagonistic relationship to determine neuronal morphology (Fig. 1.5). Indeed, an
early study by Kozma et al. (1997) demonstrated that microinjection of Rac or Cdc42 in
N1E-115 neuroblastoma cells enhanced growth cone development and neurite outgrowth,
whereas the Rho inhibitory cytotoxin Clostridium botulinum C3 coenzyme abolished
Rho-dependent growth cone collapse and neurite retraction. In the same cell line, axonal
outgrowth induced by the guidance molecule netrin-1 required both Rac and Cdc42,
while downregulation of either Rho or ROCK was sufficient to induce axonal outgrowth
(Li et al., 2002). Further, both neurite retraction and F-actin disassembly induced by LPA
in N1E-115 neuroblastoma cells were mimicked by constitutively activated RhoA and
blocked by a dominant negative mutant of RhoA (Kranenburg et al., 1997). Similarly, in
PC12 cells, constitutive activation of Rho or microinjection of the downstream effector of
Rho, Rho kinase (ROCK), induced neurite retraction while a kinase dead mutant of
ROCK was unable to stimulate neurite retraction (Katoh et al., 1998a,b; Sebök et al.,
1999). Further illustrating the antagonistic relationship between Rac and Rho in
determining neuronal morphology, PC12 cells exposed to nerve growth factor (NGF)induced neurite outgrowth in a Rac-dependent manner that was inhibited by activation of
either RhoA or ROCK (Yamaguchi et al., 2001). Collectively, these studies highlight that
the intricate balance between Rho family GTPases is a critical determinant of neuronal
morphology.
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A major downstream target of Rac and Cdc42, PAK, has been shown to mediate
growth cone development and neurite outgrowth (Fig. 1.5). For instance, membrane
targeting of PAK1 has been demonstrated to induce neurite outgrowth of PC12 cells
while expression of dominant negative PAK1 construct inhibits this effect (Daniels et al.,
1998). Further highlighting the antagonistic signaling characteristic of Rac and Rho
GTPases, PAK5-induced neurite outgrowth in PC12 cells occurred in a kinase-dependent
mechanism and was abolished by expression of constitutively active RhoA (Dan et al.,
2002). Intriguingly, early evidence provided in cortical neurons suggests that Rac may
regulate the length of PAK activation as Rac-dependent hyperphosphorylation of PAK1
was shown to decrease its kinase activity (Nikolic et al., 1998). In addition to neurite
outgrowth, Rac signaling to PAK has also been implicated in axonal guidance and
pathfinding. For example, Rac and PAK have been demonstrated to interact with the
SH2/SH3 adaptor protein DOCK to control the direction of axon extension in Drosophila
photoreceptors and olfactory neurons (Hing et al., 1999; Newsome et al., 2000; Ang et
al., 2003).
In opposition to Rac/Cdc42 signaling to PAK, Rho kinase (ROCK) has been
identified as a major downstream target of Rho-dependent neurite retraction (Fig. 1.5). In
retinal ganglion cell cultures, expression of the repulsive guidance molecule ephrin-A5
induced collapse in a mechanism consistent with activation ROCK as inhibition utilizing
the putative ROCK inhibitor, Y-27632, diminished the collapse of growth cones (Wahl et
al., 2000). In N1E-115 neuroblastoma cells, expression of a constitutively active mutant
of ROCK was sufficient to induce neurite retraction whereas expression of a dominant
negative ROCK mutant attenuated LPA-induced neurite retraction concurrent with
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enhanced phosphorylation of MLC and remodeling of intermediate filaments and
microtubules (Amano et al., 1998, Hirose et al., 1998). Interestingly, while activation of
ROCK alone is sufficient to induce neurite retraction and cell rounding in N1E-115 cells,
this effect is blocked by coexpression of dominant negative Rac or Cdc42, suggesting
that ROCK-dependent neurite retraction may be mediated, in part, through deactivation
of Rac and/or Cdc42 activity (Hirose et al., 1998).
Many studies in neurons support the general model that Rac/Cdc42 elicit neurite
outgrowth and growth cone development while Rho induces neurite retraction and
growth cone collapse. However, it is important to note that Rho family GTPases can have
opposing effects on neuronal morphology. For example, expression of a dominant
negative mutant of Rac1 has been demonstrated to promote neurite outgrowth in dorsal
root ganglion (DRG) cells (Fournier et al., 2003) and constitutively active Rac1 increases
the proportion of collapsed growth cones in DRG neurons (Jin and Strittmatter, 1997;
Vastrik et al., 1999). Similarly, constitutive activation of Rac1 was shown to decrease the
length of the longest neurite in mouse cortical neurons (Kubo et al., 2002). Furthermore,
in some studies, Rho GTPase has been demonstrated to induce neurite formation. Indeed,
expression of dominant negative RhoA inhibited axon growth in hippocampal neurons
(Ahnert-Hilger et al, 2004). While these discrepancies in Rho family GTPase functions
may reflect differences in either organism specific- or cell type-specific regulation of
neuronal morphology, they also further underscore the importance of tight regulation of
Rho GTPase activation in order for proper nervous system development.
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1.5 Rho family GTPases in regulation of neuronal survival and apoptosis
The essential functions of Rho family GTPases in regulating neuronal growth
cone formation, neurite outgrowth, and neuronal development suggest that Rho GTPases
have an important and conserved function in mediating neuronal survival and death.
Indeed, similar to the opposing functions exerted between members of the Rho GTPase
family in maintenance of neurite outgrowth and growth cone formation, Rac activation
typically promotes neuronal survival while Rho activation elicits neuronal death. In
further support of an antagonistic relationship, recent efforts have identified a key
signaling network that maintains neuronal survival downstream of Rho family GTPases,
particularly between Rac GTPase and Rho GTPase (Fig. 1.5).
1.5.1 Principal Rac-dependent pro-survival signaling pathways
In accordance with a conserved function in regulating neurite outgrowth and
growth cone formation, previous studies have demonstrated an important role for Rac
GTPase in transmitting pro-survival signals in neurons (Fig. 1.5). Rac GTPase signals to
the downstream effector PAK1 to promote survival of cerebellar granule neurons (CGNs)
(Johnson and D’Mello, 2005) and inhibition of Rac via the large cytotoxin Clostridium
difficile Toxin B induces CGN apoptosis via deactivation of PAK (Le et al., 2005;
Loucks et al., 2006). In neurons and other cells, PAK is known to promote cellular
survival through activation of mitogen activated protein kinase (MAPK) pathways. In
CGNs in particular, PAK activates a pro-survival MEK1/2/ERK1/2 signaling cascade
which functions in healthy CGNs to enhance degradation of the pro-apoptotic BH3-only
protein Bim, as well as, repress a pro-apoptotic JAK/STAT signaling cascade (Loucks et
al., 2006). In addition to transmission of pro-survival signals, PAK can also promote
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cellular survival through phosphorylation of the BH3-only protein Bad, which enhances
the association of Bad with cytosolic 14-3-3 scaffolding proteins, effectively inactivating
the BH3-only protein by targeting it away from the mitochondria where it functions to
induce apoptosis (Zha et al., 1996; Schürmann et al., 2000). In addition to PAK, Rac
often exerts pro-survival signaling through activation of the downstream effector
phosphatidylinositol 3-kinase (PI3K). Once activated, PI3K promotes cellular survival by
activating Akt or p90rsk to enhance the phosphorylation of Bad (Datta et al., 1997; del
Peso et al., 1997; Tan et al., 1999).
1.5.2 Principal Rho-dependent pro-apoptotic signaling pathway
In further support of the antagonistic relationship between members of the Rho
GTPase family, Rho GTPase signaling characteristically antagonizes Rac-dependent prosurvival signaling pathways (Fig. 1.5). The major downstream effector of Rho, ROCK,
activates phosphatase and tension homolog (PTEN) which can indirectly antagonize the
activation of Akt by Rac. Indeed, siRNA against PTEN diminished the ability of
constitutively active RhoA to reduce the phosphorylation (activation) of Akt in human
embryonic kidney cells (Li et al., 2005). Consistent with a pro-survival function for Akt
in phosphorylating the pro-apoptotic protein Bad, inhibition of ROCK prevented the
dephosphorylation (activation) of Bad in the penumbra area of rats subjected to ischemia
(Wu et al., 2012). The inhibition of Akt by the Rho/ROCK/PTEN pathway occurs
indirectly as PTEN dephosphorylates phosphatidylinositol (3, 4, 5)-triphosphate into
phosphatidylinositol (4, 5)-biphosphate to terminate Akt activation (Lai et al., 2014).
These previous studies have served to highlight that balanced signaling between Rho
GTPase and Rac GTPase is a critical determinant of neuronal survival.
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Figure 1.5 Rho GTPase signaling pathways regulating neuronal survival. Rho
activates a downstream ROCK/PTEN pathway that indirectly inactivates the pro-survival
protein Akt to suppress neurite outgrowth and neuronal survival. Rac signals to PI3K to
activate Akt to enhance neurite outgrowth and neuronal survival. Rac also activates
PAK/MEK/ERK signaling to promote neuronal survival.
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1.6 Evidence of dysregulated Rho family GTPase activity underlying the selective
motor neuron degeneration observed in ALS
ALS is a devastating neurodegenerative disorder characterized by loss of motor
neurons of the motor cortex, brain stem, and upper and lower spinal cord. Patients that
receive a diagnosis of ALS typically succumb to the disorder within 2-5 years due to
respiratory failure. Approximately 10% of ALS cases appear to be caused by a genetic
component, while the remaining 90% are considered sporadic in nature. In 1993, the
glycine to alanine substitution at position 93 in Cu, Zn- superoxide dismutase (SOD1)
was one of eleven mutations intially identified to be causative in familial ALS. Although
the G93A SOD1 mutation remains the best characterized to date, mutations in additional
genes such as Alsin (ALS2), TDP43, and FUS have also been linked to other familial
forms of ALS. Currently, the only drug that is approved for the treatment of ALS,
Riluzole, is an anti-glutamateric compound that extends the lifespan of patients a mere 3
months (Miller et al., 2007). Thus, it is imperative that new molecular targets are
identified for the treatment of ALS. Recent evidence suggests that a loss of Rac GTPase
activity or gain of Rho GTPase activity may underlie the disease progression in ALS.
1.6.1 Loss of Rac and ALS
Recessive mutations in a Rac guanine nucleotide exchange factor (GEF), alsin
(ALS2), have been reported in juvenile forms of ALS, primary lateral sclerosis, and
infantile-onset ascending hereditary spastic paralysis (Hadano et al., 2007).

When

overexpressed in cultured human cells, alsin mutants are rapidly degraded, suggesting
disease progression occurs through a mechanism consistent with alsin loss-of-function
(Yamanaka et al., 2003).

Although alsin is a GEF for both Rab5 and Rac, alsin
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colocalizes with Rac in the growth cones of neurons and regulates Rac signaling and
neurite outgrowth through its intrinsic GEF activity, thus suggesting a link between Rac
disruption and neurodegenerative disease (Topp et al., 2004; Kanekura et al., 2005; Tudor
et al., 2005). In addition to juvenile onset ALS, a recent study identified a mutation in
the PH domain of alsin that underlies the development of infantile-onset ascending
hereditary spastic paraplegia (Wakil et al., 2014). Given the specificity of the DH/PH
tandem repeat for activation of Rac GTPase, but not Rab5, (Zheng, 2001; Topp et al.,
2004; Tudor et al., 2005), this study further highlights that a loss of Rac activity may
underlie the progression of early onset forms of ALS.
The critical role of Rac in maintaining neuronal survival is evidenced by the fact
that disruptions in Rac signaling have been shown to induce apoptosis in a variety of
diverse neuronal cell types, including primary motor neurons (Kanekura et al., 2005;
Jacquier et al., 2006; Loucks et al., 2006; Stankiewicz et al., 2012). In spinal motor
neurons isolated from embryonic rats, siRNA knockdown of alsin induces neurite
retraction and cell death that is abrogated by expression of constitutively active Rac
(Jacquier et al., 2006). Furthermore, alsin antagonizes NSC34 motor neuronal death
induced by the expression of ALS-causing SOD1 mutants (mSOD1) via activation of a
pro-survival Rac/PI3K/Akt signaling cascade (Kanekura et al., 2005).

Intriguingly,

accumulating evidence suggests that SOD1 may regulate the activity of Rac GTPase. In
particular, neuronal apoptosis induced via expression of either G93A or H80R mSOD1 in
SH-SY5Y dopaminergic cells correlated with a decrease in Rac GTPase activity. Indeed,
expression of a constitutively active Rac GTPase mutant abrogated mSOD1-induced
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neuronal death while expression of dominant negative Rac GTPase alone induced
apoptosis (Pesaresi et al., 2011).
In addition to mutations that code for alsin and SOD1, recent evidence also
suggests that ARHGEF16, a GEF for Rac GTPase, is hypermethylated and
downregulated in postmortem sporadic ALS spinal cord samples when compared to
samples from neurologically normal controls (Figueroa-Romero et al., 2012). Thus,
dysregulation of Rac GTPase may be a common factor underlying both familial and
sporadic forms of ALS. While accumulating evidence has highlighted a critical function
for Rac GTPase in maintaining neuronal survival, the involvement of Rac in the etiology
of ALS has only been examined recently and the exact mechanism by which disruptions
in Rac activity may induce neuronal apoptosis remains poorly understood. Alterations in
Rac activity in motor neurons and mouse models of ALS warrants further investigation as
it has significant potential to elucidate insights into neurodegenerative disease and
delineate novel therapeutic targets.
1.6.2 Gain of Rho GTPase activity in ALS
Although recent efforts are only beginning to elucidate a role for enhanced Rho
GTPase activation in the disease progression of ALS, hyperactivation of Rho GTPase has
been underscored as a contributing factor in many other models of neurodegenerative
disease and neuronal trauma. For example, while total RhoA expression was unaltered
following lateral fluid percussion brain injury in rats, RhoA activity was increased in both
the cortex and hippocampus ipsilateral and contralateral to the injury (Dubreuil et al.,
2006). Furthermore, in an in vitro model of Phenylketonuria brain injury, phenylalanine
induced mitochondrial-dependent apoptosis of cortical neurons occurred via a mechanism
25

consistent with activation of RhoA (Zhang et al., 2010). A recent study has also
suggested a role for RhoA in calcium-dependent excitotoxic cell death in rat neurons
(Semenova et al., 2007). In addition to RhoA, RhoB has also been implicated in neuronal
apoptosis following ischemia as increases in RhoB expression occur following ischemic
injury and precede DNA fragmentation indicative of apoptosis (Trapp et al., 2001).
Moreover, corticohippocampal neurons deficient in RhoB are resistant to staurosporineinduced apoptosis and RhoB knockout mice display diminished basal levels of caspase-3
activity in the adult brain (Barberan et al., 2011). Collectively, these data implicate that
aberrant activation of RhoA and/or RhoB may contribute to neuronal apoptosis in a
variety of in vitro and in vivo models of neurodegenerative demise.
In addition to the above studies demonstrating the involvement of Rho GTPase in
various models of neurodegeneration, recent efforts have begun to highlight that aberrant
Rho GTPase activity may also underlie the pathology of ALS. For example, although the
significance remains unknown, the Rho guanine nucleotide exchange factor (RGNEF)
displays enhanced cytoplasmic inclusions in spinal motor neurons from both sporadic and
familial ALS patients (Keller et al., 2012; Droppelmann et al., 2013). However, future
studies will be required to identify the importance of RGNEF-positive spinal motor
neuron cytoplasmic inclusions. Nonetheless, in accordance with enhanced Rho GTPase
activity as a causative factor to motor neuronal death in ALS disease progression, ROCK
activity is increased in the G93A mSOD1 mouse model of ALS, as well as, sporadic ALS
patients (Hu et al., 2003; Capitanio et al., 2012; Conti et al., 2014). While the above
studies indicate that a gain of Rho GTPase activity may underlie the progression of ALS,
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relatively few studies have examined the precise mechanism by which unopposed
activation of Rho GTPase may contribute to the motor neuronal death observed in ALS.
1.7 Models to study neuronal apoptosis
1.7.1 Cerebellar granule neurons
The relatively simple process of isolating rat cerebellar granule neurons has made
their use in studies of neuronal apoptosis widespread. These primary neuronal cultures
are extremely homogeneous and have been used extensively to examine the molecular
mechanisms involved in neuronal apoptosis. Early studies conducted in CGNs exposed to
low potassium determined that CGNs undergo apoptotic cell death as evidenced by DNA
fragmentation (D’Mello et al., 1993). Further, it was previously demonstrated that CGNs
subjected to low potassium conditions undergo extrinsic apoptosis as evidenced by
increased expression of Fas ligand and caspase-3 (Ginham et al., 2001; Fig. 1.6). In
addition, CGNs also appear to be sensitive to intrinsic (mitochondrial) apoptosis as CGNs
derived from mice overexpressing the pro-apoptotic protein Bax or deficient in the prosurvival protein Bcl-2 displayed enhanced sensitivity to apoptotic cell death when
compared to CGNs isolated from wild type mice (Tanabe et al., 1997). In addition to
these prior studies demonstrating that CGNs undergo both intrinsic and extrinsic
apoptosis, we have shown that inhibition of Rac GTPase utilizing large Clostridial
cytotoxins or expression of a dominant negative Rac1 mutant induces mitochondrialdependent apoptosis of CGNs. Cell death occurred in a mechanism consistent with DNA
fragmentation and activation of the death executioner of apoptosis, caspase-3 (Linseman
et al., 2001; Le et al., 2005; Loucks et al., 2006). Thus, primary CGN cultures provide an
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excellent in vitro model that can be used to study the Rac-dependent signaling pathways
that regulate neuronal survival.
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Figure 1.6 CGNs undergo caspase-dependent apoptosis. CGNs were incubated in
either control medium or 25k- medium deprived of potassium for 24 h. Following
incubation, CGNs were fixed with 4% paraformaldehyde and stained for DAPI (blue), βtubulin (green), and active caspase-3 (red). Note that CGNs deprived of trophic support
display condensed/fragmented nuclei and enhanced activation of caspase-3 indicative of
apoptosis.
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1.7.2 Embryonic Stem Cell-Derived Motor Neurons
Traditionally, ALS has been a difficult disease to model in vitro due to the fact
that it is characterized by the loss of upper and lower spinal motor neurons. Motor
neurons isolated from embryonic mice and rats do not yield high numbers, making it
difficult to perform experiments that may require high cellular content. Furthermore, it is
unknown if motor neurons isolated from embryonic rodents are mature enough to mimic
those that are lost in aging-related disorders such as ALS. To overcome this issue,
Wichterle and colleagues (2002) developed a protocol to terminally differentiate mouse
ESCs into motor neurons which express GFP under control of the motor neuron-specific
HB9 homeobox promoter. Following a one week differentiation protocol, approximately
30% of the cultured cells are identified as GFP-expressing motor neurons (Fig. 1.7).
ESC-derived motor neurons can populate the embryonic spinal cord, project axons, and
form synapses with muscle cells (Wichterle et al., 2002). Thus, ESC-derived motor
neurons represent a novel in vitro model that can be utilized to study the involvement of
Rho family GTPases in regulating the survival of motor neurons.
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Figure 1.7 Generation and differentiation of ESC-derived motor neurons. ESCs
harboring an enhanced GFP (eGFP) transgene driven by the motor neuron-specific Hb9
promoter were cultured on a layer of mouse embryonic fibroblasts. After detachment
with trypsin, embryoid bodies (EBs) were cultured in suspension in differentiation
medium containing retinoic acid to induce the formation of motor neuron progenitors.
After 24 h, sonic hedgehog and glial cell line-derived neurotrophic factor were added to
further promote the differentiation of neural precursor cells into spinal motor neurons.
After a 48 h incubation, EBs were collected and digested with papain to produce a single
cell suspension. Cells were then plated onto matrigel-coated culture dishes (top panel).
After 24 h on matrigel, EGFP+ motor neurons appear healthy and extend long processes
as well as multiple shorter neurites (bottom panel). Consistent with Wichterle et al.
(2002), approximately 30% of cells terminally differentiated into spinal motor neurons.
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CHAPTER TWO: SIGNAL TRANSDUCER AND ACTIVATOR OF
TRANSCRIPTION (STAT)-5 MEDIATES NEURONAL APOPTOSIS INDUCED
BY INHIBITION OF RAC GTPASE ACTIVITY
2.1 Abstract

In several neuronal cell types, the small GTPase Rac is essential for survival. We
have shown previously that the Rho family GTPase inhibitor Clostridium difficile toxin B
(ToxB) induces apoptosis in primary rat cerebellar granule neurons (CGNs) principally
via inhibition of Rac GTPase function. In the present study, incubation with ToxB
activated a proapoptotic Janus kinase (JAK)/signal transducer and activator of
transcription (STAT) pathway, and a pan-JAK inhibitor protected CGNs from Rac
inhibition. STAT1 expression was induced by ToxB; however, CGNs from STAT1
knock-out mice succumbed to ToxB-induced apoptosis as readily as wild-type CGNs.
STAT3 displayed enhanced tyrosine phosphorylation following treatment with ToxB, and
a reputed inhibitor of STAT3, cucurbitacin (JSI-124), reduced CGN apoptosis.
Unexpectedly, JSI-124 failed to block STAT3 phosphorylation, and CGNs were not
protected from ToxB by other known STAT3 inhibitors. In contrast, STAT5A tyrosine
phosphorylation induced by ToxB was suppressed by JSI-124. In addition, roscovitine
similarly inhibited STAT5A phosphorylation and protected CGNs from ToxB-induced
apoptosis. Consistent with these results, adenoviral infection with a dominant negative
STAT5 mutant, but not wild-type STAT5, significantly decreased ToxB-induced
apoptosis of CGNs. Finally, chromatin immunoprecipitation with a STAT5 antibody
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revealed increased STAT5 binding to the promoter region of prosurvival Bcl-xL. STAT5
was recruited to the Bcl-xL promoter region in a ToxB-dependent manner, and this DNA
binding preceded Bcl-xL down-regulation, suggesting transcriptional repression. These
data indicate that a novel JAK/STAT5 proapoptotic pathway significantly contributes to
neuronal apoptosis induced by the inhibition of Rac GTPase.
2.2 Introduction
Rho family GTPases are important mediators of cellular development, survival,
and death. The most well characterized members of the family are RhoA, Rac1, and
Cdc42. Although best known for regulating actin cytoskeletal dynamics, Rho GTPases
also play important roles in cell cycle progression (Olson et al., 1995), gene transcription
(Hill et al., 1995), and cell-cell or cell-matrix adhesion (Clark et al., 1998; Fukata et al.,
1999). In recent years, the role of Rho GTPases in neuronal survival has begun to be
investigated. For example, inhibitors of 3-HMG-CoA reductase (statins) decrease the
localization of Rho GTPases to the plasma membrane and induce apoptosis in rat cortical
neurons (Tanaka et al., 2000). We have shown previously that the function of Rac is
essential for the survival of cerebellar granule neurons (CGNs) as the inhibition of Rac
with either large Clostridial cytotoxins or overexpression of a dominant negative Rac
mutant induces mitochondrially dependent apoptosis of these cells (Linseman et al.,
2001). In a similar manner, use of either dominant negative Rac or siRNA against the
Rac guanine nucleotide exchange factor alsin (ALS2) results in apoptosis of primary
cultured spinal motor neurons (Jacquier et al., 2006). The critical role of Rac in neuronal
survival is further evidenced by the finding that ALS2 is mutated in juvenile onset
amyotrophic lateral sclerosis. Although changes in Rac activity in patients harboring
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disease-causing ALS2 mutations have not been directly evaluated, disruption of Rac
function as a possible underlying cause of neurodegenerative disease is suggested by the
fact that alsin mediates Rac-dependent prosurvival signaling in primary motor neurons
(Jacquier et al., 2006). Collectively, these findings implicate Rac as a crucial mediator of
neuronal survival and suggest that disruption of Rac activity may contribute to the
progression of neurodegenerative disorders.
We have reported previously that inhibition of Rho GTPases with Clostridium
difficile toxin B (ToxB) and in particular inhibition of Rac lead to the derepression of an
as yet undefined proapoptotic JAK/STAT pathway (Loucks et al., 2006). The JAK/STAT
pathway has been shown to play a critical role in cytokine signaling, and JAK activation
can turn on an array of downstream effects including cell proliferation, differentiation,
and apoptosis (Igaz et al., 2001). An important feature of the JAK/STAT signaling
cascade is that it can exert either a prosurvival or proapoptotic effect depending upon the
stimulus and cell type. For example, cytoprotective signals are transmitted from the
gp130 receptor to a prosurvival JAK/STAT3 pathway in cardiac myocytes (YamauchiTakihara and Kishimoto, 2000). Moreover, data implicate constitutive activation of
STAT1 and STAT3 proteins in breast cancer cells (Watson and Miller, 1995).
Conversely, more recent data have emerged to suggest that the JAK/STAT pathway may
also induce apoptosis under certain cellular conditions. For instance, STAT1 has been
shown to mediate IFN-γ-induced apoptosis in liver cells treated with the hepatotoxic
compound galactosamine (Kim et al., 2003). In addition, chromatin immunoprecipitation
experiments performed in thymocytes suggest that glucocorticoids induce apoptosis
through repression of prosurvival Bcl-xL in a STAT5-dependent manner (Rocha-Viegas
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et al., 2006). Although it is clear that JAK/STAT activation can induce apoptosis in
diverse non-neuronal cell types, the significant involvement of this signaling pathway in
neuronal apoptosis has only recently been recognized.
In a previous study, we showed that inhibition of Rac induces CGN apoptosis by
inactivating a prosurvival p21-activated kinase PAK/mitogen-activated protein kinase
kinase (MEK)/extracellular signal-regulated kinase (ERK) cascade. Although we have
demonstrated that disruption of this pathway results in the derepression of a proapoptotic
JAK/STAT pathway, we have yet to identify which particular STAT family members
mediate neuronal apoptosis in response to ToxB (Loucks et al., 2006). Thus, the current
study focuses on identifying the STAT family members involved and the consequences
of STAT activation downstream of Rac inhibition in CGNs. These primary neuronal
cultures are extremely homogeneous and have been used extensively to examine
molecular mechanisms involved in neuronal apoptosis (Linseman et al., 2001; D’Mello et
al., 1993; Contestabile, 2002; Vaudry et al., 2003). Although we show that Rac inhibition
leads to the up-regulation of STAT1 expression and enhanced tyrosine phosphorylation
of STAT3, we report that these transcription factors are not responsible for inducing
apoptosis in ToxB-treated CGNs. Instead, we demonstrate that STAT5 is activated and
subsequently translocates into the nucleus to transcriptionally repress prosurvival Bcl-xL
in Rac-inhibited CGNs. To our knowledge, these results are the first to identify a
proapoptotic function for STAT5 in primary neurons.
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2.3 Materials and Methods
2.3.1 Reagents
C. difficile toxin B was isolated or prepared as a recombinant protein as described
previously (Just et al., 1995). The polyclonal antibodies used for immunoblotting STAT1,
STAT3, and phosphorylated STAT5 (pSTAT5) were from Cell Signaling Technology
(Beverly, MA). Horseradish peroxidase-linked secondary antibodies and reagents for
enhanced chemiluminescence detection were from Amersham Biosciences. The
polyclonal antibody used to detect active caspase-3 by immunocytochemistry was from
Promega (Madison, WI). For Western blotting, active caspase-3 was detected with a
polyclonal antibody from Abcam (Cambridge, MA). 4, 6-Diamidino-2-phenylindole
(DAPI), Hoechst dye 33258, and a monoclonal antibody against β-tubulin were from
Sigma. Anti-rat and anti-mouse Cy3- or FITC-conjugated secondary antibodies for
immunofluorescence were from Jackson ImmunoResearch Laboratories (West Grove,
PA). The monoclonal antibody against LAP-2 and the polyclonal total STAT1 and total
STAT5 antibodies used for Western blotting were from BD Biosciences. Purvalanol A,
JSI-124, roscovitine, mifepristone, JAK3 inhibitor, and the small molecule JAK inhibitor
I (2-(1, 1-dimethyl) 9-fluro-3, 6-dihydro-7H-benz[h]imidaz [4, 5,-f] isoquinolin-7-one;
pan-JAK inhibitor (pan-JI)) were from Calbiochem. The specific JAK1/2 inhibitor
ruxolitinib was purchased from ChemieTek (Indianapolis, IN), and the JAK3 inhibitor
tofacitinib was from Selleck Chemicals (Houston, TX).
2.3.2 CGN culture
Rat CGNs were isolated and cultured from 7-day-old Sprague-Dawley rat pups of
both sexes (15–19 g) as described previously (Linseman et al., 2001). Briefly, CGNs
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were plated on 35-mm-diameter plastic dishes coated with poly-l-lysine at a density of
2.0 × 106cells/ml in basal modified Eagle's medium containing 10% fetal bovine serum,
25 mm KCl, 2 mm l-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin
(Invitrogen). Cytosine arabinoside (10 µm) was added to the culture medium 24 h after
plating to limit the growth of non-neuronal cells. With this protocol, cultures were ~95%
pure for granule neurons. In general, experiments were performed after 6–7 days in
culture.
2.3.3 CGN culture from STAT1 knock-out (KO) mice
STAT1 KO mice and their wild-type littermates were obtained commercially
from Taconic (Hudson, NY). CGNs from these mice were isolated and cultured
essentially as described above.
2.3.4 Cell lysis and immunoblotting
After treatment as described under “Results,” CGN whole cell lysates or immune
complexes of STAT5A or STAT5B were prepared for Western blotting essentially as
described previously (Loucks et al., 2006). Protein concentrations were determined by a
commercially available protein assay kit (BCA, Thermo Scientific), and SDSpolyacrylamide gel electrophoresis was performed using equal amounts of protein
followed by transfer to polyvinylidene difluoride (PVDF) membranes (Amersham
Biosciences). Nonspecific binding sites were blocked in phosphate-buffered saline (PBS)
(pH 7.4) containing 0.1% Tween 20 (PBS-T), 1% bovine serum albumin (BSA), and
0.01% sodium azide for 1 h at room temperature (25 °C). Membranes were incubated for
1 h in primary antibody diluted in blocking solution. Excess primary antibody was
removed by washing the membranes with PBS-T five times over 25 min. The membranes
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were then incubated for 1 h with the appropriate horseradish peroxidase-conjugated
secondary antibodies diluted in PBS-T. Excess secondary antibody was removed by
washing the membranes with PBS-T five times over 25 min. Immunoreactive proteins
were detected by enhanced chemiluminescence. Blots shown are representative of a
minimum of three independent experiments.
2.3.5 Quantification of apoptosis
After induction of apoptosis, CGNs were fixed in 4% paraformaldehyde for 30
min, and nuclei were stained with Hoechst dye (8 µg/ml final concentration) for 30 min.
CGNs containing condensed and/or fragmented nuclei were scored as apoptotic.
Typically, 800 cells were quantified from each 35-mm well by randomly counting five
40× fields. Final counts represent data obtained from at least three independent
experiments performed in duplicate.
2.3.6 Immunocytochemistry
CGNs were plated at a density of 2.0 × 106cells/ml in 35-mm wells. After ToxB
treatment, CGNs were fixed in 4% paraformaldehyde, washed once in PBS, and then
permeabilized and blocked in PBS containing 0.2% Triton X-100 and 5% BSA. Primary
antibodies were diluted in 2% BSA and 0.2% Triton X-100 in PBS, and cells were
incubated in primary antibody overnight at 4 °C. Cells were subsequently washed five
times in PBS and then incubated for 1 h with DAPI and either Cy3- or FITC-conjugated
secondary antibody diluted in 2% BSA and 0.2% Triton X-100. The cells were washed
five additional times with PBS before the addition of an antiquench solution composed of
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured
using a 40× water oil immersion objective on a Zeiss Axioplan 2 microscope with a
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Cooke Sensicam deep cooled charge-coupled device camera and a Slidebook software
analysis program for digital deconvolution (Intelligent Imaging Innovations Inc., Denver,
CO).
2.3.7 Preparation of nuclear and cytosolic extracts from CGNs
Nuclear and cytosolic extracts were prepared as described by Li et al. (2001).
Briefly, CGNs were detached from culture dishes by a cell scraper and centrifuged at 250
× g for 5 min. The cell pellets were washed and homogenized with 15 strokes of a tightly
fitting Dounce homogenizer to release nuclei. Next, the homogenate was centrifuged at
14,000 × g for 15 s to pellet the nuclei. The supernatants (cytosolic fractions) were
removed, the pellets were resuspended in a HEPES/glycerol buffer, and nuclear proteins
were extracted at 4 °C for 45 min. Insoluble nuclei were precipitated by centrifugation at
14,000 × g for 15 min, and the supernatants were dialyzed against a Tris/glycerol buffer
for 3 h at 4 °C.
2.3.8 Adenovirus preparation and infection
Wild-type STAT5 and dominant negative STAT5 adenoviral constructs were
prepared as described previously (Ahonen et al., 2003). CGNs were infected in vitro on
day 6 with adenovirus carrying GFP, wild-type STAT5, or dominant negative STAT5 at
a multiplicity of infection of 100. At 48 h of infection, cells were treated with 40 ng/ml
ToxB. At 72 h of infection, cell lysates were prepared for immunoblot analysis, or cells
were fixed for immunocytochemistry as described above.
2.3.9 Chromatin immunoprecipitation (ChIP)
ChIP assays were performed according to the manufacturer's protocol using the
ChIP assay kit from Active Motif (Carlsbad, CA). CGNs were treated with 40 ng/ml
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ToxB for 0 and 8 h. Next, DNA-associated proteins were cross-linked with
formaldehyde. Cross-linked chromatin was extracted, sheared enzymatically, and
incubated with a ChIP grade STAT5 antibody overnight at 4 °C and protein G-agarose
beads. After washing, immune complexes were eluted from the beads, heated to reverse
the cross-links, and treated with proteinase K and RNase A to remove proteins and any
contaminating RNA. DNA was analyzed by polymerase chain reaction (PCR) using the
following primers provided by SABiosciences that generate a 114-bp product that
corresponds to the promoter region of the rat Bcl-xL gene: forward primer, 5′GAAGCTGACACCAGTGAGTGTCCGAACGGTAAATGCCTACGAAGCTGACACC
AGTGAGTG-3′; and reverse primer, 5′-GTAGGCATTTACCGTTCGGA-3′. These
primers were selected because they amplify a sequence of DNA that is near two predicted
STAT5 binding sites on the promoter region of Bcl-xL variant 1 and variant 2. As a
negative control, ChIP reactions were performed as described in the absence of STAT5
antibody followed by PCR. PCR was performed using the following conditions: one
cycle of 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s and 60 °C for 60 s.
2.3.10 Data analysis
Results represent the mean ± S.E. for the number (n) of independent experiments
performed. Statistical differences between the means of unpaired sets of data were
evaluated by one-way analysis of variance with a post hoc Tukey's test. A p value of
<0.05 was considered statistically significant. Images and immunoblots are representative
of at least three independent experiments. For the cycle threshold values reported in Fig.
2.10A, results represent the mean for four independent experiments, and statistical
differences were evaluated by a Student's t test.
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2.4 Results
2.4.1 STAT1 is up-regulated in JAK-dependent manner in CGNs treated with Rho family
GTPase inhibitor ToxB
To evaluate the involvement of Rac in CGN survival, cultures were incubated
with C. difficile toxin B. This cytotoxin monoglucosylates a key threonine residue in the
switch 1 region of Rho GTPases, thus preventing any interactions with downstream
effectors (Just et al., 1995; Jank and Aktories, 2008). We have shown previously that
inhibition of the Rho family member Rac with ToxB elicits the derepression of a
proapoptotic JAK/STAT pathway in CGNs (Loucks et al., 2006). However, the specific
STAT family protein involved in this pathway has not yet been elucidated. As STAT1 is
the most extensively described family member in studies of apoptosis (Sahni et al., 2001;
Stephanou and Latchman, 2003; Sironi and Ouchi, 2004), we examined its expression
following Rac inhibition. CGNs incubated with ToxB for 24 h exhibited a marked
increase in the expression of STAT1 (Fig. 2.1A). Moreover, co-incubation with a small
molecule pan-JI (structure shown in Fig. 2.1B) was sufficient to prevent the induction of
STAT1 by ToxB, confirming that the increase in STAT1 is dependent on JAK activation
(Fig. 2.1A).
In addition to provoking apoptosis in a variety of diverse cell types (Thomas et
al., 2004; Kaganoi et al., 2007; Soond et al., 2007), activated STAT1 has been shown to
play a proapoptotic role in neuronal death induced during ischemic brain injury (Takagi
et al., 2002). To determine whether derepression of a JAK/STAT1 pathway exerts a
similar proapoptotic effect in Rac-inhibited neurons, we examined the neuroprotective
effects of pan-JI in ToxB-treated CGNs. Examination of nuclei by Hoechst staining
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revealed increased apoptotic cell death in ToxB-treated CGNs as evidenced by nuclear
fragmentation and/or condensation. The effect of ToxB on the morphology of CGN
nuclei was significantly attenuated by co-treatment with the pan-JI (Fig. 2.1D, lower
panels). As an additional means of identifying apoptotic cells, we examined caspase-3
activation as cleavage to its active proteolytic fragments is a hallmark of apoptosis and
signifies commitment to cell death (Porter and Jänicke, 1999). CGNs treated with ToxB
alone exhibited increased activation of caspase-3, and this effect was blocked by pan-JI
(Fig. 2.1D, upper panels). Quantification of apoptosis in CGNs co-incubated with ToxB
and pan-JI revealed that the pan-JI conferred significant neuroprotection and effectively
reduced apoptosis to control levels (Fig. 2.1C). Taken together, these data suggest that
inhibition of Rac with ToxB results in the activation of a proapoptotic JAK/STAT1
signaling pathway in CGNs.
To elucidate the specific JAK family member(s) that induces STAT activation
downstream of Rac inhibition in CGNs, we evaluated the protective effects of more
targeted JAK inhibitors against ToxB. We found that two specific JAK3 inhibitors (JAK3
inhibitor and tofacitinib) did not confer significant neuroprotection in ToxB-treated
CGNs (Fig. 2.1E). However, we found that the JAK1/2 inhibitor (ruxolitinib) modestly
protected CGNs from ToxB-mediated apoptosis, although this effect did not quite reach
statistical significance. Based on the marked protective effects of the pan-JI (which
inhibits JAK1–3 and Tyk2 with similar potency) and our results showing that more
targeted inhibition of specific JAK family members (JAK1–3) is not overtly protective,
these data suggest a possible contribution of Tyk2 in mediating the apoptosis downstream
of ToxB-mediated Rac inhibition in primary CGNs.
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Figure 2.1 STAT1 is up-regulated in JAK-dependent manner during CGN apoptosis
induced by Rho family GTPase inhibitor ToxB. A. CGNs were incubated for 24 h in
complete medium containing 25 mm KCl and serum (control (Con) medium) ± ToxB (40
ng/ml) or ToxB + pan-JI (1 µm). Cells were then lysed, and proteins were resolved by
SDS-PAGE and transferred to PVDF membranes. The membrane was probed with an
antibody against STAT1. STAT1 expression was up-regulated when treated with ToxB,
and this effect was blocked by pan-JI. B. Molecular structure of pan-JI. C. Quantification
of apoptosis in CGNs incubated for 24 h as described in A. **, p < 0.01 compared with
control (Con); ††, p < 0.01 compared with ToxB. D. CGNs were incubated for 24 h as
described in A. For 4 independent experiments following incubation, cells were
incubated with a polyclonal antibody against active caspase-3 (shown in red) and a
monoclonal antibody against β-tubulin (shown in green), and nuclei were stained with
DAPI (shown in blue). Lower panels show decolorized DAPI staining of nuclei for
clarity. CGNs incubated with ToxB exhibited many condensed and/or fragmented nuclei
and displayed increased immunoreactivity for active caspase-3. CGNs co-incubated with
pan-JI were significantly protected from apoptosis and displayed nuclear morphology
similar to that in controls. Scale bar, 10 µm. E. CGNs were incubated for 24 h in control
medium ± ToxB (40 ng/ml) or ToxB + JAK3 inhibitor (JAK3 Inh; 100 µm), ruxolitinib
(Rux; 10 µm), or tofacitinib (Tof; 10 µm). Following incubation, cells were fixed with 4%
paraformaldehyde, and the nuclei were stained with Hoechst dye. Apoptotic cells were
scored as those with condensed and/or fragmented nuclei. Values are mean ± S.E. for 6
independent experiments. I acknowledge Alex Loucks for assistance with generating data
for this figure.
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2.4.2 STAT1 is not activated by tyrosine phosphorylation nor does it translocate into
nucleus of ToxB-treated CGNs
Next, we examined the phosphorylation status and localization of STAT1 in
CGNs exposed to ToxB. To translocate into the nucleus and influence gene expression,
members of the STAT family must be activated via tyrosine phosphorylation (Rawlings
et al., 2004). Whereas total STAT1 expression increased in CGNs treated for 24 h with
ToxB, time course experiments performed for up to 24 h did not show significant
activation of STAT1 as assessed by tyrosine phosphorylation (Fig. 2.2A). Furthermore,
using immunostaining to examine STAT1 localization, we found that STAT1 remained
cytosolic and perinuclear in CGNs following ToxB treatment (Fig. 2.2B). These
observations are striking in that they suggest that the observed up-regulation of STAT1
expression may not be directly involved in apoptosis following ToxB-mediated inhibition
of Rac.
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Figure 2.2 STAT1 does not display increased tyrosine phosphorylation nor does it
translocate into nucleus of ToxB-treated CGNs. A. A 24h time course of ToxB
treatment (40 ng/ml) was performed in CGNs. Cell lysates were resolved by SDS-PAGE,
and proteins were transferred to PVDF membranes. The blots were probed with
antibodies against pSTAT1 (Tyr-701) and STAT1. Little to no increase in the tyrosine
phosphorylation of STAT1 was observed in CGNs subjected to ToxB for up to 24 h. B.
CGNs were incubated with control (Con) medium ± ToxB (40 ng/ml) for 8 h. Cells were
fixed, and their nuclei were stained with DAPI. A primary antibody against pSTAT1
(Tyr-701) and a Cy3-conjugated secondary antibody were used to visualize pSTAT1.
Incubation of CGNs with ToxB did not result in translocation of pSTAT1 into the
nucleus. Scale bar, 10 µm. I acknowledge Alex Loucks for assistance with generating
data for this figure.
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2.4.3 CGNs from STAT1 knock-out mice are susceptible to ToxB-induced apoptosis
To definitively establish whether the up-regulation of total STAT1 expression in
the absence of enhanced tyrosine phosphorylation or nuclear translocation is involved in
ToxB-mediated apoptosis, we measured the effects of ToxB on primary cultures of CGNs
isolated from STAT1 KO mice versus their wild-type (WT) littermates. CGNs from WT
mice demonstrated a marked increase in STAT1 expression following ToxB treatment,
whereas CGNs from STAT1 KO mice did not demonstrate any expression of STAT1 in
either the absence or presence of ToxB (Fig. 2.3A), thus confirming effective knock-out
of STAT1 expression in these mice. Unexpectedly, CGNs from both WT and STAT1 KO
mice equally succumbed to apoptosis in response to ToxB treatment (Fig. 2.3B), whereas
inclusion of the pan-JI was equally neuroprotective for both cell types (Fig. 2.3C).
Collectively, these data indicate that although total STAT1 is up-regulated a different
member of the STAT family mediates JAK-dependent apoptosis in Rac-inhibited CGNs.
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Figure 2.3 CGNs from STAT1 knock-out and wild-type mice are equally susceptible
to ToxB-induced apoptosis. A. CGNs from WT and STAT1 KO mice were treated for
0, 24, or 48 h with ToxB (40 ng/ml). Cell lysates were resolved by SDS-PAGE, and
proteins were transferred to PVDF membranes. The blot was probed with a primary
antibody against STAT1. The Western blot shows induced expression of STAT1 in WT
CGNs after treatment with ToxB. B. WT and STAT1 KO CGNs were incubated for 48 h
in control (Con) medium ± ToxB (40 ng/ml) or with ToxB + pan-JI (1 µm). Cells were
fixed, and nuclei were stained with Hoechst. Both WT and KO cells treated with ToxB
displayed condensed and/or fragmented nuclear morphology. WT and KO CGNs coincubated with pan-JI exhibited nuclear morphologies similar to those of control cells.
Scale bar, 10 µm. C. Quantification of apoptosis in CGNs incubated for 24 or 48 h with
control medium ± ToxB (40 ng/ml) or ToxB + pan-JI (1 µm). STAT1 KO cells
succumbed to apoptosis as readily as WT CGNs after treatment with ToxB. When coincubated with pan-JI, STAT1 KO and WT CGNs showed similar protection from ToxB.
**, p < 0.01 compared with control; ††, p < 0.01 compared with ToxB. Inh, inhibitor.
Values are mean ± S.E. for 3 independent experiments. I acknowledge Alex Loucks for
assistance with generating data for this figure.
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2.4.4 STAT3 is tyrosine phosphorylated in response to ToxB, and this effect is blocked by
Pan-JI
As our data demonstrate that STAT1 up-regulation does not significantly
contribute to apoptosis in Rac-inhibited CGNs, we next evaluated the involvement of
additional members of the STAT family. Recent evidence suggests that STAT3 mediates
β-amyloid-induced apoptosis in mouse cortical neurons (Wan et al., 2010). To determine
whether ToxB-targeted inhibition of Rac acts to ultimately activate a similar proapoptotic
JAK/STAT3 pathway, we analyzed the activation of STAT3 in response to ToxB
treatment. Time course experiments demonstrated that STAT3 was tyrosine
phosphorylated as early as 6 h after ToxB treatment (Fig. 2.4A), and inclusion of pan-JI
blocked the phosphorylation of STAT3 at both 6 and 8 h in ToxB-treated CGNs (Fig.
2.4B).
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Figure 2.4 STAT3 is tyrosine phosphorylated in response to ToxB in CGNs, and this
effect is blocked by pan-JI. A. CGNs were incubated for various periods of time up to 8
h with ToxB in control medium. Cells were lysed, and proteins were resolved by SDSPAGE and transferred to PVDF membranes. The blot was probed with antibodies against
pSTAT3 (Tyr-705) or STAT3. The expression of pSTAT3 increased in response to
ToxB. B. CGNs were incubated for 6 or 8 h in control (Con) medium ± ToxB (40 ng/ml)
or ToxB + pan-JI (1 µm). Cell lysates were resolved by SDS-PAGE, and proteins were
transferred to PVDF membranes. The blot was probed with antibodies against pSTAT3
(Tyr-705) or STAT3. The pan-JI inhibitor blocked ToxB-induced STAT3
phosphorylation. I acknowledge Alex Loucks for assistance with generating data for this
figure.

49

2.4.5 The reputed STAT3 inhibitor JSI-124 protects CGNs from ToxB-induced apoptosis
To further define the potential role of STAT3 in the proapoptotic pathway
activated downstream of Rac inhibition, we examined whether or not the reputed STAT3
inhibitor JSI-124 (Blaskovich et al., 2003) exerted a protective effect in ToxB-treated
CGNs (Fig. 2.5A). Following a 24-h incubation period with ToxB alone, many CGNs
displayed condensed and/or fragmented nuclei consistent with apoptosis. In contrast,
CGNs co-incubated with JSI-124 were essentially completely protected from apoptosis,
and their nuclei were morphologically similar to those in control cells (Fig. 2.5B).
Inclusion of JSI-124 reduced CGN apoptosis in the presence of ToxB to ~10% (Fig.
2.5C). These data support a model in which a proapoptotic JAK/STAT3 pathway
mediates apoptosis in Rac-inhibited CGNs.
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Figure 2.5 The reputed STAT3 inhibitor, JSI-124, protects CGNs from ToxBinduced apoptosis. A. Molecular structure of JSI-124. B. CGNs were incubated for 24 h
in control (Con) medium ± ToxB (40 ng/ml) or ToxB + JSI-124 (JSI; 5 µm). Cells were
fixed, and their nuclei were stained with Hoechst dye. CGNs treated with ToxB exhibited
significantly more condensed and/or fragmented nuclei than control CGNs. CGNs coincubated with JSI-124 were significantly protected from apoptosis, and their nuclei were
morphologically similar to those of control cells. Scale bar, 10 µm. C. Quantification of
apoptosis in CGNs treated with ToxB or ±JSI-124. Values are mean ± S.E. JSI-124
significantly protected CGNs from ToxB-induced apoptosis. **, p < 0.01 compared with
control; ††, p < 0.01 compared with ToxB. Values are mean ± S.E. for 5 independent
experiments. I acknowledge Alex Loucks for assistance with generating data for this
figure.
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2.4.6 Phosphorylated STAT3 does not translocate into nucleus of CGNs following
treatment with ToxB, and additional STAT3 inhibitors do not protect CGNs from
apoptosis induced by ToxB
To further investigate the role of STAT3 in apoptosis, we examined whether or
not pSTAT3 translocates into the nucleus following ToxB treatment. Nuclear
fractionation

experiments

demonstrated

that

although

STAT3

was

tyrosine

phosphorylated pSTAT3 remained cytosolic following ToxB targeted inhibition of Rac
(Fig. 2.6A). Furthermore, two additional STAT3 inhibitors, STA-21 and a STAT3
inhibitory peptide, did not protect CGNs from ToxB-induced apoptosis (Fig. 2.6, B and
C). These results indicate that STAT3 does not directly regulate apoptosis downstream of
Rac inhibition. This finding was particularly surprising as the selective STAT3 inhibitor
JSI-124 exerted a neuroprotective effect in ToxB-treated CGNs. However, further
evaluation of the effects of JSI-124 in CGNs revealed that this compound in fact had no
significant inhibitory effect on ToxB-induced STAT3 phosphorylation (Fig. 2.6D). These
data suggest that the mechanism by which JSI-124 protects CGNs from apoptosis is
unrelated to attenuation of activated STAT3 and may involve a different member of the
STAT family.
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Figure 2.6 Phosphorylated STAT3 does not translocate into nucleus of CGNs
following treatment with ToxB, and additional STAT3 inhibitors do not protect
CGNs from apoptosis. A. CGNs were incubated in control (Con) medium ± ToxB (40
ng/ml) for 8 h. Following incubation, the cells were fractionated into nuclear and
cytosolic (cyto) fractions as described under “Experimental Procedures.” A monoclonal
antibody against pSTAT3 (Tyr-705) was used for Western blotting. pSTAT3 did not
translocate into the nucleus following treatment with ToxB. The purity of the nuclear
fractions was verified by immunoblotting for LAP-2. B. CGNs were incubated for 24 h in
control medium ± ToxB (40 ng/ml) or ToxB + STA-21 (20 µm). Cells were fixed, and
nuclei were stained with Hoechst dye to quantify apoptosis. STA-21 did not protect
CGNs from ToxB-induced apoptosis. Results shown are mean ± range (n = 2). C. CGNs
were incubated for 24 h in control medium ± ToxB (40 ng/ml) or ToxB + STAT3
inhibitory peptide (Inh Pep; 100 µm). Cells were fixed, and nuclei were stained with
Hoechst dye to quantify apoptosis. STAT3 inhibitory peptide did not protect CGNs from
ToxB-induced apoptosis. Results shown are mean ± range (n = 2). D. CGNs were
incubated for 24 h in control medium ± ToxB (40 ng/ml), JSI-124 (JSI; 5 µm), or ToxB +
JSI-124. The cells were lysed, and proteins were separated by SDS-PAGE and transferred
to PVDF membranes. Blots were probed for pSTAT3 (Tyr-705). ToxB increased the
expression of pSTAT3. This effect was not blocked by co-incubation with JSI-124. NS,
nonspecific band shown to indicate equal protein loading. Values are mean ± range for 2
independent experiments. I acknowledge Alex Loucks for assistance with generating data
for this figure.
53

2.4.7 Tyrosine phosphorylation of STAT5 in response to ToxB in CGNs is blocked by JSI124 and putative STAT5 inhibitor roscovitine
Recent evidence demonstrates a necessary role for STAT5 in apoptosis induced
by oncostatin M in osteosarcoma cells (Chipoy et al., 2007). In addition, both STAT5
isoforms have been implicated in the down-regulation of the prosurvival Bcl-xL protein
in thymocytes (Nelson et al., 2004). Therefore, we next examined STAT5 and found that
STAT5 was tyrosine phosphorylated in ToxB-treated CGNs. Interestingly, although
blotting for total STAT5 clearly showed the presence of both STAT5A (94 kDa) and
STAT5B (92 kDa) in CGNs (Fig. 2.7A, lower blot), Western blots for phospho-STAT5
only indicated a single tyrosine phosphorylated isoform in response to ToxB (Fig. 2.7A,
upper blot). Therefore, we next sought to determine whether STAT5A or STAT5B was
phosphorylated in response to ToxB. To establish which STAT5 isoform was
phosphorylated, we compared lysates that were immunoprecipitated for either STAT5A
or STAT5B with whole cell lysates and Western blotted for total STAT5. Using this
approach, we were able to determine where the STAT5A and STAT5B isoforms were
detected by immunoblot (Fig. 2.7B, left panel). Despite efficient immunoprecipitation of
each of the STAT5 isoforms from CGNs using isoform-specific antibodies, we were not
able to observe tyrosine phosphorylation of either isoform in response to ToxB. However,
in whole cell lysates obtained following 8 h of ToxB treatment, we observed a
pronounced increase in the tyrosine phosphorylation of the higher molecular weight
STAT5A isoform but not STAT5B using a phosphospecific antibody to STAT5 (Fig.
2.7B, right panel). The inability to observe STAT5A tyrosine phosphorylation following
immunoprecipitation may reflect the physical association of STAT5A with one or more
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protein tyrosine phosphatases, any one of which may be insensitive to the phosphatase
inhibitors present in our lysis buffer, as described previously (Chughtai et al., 2002;
Rigacci et al., 2003). Our data are consistent with several previous reports demonstrating
that STAT5A and STAT5B can be individually activated in a stimulus- and cell typespecific manner (Rosen et al., 1996; al-Shami et al., 1997; Storz et al., 1999; Grimley et
al., 1999; Faderl et al., 2003).
In addition, co-treatment of CGNs with either JSI-124 or the putative STAT5
inhibitor roscovitine (Mohapatra et al., 2003) was sufficient to block the tyrosine
phosphorylation of STAT5A in response to ToxB (Fig. 2.7, A and B). To further
substantiate the involvement of STAT5 in ToxB-treated CGNs, we examined STAT5
phosphorylation and localization by immunocytochemistry. In control CGNs, the
expression of pSTAT5 detected by immunofluorescence was negligible. In contrast,
following incubation of CGNs with ToxB, there was a profound increase in the
immunoreactivity for pSTAT5, and this transcription factor was principally localized to
CGN nuclei (Fig. 2.7C). Collectively, these data indicate that STAT5 is tyrosine
phosphorylated in response to ToxB and localizes to the nucleus under these conditions
to modulate gene transcription. Moreover, the tyrosine phosphorylation of STAT5
appears to be specific for the STAT5A isoform and is sensitive to inhibition by either
JSI-124 or roscovitine.
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Figure 2.7 STAT5A shows enhanced tyrosine phosphorylation in response to ToxB
in CGNs that is blocked by JSI-124 and STAT5 inhibitor roscovitine. A. CGNs were
incubated in control (Con) medium ± ToxB (40 ng/ml) or ToxB + JSI-124 (JSI; 5 µm) for
24 h. Cells were lysed, and proteins were resolved by SDS-PAGE and transferred to
PVDF membranes. Blots were probed for pSTAT5 (Tyr-694) and total STAT5. STAT5
was phosphorylated in response to ToxB, and this effect was blocked by JSI-124. B.
CGNs were incubated in control medium ± ToxB (40 ng/ml) or ToxB + roscovitine
(Rosc; 30 µm) for 24 h. Following incubation, cells were lysed and immunoprecipitated
(IP; right panel) for either total STAT5A or STAT5B. Immunoprecipitated proteins and a
lane containing the whole cell lysate (WCL) were resolved by SDS-PAGE and transferred
to PVDF membranes. Blots were probed for total STAT5. In the left panel, proteins were
lysed following a 24-h incubation period and resolved by SDS-PAGE. Next, proteins
were transferred to PVDF membranes. Blots were probed for pSTAT5 (Tyr-694) and
total STAT5. STAT5 was phosphorylated in response to ToxB, and this effect was
blocked by roscovitine. NS, nonspecific band shown to indicate equal protein loading;
5A, STAT5A; 5B, STAT5B. C. CGNs were incubated in control medium ± ToxB (40
ng/ml) for 24 h. Cells were fixed and incubated with a polyclonal antibody against
pSTAT5 (Tyr-694; shown in green). Nuclei were stained with DAPI (shown in blue).
pSTAT5 translocated into the nucleus in response to ToxB. Scale bar, 10 µm. IB,
immunoblotted.
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2.4.8 Roscovitine significantly protects CGNs from ToxB-induced apoptosis
Consistent with STAT5 playing a key role in ToxB-induced apoptosis, CGNs cotreated with ToxB and roscovitine displayed healthy, intact nuclei (Fig. 2.8A).
Quantification of these results shows that roscovitine significantly protected CGNs from
ToxB-induced apoptosis (Fig. 2.8B). In addition, ToxB treatment for 24 h resulted in the
cleavage of procaspase-3 to its active fragments, an effect largely attenuated by
roscovitine (Fig. 2.8C). Generally, roscovitine is used to suppress the cell cycle through
inhibition of cyclin-dependent kinases (CDKs) (Edamatsu et al., 2000). To ensure that the
protection conferred by roscovitine was not through CDK suppression but was a result of
STAT5 inhibition, CGNs were also treated with ToxB ± purvalanol A, a closely related
CDK inhibitor. Although remarkably similar in structure, purvalanol A did not protect
CGNs from ToxB-induced apoptosis and in fact significantly enhanced cell death (Fig.
2.8D). These results suggest that the neuroprotective effects of roscovitine are unrelated
to CDK suppression and are likely due to STAT5 inhibition.
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Figure 2.8 Roscovitine significantly protects CGNs from ToxB-induced apoptosis. A.
CGNs were incubated for 24 h in control (Con) medium ± ToxB (40 ng/ml) or ToxB +
Roscovitine (Rosc; 30 µm). Following incubation, cells were fixed, and the nuclei were
stained with Hoechst dye. Scale bar, 10 µm. B. Quantification of apoptosis in CGNs
treated with ToxB alone or co-treated with roscovitine. Values are mean ± S.E. (n = 6).
Roscovitine significantly protected CGNs from ToxB-induced apoptosis. **, p < 0.01
compared with control; ††, p < 0.01 compared with ToxB. C. CGNs were treated as
described in A and lysed. Proteins were separated by SDS-PAGE and transferred to
PVDF membranes. The membrane was immunoblotted (IB) for caspase-3. Roscovitine
blocked the ToxB-induced processing of caspase-3 to its active fragments. fl, full length.
D. CGNs were incubated for 24 h in control medium ± ToxB (40 ng/ml) or ToxB +
purvalanol A (Purv; 30 µm). Following incubation, cells were fixed with 4%
paraformaldehyde, and the nuclei were stained with Hoechst dye. Purvalanol A did not
protect CGNs from ToxB-induced apoptosis. Values are mean ± S.E. for 3 independent
experiments. I acknowledge Alex Loucks for assistance with generating data for this
figure.
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2.4.9 Adenoviral dominant negative STAT5 protects CGNs from ToxB-induced apoptosis
As a more specific approach to definitively establish the proapoptotic role of
STAT5 following disruption of Rac activity, we examined the neuroprotective effects of
a dominant negative mutant of STAT5 containing a C-terminal truncation at residue 713
that removes the entire transcriptional activation domain of STAT5 (Ad-DN STAT5; Ref.
Wang et al., 1996). First, adenoviruses expressing either WT STAT5 or DN STAT5 were
grown and overexpressed in HEK293AD cells, and these cells were compared with cells
that were infected with the Ad-GFP control. Infection with Ad-WT STAT5 increased
expression of full-length STAT5, and Ad-DN STAT5 appeared as a lower molecular
weight form of STAT5 (Fig. 2.9A). Next, we infected CGNs with the Ad-GFP control,
WT STAT5, and DN STAT5 and observed similar high level expression of the constructs
(Fig. 2.9B). Importantly, none of the adenoviral constructs induced any significant
increase in basal apoptosis of CGNs on their own (Fig. 2.9C). As we have consistently
shown, ToxB treatment resulted in condensed and fragmented nuclei indicative of
apoptosis. Not unexpectedly, preincubation of CGNs with WT STAT5 did not confer
neuroprotection from ToxB treatment (Fig. 2.9E). However, CGNs preincubated with
Ad-DN STAT5 and subsequently treated with ToxB displayed nuclear morphology
strikingly more similar to that of control CGNs (Fig. 2.9E). Quantification of apoptosis
revealed that inhibiting the transcriptional activity of endogenous STAT5 through
overexpression of Ad-DN STAT5 significantly protected CGNs from ToxB-induced
apoptosis (Fig. 2.9D). The protective effect of Ad-DN STAT5 was not as complete as
that with the chemical JAK/STAT inhibitors used previously. This was likely a reflection
of the infection efficiency of CGNs, which we observed to be 50–60% in cells infected
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with Ad-GFP. These data highlight a novel proapoptotic function for STAT5 downstream
of Rac inhibition in primary cerebellar neurons.
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Figure 2.9 Adenoviral dominant negative STAT5 protects CGNs from ToxBinduced apoptosis. A. HEK293AD cells were infected for 48 h with an adenovirus
carrying GFP (Ad-GFP), wild-type STAT5 (Ad-WT STAT5), or dominant negative
STAT5 (Ad-DN STAT5). Cell lysates were separated by SDS-PAGE, transferred to
PVDF membranes, and immunoblotted (IB) for STAT5 expression. There was a marked
increase in STAT5 expression in HEK cells infected with either Ad-WT or Ad-DN
STAT5. Endo, endogenous; trunc, truncated. B. CGNs were infected for 48 h with the
same adenoviruses as described in A, and cell lysates were probed for STAT5 expression.
C. CGNs were incubated for 48 h with adenoviruses as described above. The cells were
fixed, and the nuclei were stained with Hoechst. Apoptotic cells were scored as those
with condensed and/or fragmented nuclei. There was no significant difference in basal
apoptosis in CGNs infected with Ad-GFP, Ad-WT STAT5, or Ad-DN STAT5. D. CGNs
were infected for 48 h with either Ad-WT STAT5 or Ad-DN STAT5. After the initial 24
h of incubation, each experimental condition was treated ±ToxB (40 ng/ml) for 24 h. At
the end of the incubation, cells were fixed, and nuclei were stained with DAPI. Apoptotic
cells were scored as those with condensed and/or fragmented nuclei. The -fold change in
apoptosis for ToxB-treated cells versus control (Con) cells was quantified. CGNs
incubated with dominant negative STAT5 were protected from ToxB-induced apoptosis.
Data shown represent the mean ± S.E. for n = 3 experiments. **, p < 0.01 versus WT
STAT5. E. CGNs were incubated as describe in D. Cells were then fixed, and nuclei were
stained with Hoechst dye. Images shown are representative of three independent
experiments. Scale bar, 10 µm. Values are mean ± S.E. for 6 independent experiments.
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2.4.10 STAT5 transcriptionally represses Bcl-xL during ToxB-induced apoptosis
Recent studies suggest that under certain conditions STAT5 transcriptionally
represses prosurvival members of the Bcl-2 family (Chipoy et al., 2007; Nelson et al.,
2004; Moucadel and Constantinescu, 2005). Disturbances in the ratio of these proteins to
their corresponding proapoptotic family members can induce apoptosis. The prosurvival
members of the Bcl-2 family have an important and well documented role in promoting
cell survival through binding and inactivating the proapoptotic members of their same
family (Korsmeyer et al., 1993). To evaluate whether STAT5 similarly represses Bcl-2
family proteins in Rac-inhibited CGNs, we isolated and purified DNA with a ChIP grade
antibody to STAT5 in control CGNs or those treated with ToxB for 8 h. There was no
significant difference between STAT5 bound to the promoter region of Bcl-2 in control
versus ToxB-treated CGNs (data not shown). In the case of Bcl-xL, the input levels of
Bcl-xL promoter DNA amplified from the non-immunoprecipitated control and ToxBtreated CGNs were not significantly different. However, the cycle threshold values
obtained for amplification of the Bcl-xL promoter from STAT5 ChIP samples were
significantly lower for ToxB treatment compared with the control, indicating a significant
increase in STAT5 binding to the Bcl-xL promoter in Rac-inhibited CGNs (Fig. 2.10A).
Indeed, we report that there was an apparent although not statistically significant 9.5 ±
4.1 (n = 4)-fold increase in STAT5 recruitment to the Bcl-xL promoter in response to
ToxB treatment after 8 h (Fig. 2.10B). Consistent with these data, Bcl-xL expression was
down-regulated at 16 h and more significantly at 24 h after ToxB treatment (Fig. 2.10C).
In agreement with a relatively slow mechanism of death due to the transcriptional
repression of Bcl-xL, we report that ToxB did not induce caspase-3 activation or
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significant apoptotic morphology until 16 h of incubation after STAT5 is bound to the
promoter region of Bcl-xL in CGNs (Fig. 2.10, B and C).
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Figure 2.10 STAT5 transcriptionally represses Bcl-xL during ToxB-induced
apoptosis. A. CGNs were incubated in control (Con) medium ± ToxB (40 ng/ml) for 8 h.
As a control for ChIP experiments (“Input”), ChIP-quantitative PCR was performed as
described under “Experimental Procedures” in the absence of the STAT5 antibody to
determine the total concentration of input Bcl-xL promoter DNA. The graph shows the
mean ± S.E. of the results of four independent experiments. The concentration of input
DNA did not differ significantly between the control and ToxB samples. ChIP: STAT5,
CGNs were incubated in control medium ± ToxB (40 ng/ml) for 8 h. The relative binding
of STAT5 to the Bcl-xL promoter was assessed via ChIP-quantitative PCR analysis as
described under “Experimental Procedures.” The graph shows the mean ± S.E. of the
results for four independent experiments. STAT5 binding to the Bcl-xL promoter was
significantly increased in response to ToxB treatment for 8 h. *, p < 0.05 versus control
evaluated by a two-tailed Student's t test. B. The -fold enrichment of STAT5 recruitment
to the Bcl-xL promoter was quantified from the cycle threshold (Ct) value. STAT5
binding to the promoter region of Bcl-xL increased 9.5 ± 4.1-fold in response to 8-h
ToxB treatment, although it was not statistically significant. C. CGNs were incubated for
0, 16, and 24 h with ToxB (40 ng/ml). Cells were then lysed, and proteins were resolved
by SDS-PAGE and transferred to PVDF membranes. The membrane was probed with an
antibody against Bcl-xL. Subsequently, the blot was stripped and reprobed for active
caspase-3 and actin (loading control). Bcl-xL expression decreased in response to ToxB,
and active caspase-3 expression increased. The values above the Bcl-xL blot represent
optical densities (O.D.) of the Bcl-xL expression. The normalized optical density for the
time “0” control was set to 1.0. Values are mean ± S.E. for 3 independent experiments.
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2.5 Discussion
Several studies have demonstrated a critical role for Rho GTPases (i.e. Rac, Rho,
and Cdc42) in promoting neuronal survival (Kobayashi et al., 2004; Kanekura et al.,
2005; Cheung et al., 2007). Consistent with these findings, we have shown previously
that Rac activity is critical for the survival of primary CGNs (Linseman et al., 2001), and
Rac signaling functions to repress a proapoptotic JAK/STAT pathway in these neurons
(Loucks et al., 2006). Similarly, studies from other groups support a role for the
activation of a prodeath JAK/STAT pathway in neurons (Colodner and Feany, 2010;
Mäkelä et al., 2010). For instance, Takagi et al. (2002) reported that STAT1 was
phosphorylated on activating tyrosine and serine residues and translocated into neuronal
nuclei following ischemic brain injury in mice. Moreover, STAT1 KO mice displayed a
decrease in the volume of ischemic brain injury and reduced TUNEL staining when
compared with WT mice subjected to middle cerebral artery occlusion. Thus, STAT1 can
play a proapoptotic role in neurons exposed to ischemic stress. In a similar manner,
cortical neurons cultured from STAT1 KO mice showed marked resistance to interferon
γ-stimulated neurotoxicity of the human immunodeficiency virus type 1 proteins gp120
and Tat (Giunta et al., 2006). A more recent study demonstrated that exposure of SHSY5Y neuroblastoma cells to interferon β induced STAT1 tyrosine phosphorylation and
caspase-dependent apoptosis (Dedoni et al., 2010). Both STAT1 activation and caspase
activation were prevented by a JAK inhibitor. Similar to STAT1, STAT3 also has the
potential to have a proapoptotic effect in neurons under certain conditions. Wan et al.
(2010) recently showed that a proapoptotic Tyk2/STAT3 pathway mediates β-amyloid
peptide-induced neuronal death. Specifically, siRNA knockdown of STAT3 protected
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PC12 cells from β-amyloid, and a STAT3 inhibitory peptide protected cultured cortical
neurons. Finally, cortical neurons isolated from Tyk2-null mice were significantly less
sensitive than WT neurons to β-amyloid-induced apoptosis. Collectively, these studies
demonstrate that both STAT1 and STAT3 have the potential of acting as proapoptotic
mediators in neurons under specific pathological conditions. In contrast to these previous
reports, we found that although total STAT1 levels are up-regulated and STAT3 is
activated via tyrosine phosphorylation in response to ToxB neither transcription factor is
responsible for the neuronal apoptosis induced in CGNs by inhibition of Rac function.
Instead, we report that ToxB induces the enhanced tyrosine phosphorylation of
STAT5, which subsequently translocates into the nucleus of CGNs. Interestingly, we
found that the phosphorylation of STAT5 was prevented by the reputed STAT3 inhibitor
JSI-124. This finding is perhaps not surprising given that JSI-124 has been reported to
exert effects outside of STAT3 inhibition (Graness and Goppelt-Struebe, 2006). In fact,
this compound was recently shown to inhibit the neuroprotective effects of growth
hormone against glutamate-induced toxicity in hippocampal neurons, an effect that is
dependent on STAT5 activity (Byts et al., 2008). In addition to the neuroprotective
effects of JSI-124, we report that roscovitine similarly inhibits STAT5 phosphorylation
induced by ToxB and protects CGNs against ToxB targeted Rac inhibition. The effects of
roscovitine were dissociated from its effects as a CDK inhibitor because the similarly
structured compound purvalanol A did not protect CGNs from ToxB. Our data with
roscovitine are consistent with a previous study showing its ability to suppress STAT5
activation in a leukemia cell line (Mohapatra et al., 2003). Finally, we show that
adenoviral infection with a dominant negative mutant of STAT5, but not WT STAT5,
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significantly protects CGNs from Rac inhibition with ToxB. To our knowledge, these
findings are novel in that they are the first to identify a proapoptotic function for STAT5
in neurons.
Our data indicate that of the two STAT5 isoforms only STAT5A is activated via
phosphorylation in CGNs exposed to ToxB-mediated Rac blockage. Although the two
isoforms are highly homologous, this is consistent with several previous reports that have
revealed isoform-specific STAT5 activation. Similar to our results in CGNs, JAK/STAT
signaling has been shown to induce caspase-dependent apoptosis in response to
granulocyte-macrophage colony-stimulating factor (GM-CSF) in OCIM2 acute myeloid
leukemia cells (Faderl et al., 2003). However, although GM-CSF has been shown to
preferentially activate STAT5A in human monocytes (Rosen et al., 1996), this factor was
shown to induce specific STAT5B signaling in human neutrophils (al-Shami et al., 1997).
In a similar manner, insulin was demonstrated to activate STAT5B, but not STAT5A, in
Kym-1 rhabdomyosarcoma cells (Storz et al., 1999). Furthermore, targeted gene
disruptions of either STAT5A or STAT5B in mice have shown functional differences in
vivo. For example, deletion of STAT5A disrupts prolactin-derived mammary gland
maturation, whereas disruption of STAT5B diminishes growth hormone effects on
hepatic function and body mass in male mice (Grimley et al., 1999). Thus, our data are
consistent with several previous reports highlighting isoform-specific activation and
functions of STAT5.
STAT5 is activated by many diverse cytokines and growth factors, and it is well
established that this transcription factor has an important role throughout the body.
Although few studies have examined the role of STAT5 in the central nervous system,
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the majority of reports are paradoxical to our present study and suggest that STAT5
chiefly exerts a prosurvival effect in neurons. For example, STAT5 is required in
conjunction with Akt to mediate the neurotrophic and neuroprotective effects of both
growth hormone in hippocampal neurons (Byts et al., 2008) and erythropoietin in
differentiated neuroblastoma cells (Um and Lodish, 2006). Furthermore, STAT5 was
shown to elicit a prosurvival effect via induction of Bcl-2 and Bcl-xL in neural progenitor
cells subjected to apoptotic stimulation (Choi et al., 2011). Thus, the relatively few
studies conducted on STAT5 in neuronal models indicate that it mainly functions to
transmit prosurvival signals. However, critical studies in non-neuronal cells suggest that
the downstream effects of STAT5 are much more complex. STAT5 sensitizes
osteosarcoma cells to apoptosis following treatment with oncostatin M (Chipoy et al.,
2007). Moreover, in a mouse model of familial amyotrophic lateral sclerosis, a JAK3
inhibitor was shown to extend the lifespan of mutant mice when compared with those that
did not receive the inhibitor. Although the effects of this inhibitor on the activation of
specific STAT family members was not evaluated in this particular study, JAK3 has been
shown to activate STAT5 in various studies (Bingisser et al., 1998; Cavalcanti et al.,
2010; Martín et al., 2010). In evaluating various JAK isoform-selective inhibitors, we did
not observe any significant inhibition of ToxB-induced apoptosis in CGNs except with a
pan-JI. Thus, our data suggest a possible contribution of Tyk2 or multiple JAK isoforms
in the apoptosis of neurons subjected to Rac inhibition. In conjunction with our present
findings, these previous studies suggest that STAT5 functions in a cell type- and
stimulus-specific manner, and the specific role of JAK/STAT5 in the central nervous
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system and in particular with respect to neuronal survival is likely determined by many
factors.
Although we have identified Rac as a repressor of a proapoptotic JAK/STAT5
pathway, the mechanism of STAT5 activation following Rac inhibition remains
incompletely understood. Suppressors of cytokine signaling (SOCS) exist as endogenous
STAT inhibitors (Krebs and Hilton, 2001; Cooney, 2002), and previous evidence
suggests that SOCS protein expression can be regulated by ERK (Terstegen et al., 2000;
Borland et al., 2009). This is consistent with our previous finding that a prosurvival
MEK/ERK pathway functions downstream of Rac GTPase to actively repress
proapoptotic JAK/STAT signaling in healthy CGNs (Loucks et al., 2006). Whether
SOCS proteins are indeed mediators of the Rac-dependent repression of proapoptotic
JAK/STAT signaling in neurons remains to be investigated.
In agreement with our work identifying a proapoptotic JAK/STAT5 pathway in
CGNs, recent examination of the genetic targets of STAT5 demonstrates transcriptional
regulation of prosurvival members of the Bcl-2 family. For example, STAT5 has been
shown to negatively regulate the levels of Bcl-2 in osteosarcoma cells sensitized to
undergo apoptosis (Chipoy et al., 2007). Similarly, both STAT5 isoforms were shown to
bind to the promoter region of Bcl-x, a gene that is transcribed into prosurvival Bcl-xL
and proapoptotic Bcl-extra short (Bcl-xS) (Boise e al., 1993; Nelson et al., 2004;
Moucadel and Constantinescu, 2005). Therefore, it was of interest to determine whether
Bcl-2 and/or Bcl-xL were transcriptional targets of STAT5 in CGNs subjected to Rac
inhibition with ToxB. Our ChIP data show that STAT5 is recruited to the Bcl-xL
promoter in ToxB-treated CGNs. These results suggest that STAT5 may transcriptionally
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repress Bcl-xL to tip the delicate balance between prosurvival and proapoptotic Bcl-2
proteins toward apoptosis. Consistent with this interpretation, we observed caspase-3
activation and classical apoptotic morphology subsequent to down-regulation of Bcl-xL
protein levels. Although we show that STAT5 binding to the promoter region of Bcl-xL
increases in response to Rac inhibition, an alternative mechanism by which STAT5 may
mediate transcriptional repression of Bcl-2 family proteins in the nucleus is through
competitive binding to the transcriptional co-activator p300/cAMP-response elementbinding protein (CREB)-binding protein (CBP) (Zhu et al., 1999; Zhang et al., 2008). At
the present time, we cannot exclude this as a possible mechanism of STAT5-dependent
transcriptional repression of Bcl-xL during Rac inhibition.
Another potential mechanism by which STAT5 has been proposed to repress BclxL transcription involves a cooperative interaction with the glucocorticoid receptor (GR).
A recent report found that glucocorticoid treatment in lymphoid cells inhibited the
transcription of Bcl-xL and decreased the ratio of Bcl-xL to the proapoptotic Bcl-xS in a
STAT5B-dependent manner to induce apoptosis (Rocha-Viegas et al., 2006). Conversely,
another report found that the GR can interact with STAT5 to up-regulate Bcl-xL as part
of a prosurvival pathway activated by the GR agonist methylprednisolone in
oligodendrocytes (Xu et al., 2009). Given the evidence suggesting that the GR can act in
a cooperative manner with STAT5 to regulate the transcription of Bcl-xL, we sought to
determine whether or not the GR was involved in STAT5A-mediated apoptotic signaling
in CGNs subjected to ToxB treatment. In CGNs exposed to ToxB, the GR antagonist
mifepristone provided no significant protection, indicating that the STAT5-dependent
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effects on Bcl-xL transcription are likely GR-independent in this cell system (data not
shown).
In summary, we show that ToxB-induced inactivation of Rac GTPase results in
the derepression of a novel proapoptotic JAK/STAT5 pathway. Although STAT1 was
induced and STAT3 was phosphorylated following ToxB treatment, neither protein was
responsible for inducing apoptosis of CGNs downstream of Rac inhibition. Rather, our
data support a model in which ToxB-induced Rac inhibition in CGNs activates a novel
proapoptotic JAK/STAT5 pathway that, following STAT5A phosphorylation and
translocation to the nucleus, results in the transcriptional repression of prosurvival Bcl-xL
and subsequent activation of caspase-3 and apoptosis. To our knowledge, our findings are
novel in that they are the first to demonstrate a proapoptotic function for a JAK/STAT5
pathway in neurons.
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CHAPTER THREE: NEURONAL APOPTOSIS INDUCED BY SELECTIVE
INHIBITION OF RAC GTPASE VERSUS GLOBAL SUPRESSION OF RHO
FAMILY GTPASES IS MEDIATED BY ALTERATIONS IN DISTINCT
MITOGEN-ACTIVATED PROTEIN KINASE SIGNALING CASCADES
3.1 Abstract
Rho family GTPases play integral roles in neuronal differentiation and survival. We
have previously shown that Clostridium difficile toxin B (ToxB), an inhibitor of RhoA,
Rac1, and Cdc42, induces apoptosis of cerebellar granule neurons (CGNs). In the current
study, we compared the effects of ToxB to a selective inhibitor of the Rac-specific
guanine nucleotide exchange factors (GEFs), Tiam1 and Trio (NSC23766). In a manner
similar to ToxB, selective inhibition of Rac induces CGN apoptosis that is associated
with enhanced caspase-3 activation and reduced phosphorylation of the Rac effector,
p21-activated kinase (PAK). In contrast to ToxB, caspase inhibitors do not protect CGNs
from targeted inhibition of Rac. Also dissimilar to ToxB, selective inhibition of Rac
neither inhibits MEK1/2/ ERK1/2 nor activates JNK/c-Jun. Targeted inhibition of Rac
instead suppresses distinct MEK5/ERK5, p90Rsk and Akt-dependent signaling cascades
known to regulate the localization and expression of the Bcl-2 homology-3 domain
(BH3)-only protein Bad. Adenoviral expression of a constitutively active mutant of
MEK5 is sufficient to attenuate neuronal cell death induced by selective inhibition of Rac
with NSC23766, but not apoptosis induced by global inhibition of Rho GTPases with
ToxB. Collectively, these data demonstrate that global suppression of Rho family
GTPases with ToxB causes a loss of MEK1/2/ERK1/2 signaling and activation of JNK/c72

Jun, resulting in diminished degradation and enhanced transcription of the BH3-only
protein Bim. In contrast, selective inhibition of Rac induces CGN apoptosis by repressing
unique MEK5/ERK5, p90Rsk, and Akt-dependent pro-survival pathways, ultimately
leading to enhanced expression, dephosphorylation, and mitochondrial localization of
pro-apoptotic Bad.
3.2 Introduction
Rho family GTPases belong to the Ras superfamily of monomeric G-proteins and
include the well described proteins Rac, Rho, and Cdc42. While Rho GTPases are best
recognized for their prominent roles in regulating actin cytoskeletal dynamics, more
recent studies have demonstrated an important role for Rho GTPases in regulating
neuronal survival (Linseman and Loucks, 2008). Indeed, apoptosis induced by inhibitors
of 3-HMG-CoA reductase (statins) was correlated with loss of plasma membraneassociated Rho GTPase family members in rat cortical neurons (Tanaka et al., 2000), and
downregulation of Rho family GTPases is closely associated with an increase in neuronal
apoptosis (Desagher et al., 2005). More recently, Rac has been highlighted as a specific
member of the Rho GTPase family critical for maintaining neuronal survival. For
example, prior studies demonstrated that either dominant negative Rac expression or
siRNA-mediated knockdown of the Rac GEF, Alsin (ALS2), induces apoptosis of
cultured motor neurons (Topp et al., 2004; Jacquier et al., 2006).

The critical

involvement of Rac in neurodegeneration is further evidenced by studies demonstrating
that loss-of-function mutations in ALS2 are causative in juvenile onset ALS (Yamanaka
et al., 2003). Collectively, these data highlight Rac as a crucial modulator of neuronal
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survival and suggest that Rac dysregulation may underlie some forms of
neurodegenerative disease.
In previous studies, we have examined the neurotoxic effects of the large
cytotoxin Clostridium difficle toxin B (ToxB) in CGNs. ToxB monoglucosylates a key
threonine residue in the switch 1 region of Rho GTPases, preventing Rho, Rac, and
Cdc42 from interacting with their downstream effectors (Just et al., 1995). Global
inhibition of Rho GTPases with ToxB induces CGN apoptosis through dysregulation of
critical pro-survival and pro-apoptotic signaling cascades (Loucks et al., 2006;
Stankiewicz et al., 2012). Specifically, ToxB induces downregulation of Rac1 GTPase,
as well as elements of a Rac-dependent mitogen-activated protein (MAP) kinase
pathway, including the p21-activated kinase (PAK), MAP kinase kinase (MEK)1/2, and
extracellular signal-regulated kinase (ERK)1/2 signaling cascade. Inhibition of this
pathway in CGNs induces apoptosis, in part, through reduced degradation of the proapoptotic BH3-only protein Bim.

In addition to repression of a pro-survival

MEK1/2/ERK1/2 signaling cascade, we have previously reported that broad Rho GTPase
inhibition with ToxB induces CGN death through activation of a c-Jun N-terminal kinase
(JNK)/c-Jun pathway that stimulates transcription of Bim (Le et al., 2005). Thus, ToxB
globally suppresses Rho GTPase function and induces CGN apoptosis through
dysregulation of specific MAP kinase signaling cascades, leading to enhanced expression
and diminished degradation of the pro-apoptotic BH3-only protein Bim.
The focus of the current study was to compare the effects of ToxB on neuronal
survival to those of a more targeted inhibitor of Rac GTPase. While ToxB has been
shown to inhibit Rac, Rho, and Cdc42, NSC23766 suppresses a more discrete pool of
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Rho family GTPases through inhibition of the Rac-specific GEFs, Tiam1 and Trio, which
are two of the most prominent regulators of Rac in the brain (Schmidt and Hall, 2002).
The application of this targeted Rac inhibitor allows for a refined understanding of the
Rho-family GTPase-regulated signaling pathways essential to neuronal survival.
Contrary to our results with ToxB, we demonstrate that targeted inhibition of Rac with
NSC23766 does not turn off pro-survival MEK1/2/ERK1/2 signaling in CGNs, nor does
it activate the JNK/c-Jun cascade. Instead, NSC23766 induces apoptosis via repression
of the distinct MAP kinase pathway, MEK5/ERK5. Further establishing these findings,
adenoviral expression of constitutively active MEK5 significantly protects CGNs from
NSC23766-mediated Rac inhibition but is unable to protect CGNs from ToxB-mediated
global Rho GTPase inhibition. We report that loss of MEK5/ERK5 signaling in
NSC23766-treated CGNs results in deactivation of the downstream effectors p90Rsk and
Akt, leading to induction, dephosphorylation, and mitochondrial localization of the BH3only, pro-apoptotic protein Bad. These findings are novel in that they are the first to
distinguish the precise MAP kinase signaling pathways that regulate neuronal apoptosis
in response to selective inhibition of Rac versus global suppression of Rho family
GTPases.
3.3 Materials and Methods
3.3.1 Reagents
NSC23766, JNK inhibitor II (SP600125), caspase inhibitors BOC, LEHD, and QVD
(Non-O-Methylated) were obtained from Calbiochem (San Diego, CA). Clostridium
difficile Toxin B was prepared using a method published previously (Just et al., 1995).
The monoclonal antibody for active Rac1 was procured from NewEast Biosciences
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(Malvern, PA). Hoechst dye 33258 and 4,5-di-amidino-2-phenylindole (DAPI) were
purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal antibody to
active caspase-3 was from Promega (Madison, WI). Cy3- and FITC-conjugated
secondary antibodies for immunoflourescence were from Jackson Immunoresearch
Laboratories (West Grove, PA). The CellQuanti-MTT viability assay kit was obtained
from Bioassay Systems (Hayward, CA). The monoclonal β-tubulin antibody conjugated
to Alexa Fluor® 555, polyclonal antibodies for pPAK1 (Ser144)/pPAK2 (Ser 141),
PAK1/2/3,

pERK1/2

(Thr202/Tyr204),

pMEK1/2

(Ser217/

221),

pERK5

(Thr218/Tyr220), pAkt (Ser473), ERK5, and the monoclonal antibodies against Actin, cJun, and pBad (Ser136), pP90Rsk (Ser380) were purchased from Cell Signaling
Technology (Beverly, MA). Polyclonal antibodies for pMEK5 (S311/T315) and MAP2
monoclonal were obtained from Abcam (Cambridge, MA). The monoclonal antibody
used to detect β-tubulin was purchased from Sigma (St. Louis, MO), The rabbit
monoclonal antibody for Bad (N-term) was purchased from Millipore (Billerica, MA).
Horseradish peroxidase-linked secondary anti-bodies and reagents for enhanced
chemilumine-scence detection were from Amersham Bio-sciences (Piscataway, NJ,
USA).
3.3.2 CGN culture
CGNs were isolated from 7-day old Sprague-Dawley rat pups of both sexes (1519 g) as described previously (Linseman et al., 2001). Briefly, neurons were plated on 35mm diameter plastic dishes coated with poly-L-lysine at a density of approximately 2.0 x
106 cells/mL in basal modified Eagle’s medium containing 10% fetal bovine serum,
25mM KCl, 2mM L-glutamine, and penicillin (100 units/mL)/streptomycin (100 µg/mL)
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(Life Technologies, Grand Island, NY).

At 24 h after plating the CGNs, cytosine

arabinoside (10 µM) was added to the culture medium to limit the growth of nonneuronal cells. In general, experiments were performed after 6-7 days in culture.
3.3.3 Cell lysis and immunoblotting
Following treatments as described in the Results section, cell lysates were
prepared for Western blotting as previously described (Loucks et al., 2006). The protein
concentration of the samples was determined using a protein assay kit (BCA,
Thermoscientific, PA, USA) and SDS-polyacrylamide gel electrophoresis was performed
using equal amounts of protein followed by transfer to polyvinylidene difluoride (PVDF)
membranes (Amersham Biosciences). The entire PVDF membranes, once processed,
were blocked in PBS (pH 7.4) containing 0.1% Tween 20 (PBS-T) and 1% bovine serum
albumin (BSA) for 1 h at room temperature (25°C). Subsequently, membranes were
incubated for 1 h with primary antibodies diluted in blocking solution. Excess primary
antibody was removed by washing the membranes with PBS-T five times over 25 min.
The corresponding horseradish peroxidase-conjugated secondary antibodies diluted in
PBS-T were incubated with the membranes for 1 h following the washes. Excess
secondary antibody was removed by washing with PBS-T five times over 25 min.
Immunoreactive proteins were detected by enhanced chemiluminescence.
3.3.4 Immunofluorescence microscopy
After treatment, CGNs were washed once with PBS (1 mL/well) and then fixed
in 4% paraformaldehyde (1 mL/well) for 1 h at room temperature (25°C). Cells were
washed once with PBS (1 mL/well) and then permeabilized and blocked in 0.2% Triton
X-100 and 5% BSA in PBS (pH 7.4). Primary antibodies were diluted in 2% BSA and
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0.2% Triton X-100 in PBS. Cells were incubated in the primary antibody for 1 h at room
temperature or overnight at 4°C depending on the antibody. After incubation, cells were
washed five times in PBS (5 minutes per wash) and then incubated for 1 h at 25°C with
Cy3- or FITC-conjugated secondary antibodies and DAPI diluted in 2% BSA and 0.2%
Triton X-100 in PBS. Following the second incubation, neurons were washed an
additional five times with PBS (5 minutes per wash) before the addition of anti-quench
(0.1% p-phenylenediamine in 75% glycerol) in PBS. Fluorescent images were captured
by using a 63x oil immersion objective on a Zeiss Axioplan 2 microscope equipped with
a Cooke Sensicam deep-cooled charge-coupled device (CCD) camera and a Slidebook
software-analysis program for digital deconvolution (Intelligent Imaging Innovations,
Inc., Denver, CO).
3.3.5 Quantification of apoptosis
Following treatment, Hoechst dye (8µg/mL, final concentration) was added
directly to each well and incubated at 25°C for 30 minutes to stain CGN nuclei. Cells
were then washed with PBS (1mL/well) and fixed by incubation in 4% paraformaldehyde
(in PBS) for 30 minutes at 25°C. Cells were subsequently washed twice with PBS
(1mL/well). To quantify apoptosis CGNs displaying condensed chromatin or nuclear
fragmentation were scored as apoptotic. Approximately 300 neurons were counted in a
minimum of three 63x fields of a 35-mm dish, and final counts represent data collected
from a minimum of three independent experiments performed in duplicate.
3.3.6 MTT viability assay
Following treatment, 187.5 µL of CellQuanti-MTT assay reagent (calculated at 15
µL per 80 µL of culture medium) was added directly to each well. CGNs were incubated
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for 4 h at 37°C in 10% CO2.

Blanks, wells containing control media alone, were

incubated with 187.5 µL of assay reagent along with samples. Subsequently, the media
was

aspirated

and

DMSO

was

added

(2mL/well).

Following

solubilization

(approximately 10 minutes at room temperature), 200 µL of each blank or sample was
diluted and mixed in spectrophotometer cuvettes containing 800 µL of sterile water.
Samples and blanks were made up in triplicate. Absorbance readings were taken at a
wavelength of 570 nm. Data represent five independent experiments performed in
triplicate.
3.3.7 Adenovirus preparation and infection
Adenoviral constitutively active MEK5 was purchased from Cell BioLabs (San
Diego, CA) and Adenoviral GFP was a kind gift from Marja T. Nevalainen (Thomas
Jefferson University, PA, USA) and was prepared as previously described (Ahonen et al.,
2003). CGNs were infected on day 5 in vitro with 35 moi (multiplicity of infection) of
adenovirus carrying GFP or constitutively active MEK5. At 48 h post-infection, some
cells were treated with 175 µM NSC23766 for an additional 48 h. At 72 h post-infection,
another group of cells were treated with 60 ng/mL ToxB for an additional 24 h. At 96 h
post-infection, cells were fixed for fluorescent imaging and quantification of apoptosis, as
described above.
3.3.8 Data analysis
In general, western blotting observations were based upon three independent
experiments. Graphical data represent the mean ± SEM for the number of independent
experiments performed (n). Statistical differences between the means of unpaired sets of
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data were assessed by one-way ANOVA, and further analyzed using a post hoc Tukey’s
test. A p-value of <0.05 was considered statistically significant.
3.4 Results
3.4.1 The specific Rac inhibitor NSC23766 induces inactivation of Rac-GTP resulting in
CGN apoptosis
The targeted Rac inhibitor, NSC23766, selectively and reversibly hinders
GDP/GTP exchange carried out by the Rac-specific guanine nucleotide exchange factors
(GEFs), Tiam1 and Trio. Specifically, this cell-permeable pyrimidine compound targets a
tryptophan within the GEF binding site, prohibiting Tiam1 and Trio from binding and
activating Rac (Fig. 3.1) (Gao et al., 2004). Consistent with this mechanism of inhibition,
CGNs incubated for 48 h with NSC23766 (200 µM) exhibited significantly decreased
immuno-reactivity for active Rac (Rac-GTP) compared to control CGNs (Fig. 3.2A). The
maintenance of an intact microtubule network, visualized by β-tubulin and MAP2
immunoreactivity, confirmed that the relative lack of Rac-GTP staining observed in
NSC23766-treated cells was not due to the global absence or disruption of cellular
components (Fig. 3.2B, upper panels). Moreover, examination of nuclei by Hoechst
staining revealed significantly increased apoptotic cell death in NSC23766-treated CGNs
compared to untreated controls as evidenced by nuclear fragmentation and/or
condensation (Fig. 3.2B, lower panels and 3.2C). Collectively, these data indicate that the
targeted inhibition of a select pool of Rac GTPase activated by Tiam1 and Trio is
sufficient to induce CGN apoptosis.
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Figure 3.1 NSC23766 acts by specifically inhibiting the activation of Rac by GEFs
Tiam1 and Trio. A. Chemical structure of NSC23766. B. The cell-permeable pyrimidine
compound selectively and reversibly hinders GDP/GTP exchange carried out by the Racspecific guanine nucleotide exchange factors (GEFs), Tiam 1 and Trio. Specifically,
NSC23766 targets a key tryptophan residue within the GEF binding site, prohibiting
Tiam1 and Trio from binding and activating Rac.
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Figure 3.2 The specific Rac inhibitor NSC23766 reduces activation of Rac1,
resulting in CGN apoptosis. CGNs were incubated for 48 h in either control medium
alone (Con) or containing NSC23766 (200 µM; NSC). A. Cells were then fixed and their
nuclei stained with DAPI. Active Rac1 was visualized using a monoclonal antibody that
specifically detects Rac1-GTP and a FITC-conjugated secondary antibody. Scale bar = 10
microns. B. Cells were fixed and their nuclei stained with DAPI. The microtubule
network was visualized using a monoclonal antibody for β-tubulin conjugated with Cy3
Alexa Fluor 555 and a mouse monoclonal MAP2 antibody followed by a FITCconjugated secondary antibody. While the microtubule network remains largely intact,
CGNs display condensed or fragmented nuclei characteristic of apoptosis following
treatment with NSC23766. Bottom panels: black and white images of DAPI-stained
nuclei. Scale bar = 10 microns. C. Quantification of CGN apoptosis. Hoechst-stained
CGNs displaying condensed and/or fragmented nuclei were scored as apoptotic. Data
represent the mean ± SEM of four independent experiments. **Significantly different
from control (p< 0.01). I acknowledge Anandi Ramaswami for assistance with
generating data for this figure.
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3.4.2 CGN death induced by NSC23766 is largely caspase-independent
To determine whether NSC23766-mediated CGN death occurs via a mechanism
that is dependent upon activation of caspases, we examined activation of caspase-3 as its
proteolytic cleavage signifies commitment to apoptotic cell death (Porter and Jänicke,
1999). In agreement with this mechanism of cell death, CGNs treated with NSC23766
displayed increased immunoreactivity for active (cleaved) caspase-3 (Fig. 3.3A). To
definitively establish the involvement of caspase-3 activation in NSC23766-mediated
CGN death, we next examined the potential protective effects of caspase inhibitors. CGN
viability assessed by an MTT assay was notably reduced in NSC23766-treated cells
compared to untreated controls; however, inclusion of either BOC or QVD, pan-caspase
inhibitors, had no apparent protective effects against this Rac inhibitor (Fig. 3.3B). In
marked contrast, BOC and LEHD, a pan-caspase and caspase-9-selective inhibitor,
respectively, significantly protected CGNs treated with the global Rho GTPase inhibitor
ToxB (Fig. 3.3C). These data suggest that CGN death induced by targeted inhibition of
Rac GTPase occurs via a mechanism that involves a dispensable activation of caspase-3.
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Figure 3.3 CGN death induced by NSC23766 is largely caspase-independent, unlike
Toxin B-induced apoptosis. A. Cells were incubated for 48 h in either control medium
alone (Con) or containing NSC23766 (200 µM; NSC). Cells were then fixed and their
nuclei stained with DAPI. Active caspase-3 was visualized using a polyclonal antibody
and a Cy3-conjugated secondary. NSC23766 treatment causes increased activation of
caspase-3 in CGNs (See arrows) Scale bar = 10 microns. B. Cells were incubated for 48 h
in either Con medium or medium containing NSC23766 (200 µM; NSC) ± either BOC
(50 µM) or QVD (20 µM). Percentage cell viability was measured by the reduction of
MTT. The Con was set as the standard at 100% cell viability. Data represent the mean ±
SEM of five independently performed experiments. *Significantly different from control
(p< 0.05); NS = No significant difference between NSC and NSC co-treated with caspase
inhibitors (BOC or QVD). C. Cells were incubated for 24 h in either Con medium or
medium containing ToxB (60 ng/mL) ± BOC (50 µM) or LEHD (100 µM; a caspase-9
inhibitor). Data represent the mean ± SEM of four independently performed experiments.
*Significantly different from control (p< 0.05); †† Significantly different from ToxB (p<
0.01). I acknowledge Anandi Ramaswami for assistance with generating data for this
figure.
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3.4.3 NSC23766 reduces the phosphorylation of PAK, but does not suppress the
downstream MEK1/2 and ERK1/2 signaling cascade in CGNs
We have previously reported that broad Rho GTPase inhibition with ToxB
deactivates a pro-survival MAP kinase signaling cascade involving PAK1/2/3, MEK1/2,
and ERK1/2. Thus, we examined if this signaling cascade was similarly suppressed in
NSC23766-treated CGNs. While decreased levels of pPAK1/2/3 were detected in CGNs
incubated with NSC23766 for 48 h, specific Rac inhibition did not result in decreased
phosphorylation of MEK1/2 or ERK1/2 (Fig. 3.4). These data suggest that targeted
inhibition of a select pool of Rac activated by Tiam1 and Trio in CGNs induces cell death
through a mechanism that is distinct from global inhibition of Rho GTPases with ToxB.
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Figure 3.4 NSC23766 reduces the phosphorylation of PAK, but does not suppress
the downstream MEK1/2 and ERK1/2 signaling cascade in CGNs. CGNs were
incubated for 48 h in either control medium alone (Con) or containing NSC23766 (200
µM; NSC). Cells were then lysed, proteins were resolved using SDS-PAGE, and PVDF
membranes were immunoblotted with antibodies to pPAK1/2, total PAK1/2/3, pMEK1/2,
pERK1/2, and Actin. The blots shown are representative of three independent
experiments. I acknowledge Anandi Ramaswami for assistance with generating data for
this figure.
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3.4.4 NSC23766, but not ToxB, decreases MEK5/ERK5 phosphorylation in CGNs
The above results suggested the possibility that the more targeted Rac inhibitor
may work through suppressing MEK5 and ERK5, components of an alternative MAP
kinase signaling cascade, to repress pro-survival signaling downstream of Rac and PAK.
Indeed, immunoblot analysis indicated that NSC23766 treatment caused decreased
phosphorylation of both MEK5 and ERK5 in CGNs. Conversely, ToxB treatment had
little to no effect on either pMEK5 or pERK5 expression in CGNs (Fig. 3.5). These data
indicate that the targeted inhibition of Rac GTPase may elicit cell death via deactivation
of an alternative pro-survival MAP kinase pathway downstream of PAK, MEK5/ERK5,
when compared to ToxB-treated CGNs.
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Figure 3.5 NSC23766, but not ToxB, decreases MEK5/ERK5 phosphorylation in
CGNs. CGNs were incubated in either control medium alone (Con), medium containing
NSC23766 (200 µM; NSC) for 48 h, or medium containing ToxB (60 ng/mL) for 24 h.
Cells were then lysed, proteins were resolved using SDS-PAGE, and PVDF membranes
were immunoblotted with antibodies to pMEK5, pERK5, and total ERK5. The blots
shown are representative of three independent experiments. I acknowledge Anandi
Ramaswami for assistance with generating data for this figure.
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3.4.5 NSC23766 treatment in CGNs induces dephosphorylation of p90Rsk and Akt,
leading to the upregulation and mitochondrial localization of the pro-apoptotic BH3-only
protein Bad
A recent study demonstrated that neuronal cell death induced by deletion of
ERK5 is correlated with a marked decrease in phosphorylation of p90Rsk and Akt
(Finegan et al., 2009). To determine if the loss of ERK5 phosphorylation induced by
selective inhibition of Rac has a similar effect in CGNs, we examined the
phosphorylation of p90Rsk and Akt in NSC23766-treated CGNs. Consistent with this
previous study, we report distinct decreases in phosphorylated p90Rsk and Akt in
NSC23766-treated CGNs when compared to controls (Fig. 3.6A and 3.6B). One of the
shared pro-survival functions of p90Rsk and Akt is to suppress the expression of Bad via
repression of Bad transcription by the cAMP response element-binding protein (CREB)
(Bonni et al., 2009; Finegan et al., 2009). Bad is a member of the Bcl-2 family of
proteins that promotes apoptosis through its ability to heterodimerize with, and thus
inhibit, pro-survival members of this family, such as Bcl-xL (Kelekar et al., 1997; Kitada
et al., 1998). We report that treatment with the targeted Rac inhibitor, NSC23766,
resulted in upregulation of pro-apoptotic Bad, an effect that was not observed with ToxB
(Fig. 3.6C). Interestingly, both of the inhibitors also triggered the cleavage of Bad (Fig.
3.6C), producing a 15kDa truncated form of the protein which is reportedly a more potent
inducer of apoptosis (Condorelli et al., 2001).
We next examined Bad phosphorylation as it has been demonstrated that the
addition of a phosphate group at either Ser112 or Ser136 inactivates the pro-apoptotic
function of Bad by sequestering the protein away from the mitochondria to 14-3-3
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scaffolding proteins in the cytosol (Zha et al., 1996). While we did not detect a change in
pBad (Ser112; data not shown), expression of pBad (Ser136) was markedly reduced in
NSC23766-treated, but not ToxB-treated, CGNs (Fig. 3.6D). Prior reports have
characterized a critical pro-survival function for Akt–dependent phosphorylation of Bad
at Ser136 (Datta et al., 1997; del Peso et al., 1997). In agreement with these studies,
NSC23766-treated CGNs also displayed a marked reduction in pAkt (Ser473; Fig. 3.6B).
In contrast, we have previously reported that ToxB treatment does not alter the
phosphorylation of Akt in CGNs (Linseman et al., 2001). Because the Akt-mediated
phosphorylation of Bad targets it to 14-3-3 scaffolding proteins in the cytosol, we next
analyzed if the dephosphorylation of Bad induced by inhibition of Rac was associated
with translocation of this BH3-only protein to mitochondria. Immunofluorescent staining
for Bad in control CGNs revealed a diffuse localization in the cytosol of the cell bodies
with little detectable staining in cell processes (Fig. 3.6E, left panels). In ToxB-treated
CGNs, a similar distribution of Bad was observed in cells not actively undergoing
apoptosis, while clearly apoptotic cells displayed undetectable levels of Bad expression
(Fig. 3.6E, right panels). In marked contrast to these results, CGNs incubated with the
selective Rac inhibitor, NSC23766, showed a striking redistribution of Bad to neuronal
processes and an overall punctuate distribution of the protein (Fig. 3.6E, middle panels).
To establish if the punctuate appearance of Bad induced by the inhibition of Rac was due
to its translocation to mitochondria, CGNs were subfractionated into mitochondrial and
cytosolic fractions which were then immunoblotted for Bad. In control CGNs Bad was
exclusively localized to the cytosolic fraction, while in NSC2376-treated CGNs Bad was
exclusively found in the mitochondrial fraction (Fig. 3.6F). Collectively, these data
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indicate that targeted inhibition of Rac with NSC23766 induces CGN apoptosis by
turning off p90Rsk and Akt, likely downstream of MEK5/ERK5, leading to enhanced
expression, dephosphorylation, and mitochondrial localization of pro-apoptotic Bad. In
contrast, neither Bad desphosphorylation nor Bad translocation to mitochondria appears
to be induced by ToxB.
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Figure 3.6 NSC23766 treatment in CGNs deactivates p90Rsk and Akt leading to
increased expression, dephosphorylation, and mitochondrial localization of the proapoptotic BH3-only protein Bad. A. CGNs were incubated in either control medium
alone (Con) or medium containing NSC23766 (200 µM; NSC) for 48 h. Cells were then
lysed, proteins were resolved using SDS-PAGE, and PVDF membranes were
immunoblotted with antibodies to phospho-p90Rsk and subsequently stripped and
reprobed for β-tubulin as a loading control. B. CGNs were incubated in either control
medium alone (Con) or medium containing NSC23766 (200 µM; NSC) for various
periods up to 48 h. Cell lysates were prepared for immunoblotting as described in (A) and
PVDF membranes were blotted for pAkt (Ser473). Subsequently, membranes were
stripped and reprobed for Actin as loading control. C. CGNs were treated and prepared
for immunoblotting as described in (A) with the addition of a ToxB-treated condition for
24 h. Cell were lysed and PVDF membranes were blotted for total Bad and subsequently
stripped and reprobed for Actin as a loading control. D. CGNs were incubated as
described in (C). Cell lysates were prepared and PVDF membranes were blotted for pBad
(Ser136) and subsequently stripped and reprobed for Actin as a loading control. E. CGNs
were incubated as described in (C). Cells were then fixed and their nuclei stained with
DAPI. Bad was visualized using a polyclonal antibody and a Cy3-conjugated secondary.
Images are representative of three independent experiments. Scale bar = 10 microns. F.
CGNs were incubated as described in (C) and cells were subfractionated into
mitochondrial and cytosolic fractions. Subcellular fractions were immunoblotted for Bad
and OPA1 (mitochondrial marker). Blots shown are representative of three independent
experiments.
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3.4.6 Unlike ToxB, NSC23766 treatment does not activate a pro-apoptotic JNK/cJun/Bim pathway in CGNs
We have previously shown that ToxB-mediated repression of MEK1/2/ERK1/2
signaling induces intrinsic apoptosis of CGNs via decreased phosphorylation, and thus
diminished degradation, of the pro-apoptotic BH3-only protein Bim (Loucks et al., 2006).
In addition, we revealed that ToxB-treated CGNs displayed increased activation of a
JNK/c-Jun signaling cascade that led to enhanced transcription of Bim (Le et al., 2005).
Therefore, we next examined whether targeted inhibition of Rac in CGNs had a similar
effect on c-Jun and/or Bim. NSC23766-treated CGNs did not display increased c-Jun
expression at any time point up to 48 h. As expected, ToxB treatment elevated c-Jun
expression in CGNs within 8 h of treatment (Fig. 3.7A). To investigate the potential
involvement of JNK activation in promoting CGN death downstream of Rac inhibition,
we examined the neuroprotective effects of the JNK inhibitor SP600125 (JNK Inh).
While inclusion of the JNK Inh did not significantly protect CGNs from selective Rac
inhibition with NSC23766, the inhibitor significantly mitigated CGN apoptosis in
response to ToxB treatment (Fig. 3.7B, and 3.7C). Consistent with activation of a prodeath JNK/c-Jun signaling pathway acting upstream of the BH3-only protein Bim, the
expression of Bimshort was elevated in ToxB-treated CGNs. In contrast, we did not detect
an increase in Bim expression in NSC23766-treated CGNs at any time point up to 48 h
(Fig. 3.7D). These results indicate that broad inhibition of Rho GTPases with ToxB
elicits CGN apoptosis primarily through the upregulation of Bim in a JNK/c-Jundependent manner, while neither JNK/c-Jun signaling nor Bim appear to play a
significant role in NSC23766-mediated CGN death.
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Figure 3.7 Unlike ToxB, NSC23766 treatment does not activate a pro-apoptotic
JNK/c-Jun/Bim pathway in CGNs. A. CGNs were incubated in either control medium
alone (Con), medium containing ToxB (60 ng/mL), or medium containing NSC23766
(200 µM; NSC) for various periods up to 8 h and 48 h, respectively. Cells were then
lysed, proteins were resolved using SDS-PAGE, and PVDF membranes were
immunoblotted with an antibody against c-Jun and subsequently stripped and reprobed
for Actin as a loading control. B. CGNs were incubated in either control medium alone
(Con), medium containing ToxB (40ng/mL) for 24 h, or medium containing NSC23766
(200 µM; NSC) for 48 h. In addition, some cells were exposed to NSC or ToxB in the
presence of the JNK inhibitor (JNK inhibitor; 20 µM). Cells were then fixed and their
nuclei stained with Hoescht dye. C. Quantification of CGN apoptosis from three
independent experiments conducted as described in (B). *** Significantly different from
Con (p<0.001); ††† Significantly different from ToxB (p<0.001); NS = no significant
difference from NSC. D. CGNs were incubated in either control medium alone (Con),
medium containing ToxB (60 ng/mL) for 8 h, or medium containing NSC23766 (200
µM; NSC) for various periods up to 48 h. Cells were then lysed, proteins were resolved
using SDS-PAGE, and PVDF membranes were immunoblotted with an antibody against
Bim and subsequently stripped and reprobed for β-tubulin as a loading control. Blots
shown are representative of three independent experiments.
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3.4.7 Adenoviral infection with constitutively active MEK5 protects CGNs from
NSC23766 treatment, but not ToxB.
To definitively establish the precise MAP kinase signaling pathway that is
deactivated in CGNs exposed to NSC23766-targeted Rac inhibition versus ToxBmediated global Rho GTPase inhibition, we examined the protective effects of an
adenoviral constitutively active mutant of MEK5 (Ad-CA MEK5), in which the dual
phosphorylation site S311/S315 has been changed to D311/D315. Infection with Ad-CA
MEK5, but not Ad-GFP, increased the expression of MEK5 in CGNs (Fig. 3.8A). It is
important to note that neither adenoviral construct increased the basal level of apoptosis
on their own (data not shown). As we have previously shown, global inhibition of Rho
GTPases with ToxB resulted in significant CGN apoptosis (Fig. 3.8B). Consistent with
ToxB inducing death through a mechanism independent of MEK5/ERK5 signaling, preincubation of CGNs with either Ad-GFP or Ad-CA MEK5 did not confer significant
protection against ToxB treatment (Fig. 3.8B and 3.8C). Conversely, while CGNs
exposed to selective inactivation of Rac GTPase with NSC23766 showed condensed and
fragmented nuclei indicative of apoptotic cell death, CGNs pre-incubated with Ad-CA
MEK5, but not Ad-GFP, displayed nuclear morphology strikingly more similar to
controls (Fig. 3.8D). Quantification of these results demonstrated that adenoviral
infection with Ad-CA MEK5 significantly protected CGNs from NSC23766 treatment
(Fig. 3.8E). It is worth noting that the protection conferred in CGNs pre-incubated with
Ad-CA MEK5 and subsequently treated with NSC23766 was not complete, presumably
because the infection efficiency was approximately 40-50% as estimated by the
percentage of CGNs expressing Ad-GFP. Nonetheless, these results further corroborate
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that selective inactivation of Rac GTPase versus global inhibition of Rho GTPases
induces CGN death through deactivation of unique pro-survival MAP kinase signaling
pathways.
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Figure 3.8 Adenoviral infection with constitutively active MEK5 protects CGNs
from NSC23766 treatment, but not ToxB. A. CGNs were incubated in control medium
(Con) or infected for 48 h with an adenovirus carrying GFP (Ad-GFP) or constitutively
active MEK5 (Ad-CA MEK5). Cell lysates were separated by SDS-PAGE, transferred to
PVDF membranes, and immunoblotted for MEK5 expression. Blots were subsequently
stripped and reprobed for actin expression. B. CGNs were infected for 48 h with either
Ad-GFP or Ad-CA MEK5. After the 48 h incubation period, CGNs were treated with
ToxB (40ng/mL) for an additional 24 h as indicated. At the end of the incubation, cells
were fixed and nuclei were stained with DAPI. Scale bar = 10 microns. C. Quantification
of apoptosis from cells treated as described in (B) D. CGNs were infected for 48 h with
either Ad-GFP or Ad-CA MEK5. After the 48 h incubation period, CGNs were treated
with NSC23766 (NSC; 175 µm) for an additional 48 h as indicated. At the end of the
incubation, cells were fixed and nuclei were stained with DAPI. Scale bar = 10 microns.
E. Quantification of apoptosis from cells treated as described in (D). Data represent the
mean ± S.E. of three independently performed experiments. *Significantly different from
control (p< 0.05); *** Significantly different from control (p< 0.001); † Significantly
different from NSC (p< 0.05). NS denotes not significant.
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3.5 Discussion
While a number of studies have highlighted a critical pro-survival role for Rho
family GTPases in various neuronal cell types (Linseman et al., 2001; Kobayashi et al.,
2004; Kanekura et al., 2005; Le et al., 2005; Loucks et al., 2006; Stankiewicz et al.,
2012), the mechanisms by which these G-proteins induce their neuroprotective effects
remain largely unknown. In previous studies, we have utilized Clostrium difficile ToxB
as a selective inhibitor of Rac, Rho, and Cdc42 to reveal that PAK/MEK/ERK and
JNK/c-Jun signaling cascades, components of the Rac-activated MAP kinase pathway,
critically regulate CGN survival (Le et al., 2005; Loucks et al., 2006). To advance our
understanding of Rho family GTPases in neuronal survival, we compared the effects of
ToxB to NSC23766, an inhibitor which specifically prevents Rac activation by the GEFs
Tiam1 and Trio (Gao et al., 2004). Initial results confirmed that NSC23766 promotes
CGN death through the loss of GTP-bound (active) Rac. However, while both ToxB and
NSC23766 induce CGN death in the presence of serum and depolarizing potassium, our
current study indicates that CGNs succumb to cell death via unique signaling pathways in
response to specific Rac inhibition versus global Rho GTPase inhibition.
Similar to ToxB, NSC23766 induces activation of caspase-3 in CGNs; however,
while ToxB-induced CGN death was sensitive to caspase inhibitors, the effects of
NSC23766 on neuronal death were not mitigated to a significant degree by co-incubation
with pan-caspase inhibitors. This is a key point of divergence between the effects of
ToxB and NSC23766 on neuronal survival and indicates that NSC23766 is capable of
promoting CGN death through a caspase-independent pathway. Given the antagonistic
relationship between Rac and Rho signaling, it is possible that specific inhibition of only
98

Rac via NSC23766 unmasks a Rho-dependent pathway that does not rely on caspase
activation for the execution of CGN death. Indeed, Rac directly suppresses Rho activity
through binding and activating the Rho GAP, p190RhoGAP, in HeLa cells (Wildenberg
et al., 2006). Moreover, the downstream effector of Rac, PAK, has been shown to
regulate the activation of Rho through GEFs in a variety of cell types (Hakoshima et al.,
2003). Consistent with this idea, Rho has been demonstrated to sensitize
corticohippocampal neurons to cell death (Barberan et al., 2011), and inhibition of the
Rho effector, ROCK, exerts a neuroprotective effect in various in vitro and in vivo
models of neuronal cell death such as, cerebral ischemia and excitotoxicity (Rikitake et
al., 2005; Jeon et al., 2013). In addition to ROCK, Rho GTPase has many other
downstream effectors that could contribute to neuronal death via a mechanism that is
independent of caspase activation.
The second contrast between the activities of ToxB and NSC23766 was apparent
in their divergent effects upon MAP kinase signaling. While ToxB suppressed
MEK1/2/ERK1/2 signaling, the selective Rac inhibitor had no effect of this MAP kinase
pathway and instead suppressed a unique MEK5/ERK5 cascade. Indeed, adenoviral
expression of constitutively active MEK5 was only sufficient to mitigate the toxic effects
of the selective Rac inhibitor, NSC23766, in CGNs and displayed no protective effect
against global Rho GTPase inhibition with ToxB. It is possible that this stark contrast
may be attributed to differential regulation of PAK. Upstream of the MEK/ERK signaling
cascades, both Rho family GTPase inhibitors reduced the phosphorylation of PAK in
CGNs. However, one limitation of these findings is that although we have utilized an
antibody that detects phosphorylation of PAK1/2/3, there are six known isoforms of
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PAK. Thus, regulation of unique MAP kinase pathways in response to Rac inhibition
may be a result of differential inactivation of specific PAK isoforms. Furthermore, an
additional member of the Rho GTPase family that is inhibited by ToxB, Cdc42, also
regulates PAK activity in a manner similar to Rac (Kreis et al., 2007). Inactivation of
distinct PAK isoforms in response to targeted inhibition of Rac versus global inhibition
of Rho GTPases may represent a key point at which the signaling cascades regulated by
these inhibitors deviate.
Although deactivation of specific PAK isoforms is a potential point at which the
signaling cascades regulated by distinct Rho family GTPases may diverge, this could also
be accomplished downstream of PAK signaling through mitogen-activated protein kinase
kinase kinases (MEKKs). MEKKs are upstream regulators of MAP kinase pathways,
such as MEK/ERK, c-Jun NH2-terminal kinases (JNK), and p38 (Fanger et al., 1997; Sun
et al., 2001). As the most well studied MAP kinase signaling pathway, MEK1/2
activation has largely been attributed to MEKKs that belong to the Raf family of proteins
(i.e., A-Raf, Raf-1, B-Raf). This may be a critical point of divergence in MEK/ERK
signaling as recent studies have demonstrated that MEKK2 and MEKK3 specifically
activate the downstream effector MEK5 via heterodimerization of a PB1 domain that is
specific to MEKK2, MEKK3, and MEK5 (Sun et al., 2001; Nakamura and Johnson,
2003). Furthermore, while both MEKK2 and MEKK3 bind to MEK5 and activate the
MEK5/ERK5 pathway, it was shown that MEKK2 binds MEK5 with higher affinity,
stimulating ERK5 activity to a greater extent (Sun et al., 2001). Collectively, these
previous studies suggest that the distinct MAP kinase pathways which are deactivated by
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either ToxB or NSC23766 in CGNs may diverge downstream of PAK at the level of
specific MEKK activation.
Overall, these data suggest that CGN death triggered by the targeted inhibition of
a select pool of Rac activated by the GEFs Tiam1 and Trio, involves the suppression of a
MEK5/ERK5 signaling cascade to induce apoptosis. This is in agreement with previous
studies highlighting a critical pro-survival function for ERK5 in dopaminergic neurons,
as well as, sympathetic neurons (Cavanaugh et al., 2006; Finegan et al., 2009). Moreover,
past studies have indicated that ERK5 is activated by MEK5 but not by MEK1 or MEK2,
speaking to the highly specific nature of the MEK5/ERK5 interaction (English et al.,
1995; Zhou et al., 1995). Finally, others have demonstrated that Rac1 can signal to
MEK5/ERK5 (Cheng et al., 2012). This Rac effect presumably occurs through PAKmediated activation of MEKK2/3 and their subsequent activation of MEK5 (Porter et al.,
1999; Nakamura and Johnson, 2003). Thus, selective inhibition of Rac is capable of
suppressing a putative PAK/MEKK2/3/MEK5/ERK5 pro-survival pathway.
Previous experimentation has shown that ERK5 is capable of triggering a
phosphorylation cascade that results in the phosphorylation of the MAPK-activated
kinase, p90Rsk, and the subsequent activation of the transcription factor cAMP response
element binding protein (CREB), which regulates transcription of pro-survival and proapoptotic genes in neurons, including repression of the pro-apoptotic Bad gene (Watson
et al., 2001; Park and Cho, 2006; Ranganathan et al., 2006; Ha and Redmond, 2008).
Accordingly, recent findings in neurons indicate that, in the absence of ERK5,
phosphorylation of p90Rsk is impaired and cell death is elicited in a Bad-dependent
manner (Finegan et al., 2009). Consistent with the observed reduction in phosphorylated
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p90Rsk in response to NSC23766, we report that NSC23766 treatment also elicited
upregulation of Bad in CGNs. Given that ToxB did not enhance Bad expression, it
appears that deactivation of p90Rsk is unique to NSC23766-treated CGNs. Interestingly,
both NSC23766 and ToxB induced the cleavage of Bad, generating elevated levels of a
15kDa cleavage product. This is consistent with a previous report which revealed that
caspase cleavage of Bad at its N-terminus produces a 15 kDa truncated form of Bad that
is a more effective inducer of apoptosis than the full length protein (Condorelli et al.,
2001). However, given that pan-caspase inhibitors do not protect NSC23766-treated
CGNs to a significant extent, our data suggest that caspase cleavage of Bad is not the
prominent mechanism of death in CGNs exposed to NSC23766. Together, these data
suggest an important role for the MEK5/ERK5 pathway in neuronal survival.
Specifically, targeted inhibition of a discrete pool of Rac activated by Tiam1 and Trio
appears to trigger CGN death through repression of a novel pro-survival pathway
involving PAK, possibly MEKK2/3, and the MEK5/ERK5 signaling cascade including
its downstream targets, p90Rsk and Bad (Fig. 3.9).
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Figure 3.9 Conclusion: comparing CGN death induced by NSC23766 and ToxB. The
concluding schematic illustrates the Rac-dependent signaling cascades examined in this
study. A. Pathway regulated by the Rho GTPases Rac, Rho, and Cdc42. B. Pathway
regulated by the specific pool of Rac activated by the GEFs Tiam1 and Trio. Dashed lines
represent hypothesized effects. Our findings suggest that targeted inhibition of the
specific pool of Rac activated by the GEFs, Tiam1 and Trio, promotes CGN death
through an alternative pathway to that employed by the broad-spectrum Rho family
inhibitor, ToxB. These pathways diverge downstream of PAK, with NSC23766
repressing the MEK5/ERK5 signaling cascade while ToxB inhibits MEK1/2 and
ERK1/2. ToxB also induces the activation of JNK/c-Jun, a pathway that is not activated
by NSC23766. ToxB ultimately results in decreased degradation and enhanced
transcription of Bim while NSC23766 promotes the dephosphorylation, mitochondrial
localization, and induction of Bad.
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In addition to regulation of Bad at the transcriptional level via CREB, p90Rsk
also catalyzes the phosphorylation of Bad at serine 112, suppressing Bad-mediated
apoptosis in neurons (Bonni et al., 1999, Bertolotto et al., 2000). However, we did not
detect any decrease in the phosphorylation of Bad at Ser112 (data not shown). Instead,
we observed that NSC23766-treated CGNs exhibited a marked reduction in levels of
pBad (Ser136). Interestingly, several studies have highlighted that phosphorylation of
Bad at Ser136 may be the more critical 14-3-3 binding site which enhances the
association of Bad with cytosolic 14-3-3 scaffolding proteins, effectively sequestering
Bad away from mitochondria (Zha et al., 1996, Masters et al., 2001). Several reports have
indicated that phosphorylation of Bad at this particular site is largely attributed to Akt
activation (Datta et al., 1997; del Peso et al., 1997). This is consistent with our data
demonstrating reduced phosphorylation (activation) of Akt (Ser473) in NSC23766treated CGNs. As we have previously reported that ToxB does not regulate Akt signaling
in CGNs (Linseman et al., 2001), the finding that NSC23766-treated CGNs display a
marked reduction in activated Akt highlights an additional signaling pathway that is
differentially regulated in response to specific Rac inhibition versus global Rho GTPase
inhibition. However, the particular mechanism by which Akt is deactivated in
NSC23766-treated CGNs is currently unknown. For instance, although it is well
documented that Akt can be phosphorylated and activated by Rac through phosphatidylinositol-3 kinase (del Peso et al., 1997; Kanekura et al., 2005), ERK5 has also been
shown to modestly activate Akt to promote survival of non-neuronal cells (Lennartsson et
al., 2010). Thus, the precise mechanism by which Akt is dephosphorylated following
Rac inhibition warrants further investigation. Despite these considerations, our data
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indicate that inhibition of a specific pool of Rac activated by the GEFs Tiam1 and Trio
induces apoptosis through a mechanism consistent with Akt deactivation and subsequent
dephosphoylation and translocation of Bad to the mitochondria.
Finally, in addition to the distinct differences in MEK/ERK, p90Rsk, and Akt
signaling, ToxB and NSC23766 also appear to dissimilarly regulate JNK/c-Jun signaling
in CGNs. While we previously reported that ToxB induced mitochondrial-dependent
CGN

apoptosis

through

a

mechanism

consistent

with

JNK/c-Jun-dependent

transcriptional upregulation of the BH3-only protein Bim (Le et al., 2005), we currently
report that c-Jun was not induced in CGNs exposed to the specific Rac inhibitor
NSC23766.

Moreover, inclusion of the JNK inhibitor, SP600125, did not exert a

protective effect in NSC23766-treated CGNs.

Furthermore, although we report an

increase in expression of the pro-apoptotic protein Bim in response to ToxB in CGNs,
Bim was not elevated above control levels in NSC23766-treated CGNs. Thus, while
ToxB appears to induce CGN death through a mechanism dependent upon JNK/c-Junmediated induction of Bim, Bim does not appear to execute cell death in CGNs exposed
to the specific Rac inhibitor NSC23766. Many studies have indicated that Rac and Cdc42
can regulate JNK activation; thus this distinction in signaling may be due to the intrinsic
differences between inactivation of specifically Rac versus global inhibition of Rho
GTPases.
In conclusion, the specificity with which NSC23766 suppresses Rac activity
allowed us to further investigate signaling pathways regulated by this Rho family GTPase
which are involved in neuronal survival. We have revealed that CGNs exposed to ToxB
or NSC23766 succumb to neuronal death through inactivation of distinct MAP kinase
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signaling pathways. Comparison of the mechanisms behind specific Rac inhibition with
those associated with broader Rho family GTPase inhibition has been central to
elucidating the signaling pathways that regulate survival in CGNs. It is interesting to
note that inhibition of the select pool of Rac activated by Tiam1 and Trio is sufficient to
induce dysregulation of multiple signaling pathways including MEK5/ERK5, p90Rsk,
and Akt. Furthermore, the critical function of Rac in maintaining neuronal survival is
highlighted by the fact that targeted inhibition of Rac is sufficient to induce CGN death in
the presence of both serum and depolarizing potassium. Accordingly, this study serves to
advance our understanding of the key pro-survival roles of Rho family GTPases in
neurons. These findings may ultimately contribute to the discovery of novel signaling
molecules which could be targeted therapeutically for debilitating neurodegenerative
diseases, such as amyotrophic lateral sclerosis, for which loss of Rac function is thought
to play a significant role in neuronal cell death.
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CHAPTER FOUR: C-TERMINAL BINDING PROTEINS ARE ESSENTIAL
PRO-SURVIVAL FACTORS THAT UNDERGO CASPASE-DEPENDENT
DOWNREGULATION DURING NEURONAL APOPTOSIS
4.1 Abstract
C-terminal binding proteins (CtBPs) are transcriptional co-repressors that are
subject to proteasome-dependent downregulation during apoptosis. Alternative
mechanisms that regulate CtBP expression are currently under investigation and the role
of CtBPs in neuronal survival is largely unexplored. Here, we show that CtBPs are
downregulated in cerebellar granule neurons (CGNs) induced to undergo apoptosis by a
variety of stressors. Moreover, antisense-mediated downregulation of CtBP1 is sufficient
to cause CGN apoptosis. Similarly, the CtBP inhibitor, 4-methylthio-2-oxobutyric acid,
induces expression of the CtBP target Noxa and causes actinomycin-sensitive CGN
apoptosis. Unexpectedly, we found that the mechanism of CtBP downregulation in CGNs
undergoing apoptosis varies in a stimulus-specific manner involving either the
proteasome or caspases. In the case of CGNs deprived of depolarizing potassium (5K
apoptotic condition), caspases appear to play a dominant role in CtBP downregulation.
However, incubation in 5K does not enhance the kinetics of CtBP1 degradation and
recombinant CtBP1 is not cleaved in vitro by caspase-3. In addition, 5K has no
significant effect on CtBP transcript expression. Finally, mouse embryonic stem cells
display

caspase-dependent

downregulation

of

CtBP1

following

exposure

to

staurosporine, an effect that is not observed in DGCR8 knockout cells which are deficient
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in miRNA processing. These data identify caspase-dependent downregulation of CtBPs
as an alternative mechanism to the proteasome for regulation of these transcriptional corepressors in neurons undergoing apoptosis. Moreover, caspases appear to regulate CtBP
expression indirectly, at a post-transcriptional level, and via a mechanism that is
dependent upon miRNA processing. We conclude that CtBPs are essential pro-survival
proteins in neurons and their downregulation contributes significantly to neuronal
apoptosis via the de-repression of pro-apoptotic genes.
4.2 Introduction
C-terminal binding proteins (CtBPs) were originally identified as binding partners
for the adenovirus E1A transforming proteins (Schaeper et al., 1995). CtBP1 and CtBP2
are highly homologous transcriptional co-repressors that function as partners for
repressor proteins like ZEB and basic krüppel-like factor (BKLF) (Postigo and Dean,
1999 and Turner and Crossley, 1998). CtBPs recruit a number of key chromatin
modifying enzymes (e.g., histone deacetylases) to gene promoters primarily via PXDLSdependent interactions with the CtBP hydrophobic cleft (Kuppuswamy et al.,
2008 and Quinlan et al., 2006). In a similar manner, CtBPs repress p300-dependent
transcriptional activation by directly binding to a PXDLS motif in the bromodomain of
this co-activator (Kim et al., 2005). CtBPs are directed to the nuclear compartment either
via a nuclear localization signal (which is unique to CtBP2) or by binding to PXDLS
motif-containing partners like BKLF (Verger et al., 2006). CtBPs are functional
dehydrogenases which bind to NADH with greater than 100-fold higher affinity than
NAD + (Fjeld et al., 2003, Kumar et al., 2002 and Zhang et al., 2002). Binding of
NAD(H) appears to stabilize the protein and promotes dimerization of CtBPs which is
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required for transcriptional repression (Fjeld et al., 2003, Kuppuswamy et al.,
2008 and Mani-Telang et al., 2007). Thus, CtBPs act as redox-sensitive transcriptional
co-repressors of a specific subset of target genes.
CtBPs are key transcriptional co-repressors of epithelial and pro-apoptotic gene
expression programs (Bergman and Blaydes, 2006 and Grooteclaes et al., 2003). By
repressing epithelial cell adhesion (via repression of E-cadherin) and concomitantly
suppressing apoptosis and anoikis, CtBPs promote cancer cell migration, invasion, and
survival (Grooteclaes and Frisch, 2000 and Straza et al., 2010). In the context of
apoptosis, CtBPs act as co-repressors at several pro-apoptotic Bcl-2 family member gene
promoters, such as Bax and the Bcl-2 homology-3 domain (BH3)-only proteins, Noxa,
Bik, Bim, and Bmf (Bergman and Blaydes, 2006, Grooteclaes et al., 2003 and Kovi et al.,
2010). Murine embryonic fibroblasts (MEFs) isolated and immortalized from
Ctbp1/Ctbp2 double knockout embryos show constitutive upregulation of Bax and Noxa,
and demonstrate enhanced sensitivity to diverse apoptotic stimuli (Grooteclaes et al.,
2003). Both the increased expression of Bax and Noxa, as well as the enhanced
susceptibility to apoptosis, were reversed by Ctbp1 or Ctbp2 rescue expression.
To date, relatively few studies have examined the roles of CtBPs in CNS
development or neuronal survival. Based largely on the results of genetic deletion
experiments, it appears that Ctbp1 and Ctbp2 display both duplicative and independent
roles in mouse development including maturation of the CNS (Hildebrand and Soriano,
2002). Ctbp2 homozygous null mice display delayed development of the forebrain and
midbrain, and typically die by E10.5. In contrast, Ctbp1 homozygous null mice are viable
and fertile. In a genetic interaction experiment, increasing the dosage of Ctbp1 decreased
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the severity of the Ctbp2 null phenotype. For instance, Ctbp1+/- Ctbp2-/- embryos did not
complete neural tube closure and arrested at the turning stage while Ctbp1+/+ Ctbp2-/embryos completed both processes. In the context of cell survival, CtBPs are targeted for
proteasomal degradation in response to pro-apoptotic stimuli that induce p53-independent
apoptosis in non-neuronal cells (Paliwal et al., 2006, Wang et al., 2006, Zhang et al.,
2003 and Zhang et al., 2005). In contrast, the role of CtBPs in neuronal apoptosis has not
previously been explored. Here, we identify a novel caspase-dependent pathway for CtBP
downregulation during neuronal apoptosis and further show that loss of CtBP function is
sufficient to induce neuronal cell death.
4.3 Materials and Methods
4.3.1 Reagents
Clostridium difficile Toxin B (ToxB) and Clostridium sordellii lethal toxin
(LTox) were kindly provided by Dr. Klaus Aktories (Albert-Ludwigs-Universität
Freiburg, Germany). The high-throughput immunoblotting screen was performed by BD
Pharmingen (Palo Alto, CA, USA) and monoclonal antibodies used for subsequent
western blotting of CtBP1 and CtBP2 were obtained from BD Biosciences (San Diego,
CA, USA). Polyclonal antibody against actin was obtained from Cell Signaling
(Berverly, MA, USA). The polyclonal antibody used to detect Noxa was from Abcam
(Cambridge, MA, USA). Horseradish peroxidase-linked secondary antibodies and
reagents for enhanced chemiluminescence detection were from Amersham Biosciences
(Piscataway, NJ, USA). The polyclonal antibody used to detect active caspase-3 was
from Promega (Madison, WI, USA). 4,6-Diamidino-2-phenylindole (DAPI), Hoescht dye
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33258, monoclonal antibody against β-tubulin, 1-methyl-4-phenylpyridinium (MPP +), 6hydroxydopamine (6-OHDA), 4-methylthio-2-oxobutyric (MTOB),

staurosporine,

actinomycin D, and recombinant PARP were from Sigma (St. Louis, MO, USA). Cy3and FITC-conjugated secondary antibodies for immunofluorescence were from Jackson
Immunoresearch Laboratories (West Grove, PA, USA). HA14-1 and BOC were obtained
from Alexis (San Diego, CA, USA). MG-132, sodium nitroprusside (SNP), and
recombinant caspase-3 were from Calbiochem (Darmstadt, Germany). The polyclonal
antibody to PARP was from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Morpholino-antisense oligonucleotides and the EndoPorter delivery reagent were
obtained from Gene Tools (Philomath, PA, USA). Wild type and DGCR8 knockout
mouse embryonic stem cells, as well as, recombinant CtBP1 were obtained from Novus
Biologicals (Littleton, CO, USA).
4.3.2 Cerebellar granule neuron (CGN) culture
Rat CGNs were isolated from 7-day-old Sprague-Dawley rat pups of both sexes
(15–19 g) as previously described (Linseman et al., 2001). CGNs were plated on 35-mm
diameter plastic dishes coated with poly-L-lysine at a density of 2.0 × 106 cells/ml in
basal modified Eagle's medium containing 10% fetal bovine serum, 25 mM KCl, 2 mM
L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (Life Techonologies,
Grand Island, NY, USA). Cytosine arabinoside (10 µM) was added to the culture medium
24 h after plating to limit the growth of non-neuronal cells. With use of this protocol, the
cultures were approximately 95% pure for granule neurons. In general, experiments were
performed after 6–7 days in culture.
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4.3.3 BD Pharmingen PowerBlot™ analysis
CGNs were incubated in either control medium or medium containing 40 ng/ml
Clostridium difficile Toxin B (ToxB) for 24 h and subsequently lysed according to the
manufacturer's protocol. Lysates from three independent experiments were pooled and
subjected to high-throughput immunoblotting against a panel of 1009 purified
monoclonal antibodies (BD PowerBlot™). Raw data was obtained from the manufacturer
in the form of image files of the actual blots and densitometric measurements of the
immunoreactive proteins. The blots shown for CtBP1, CtBP2, and G protein-coupled
receptor kinase-interacting protein-z-short are representative of 2 × 2 comparisons of
duplicate control and ToxB lysates.
4.3.4 Cell lysis and immunoblotting
Following treatment, whole cell lysates of CGNs were prepared essentially as
previously described (Loucks et al., 2006). Briefly, protein concentrations were
determined by a commercially available protein assay kit (BCA; Thermo Fisher
Scientific, Waltham, MA, USA), and SDS-polyacrylamide gel electrophoresis was
performed using equal amounts of protein followed by transfer to polyvinylidene
difluoride membranes. Nonspecific binding sites were blocked in PBS-T (1X phosphatebuffered saline (PBS, pH 7.4) containing 0.1% Tween 20) containing 1% BSA and
0.01% sodium azide for 1 h at room temperature (22 °C). Membranes were incubated for
1 h in primary antibody diluted in blocking solution. Membranes were subsequently
washed 5 times over 30 min in PBS-T to remove excess primary antibody. Membranes
were then incubated for 1 h with horseradish peroxidase-conjugated secondary antibodies
diluted in PBS-T. Following secondary incubation, membranes were washed 5 times over
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30 min in PBS-T to remove excess secondary antibody. Immunoreactive proteins were
detected by enhanced chemiluminescence. Blots shown are representative of a minimum
of three independent experiments.
4.3.5 Immunofluorescence microscopy
CGNs were plated at a density of 4.5 × 105 cells per ml on glass coverslips coated
with polyethylene-imine. After treatment, cells were fixed in 4% paraformaldehyde,
washed once in PBS, and permeabilized and blocked in 0.2% Triton X-100 and 5% BSA
in PBS (pH 7.4). Cells were incubated for 16 h at 4 °C in primary antibodies diluted in
2% BSA and 0.2% Triton X-100 in PBS. They were subsequently washed 5 times in PBS
over 30 min and then incubated for 1 h at room temperature with Cy3- or FITCconjugated secondary antibodies and DAPI diluted in 2% BSA and 0.2% Triton X-100 in
PBS. The cells were washed five additional times over 30 min with PBS before mounting
coverslips onto slides with anti-quench composed of 0.1% p-phenylenediamine in 75%
glycerol in PBS. Fluorescent images were captured using a 63x oil immersion objective
on a Zeiss Axioplan 2 epifluorescence microscope that was equipped with a Cooke
Sensicam deep-cooled charge-coupled device (CCD) camera and a Slidebook software
analysis program for digital deconvolution (Intelligent Imaging Innovations Inc., Denver,
CO, USA).
4.3.6 Morpholino-antisense oligonucleotide treatment
CGNs were plated at a density of 4.5 × 105 cells per ml on glass coverslips coated
with polyethylenimine. On day 6 in vitro, cells were treated with EndoPorter reagent
(6 µM) alone or in combination with morpholino-antisense or inverse oligonucleotides
(3 µM final concentration). After 72 h of treatment, cells were fixed with 4%
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paraformaldehyde and nuclei were stained with Hoechst dye. CGNs containing
condensed and/or fragmented nuclei were scored as apoptotic.
4.3.7 N27 dopaminergic cell culture
N27 cells were maintained in culture in RPMI medium containing 10% fetal
bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.
4.3.8 6-Hydroxydopamine treatment
For treatment with 6-OHDA, the compound was diluted in a vehicle solution
consisting of ddH2O containing 0.15% ascorbic acid and 10 mM DETAPAC. This
solution was purged with nitrogen gas for 30 min while on ice. After removal of oxygen,
6-OHDA was added to the solution and used to treat N27 cells at a concentration of
25 µM or 50 µM for 24 h.
4.3.9 Pulse-chase assay
CGNs were incubated for 4 h in cysteine-methionine-free medium containing 35Smethionine. Following this labeling “pulse”, cells were washed and medium was replaced
with control (25K) or apoptotic (5K) medium for the “chase” period. At the times
indicated, cells were lysed, CtBP1 was immunoprecipitated, and immune complexes
were resolved by SDS-PAGE followed by transfer to polyvinylidine difluoride
membranes. Membranes were exposed directly to film and bands representing 35S-CtBP1
were quantified by densitometry.
4.3.10 In vitro caspase-3 cleavage assay
In separate microcentrifuge tubes, 5 µg of recombinant PARP or 1.5 µg of
recombinant CtBP1 were incubated alone or in combination with 100 units of
recombinant caspase-3. All samples were queued to 100 µl with caspase buffer (100 mM
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NaCl, 5 mM DTT, 50 mM EDTA, 20 mM PIPES, 1% Chaps, and 10% sucrose in
ddH20). Samples were incubated for 4 h at 37 °C in a thermomixer. Following
incubation, proteins were resolved by SDS-PAGE, proteins transferred onto membranes,
and immunoblotted as previously described.
4.3.11 RT-PCR
CGNs were incubated in control (25K) or apoptotic (5K) medium for 24 h. RNA
was isolated using a miRCURY RNA isolation kit purchased from Exiqon (Woburn, MA,
USA). cDNA was synthesized from the isolated RNA samples using an Omniscript
reverse transcriptase kit that was purchased from Qiagen (Valencia, CA, USA). DNA
was analyzed by polymerase chain reaction (PCR) using an Accuprime Pfx Supermix kit
from Life Technologies (Grand Island, NY, USA). Primers were purchased from
Integrative DNA Technologies (Coralville, IA, USA) corresponding to CtBP1, CtBP2,
and

beta-actin.

The

forward

primer

to

CtBP1

was

5′-TTGGGCAT

CATTGGACTAGGTCGT-3′ and the reverse primer was 5′-TCAGGTGGTCCTTGTT
GACACAGT-3′.

The

forward

TGTGATGCACAGTCCACTCAG

primer

GAA-3′

and

to
the

CtBP2
reverse

was

primer

was

5′5′-

CCATTGAACACGGCATTGTCACCA-3′. The forward primer to beta-actin was 5′CCATTG

AACACGGCATTGTCACCA-3′

and

the

reverse

primer

was

5′-

ACTCCTGCTTGCTGA TCCACATCT-3′. PCR was performed using the following
conditions: 95 °C for 5 min followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and
68 °C for 1 min.
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4.3.12 Mouse embryonic stem cell culture
Wild type and DGCR8 knockout mouse embryonic stem cells were purchase from
Novus Biologicals (Littleton, CO, USA). Cell culture plates were coated with a solution
containing 1% gelatin that was purchased from Millipore (Billerica, MA, USA). Cells
were maintained in basal modified Eagle's medium containing 10% fetal bovine serum,
1X non essential amino acids, 1% beta-mercaptoethanol, and 1000 units/ml leukemia
inhibitory factor (Millipore). In general, the culture medium of both wild type and
DGCR8 knockout cells was replaced daily.
4.3.13 Data analysis
Results represent the mean ± S.E. for the number (n) of independent experiments
performed. Statistical differences between the means of unpaired sets of data were
evaluated by one-way analysis of variance with a post hoc Tukey's test. A p value
of < 0.05 was considered statistically significant. Images and immunoblots shown are
representative of at least three independent experiments.
4.4 Results
4.4.1 CtBP1 and CtBP2 are downregulated in CGNs exposed to Clostridium difficile
Toxin B, an inhibitor of Rho family GTPases
In our initial studies using a high throughput immunoblotting screen (BD
PowerBlot™), we identified CtBP1 and CtBP2 as two proteins that were significantly
downregulated in CGNs following a 24 h incubation with the Rho family GTPase
inhibitor, Clostridium difficile toxin B (Fig. 4.1A). Toxin B is a monoglucosyltransferase
that directly glucosylates and inhibits the small GTPases Rho, Rac, and Cdc42 (Just et al.,
1995). We have previously shown that toxin B induces intrinsic apoptosis in CGNs that is
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largely dependent on its capacity to inhibit pro-survival signaling by Rac GTPase (Le et
al., 2005, Linseman et al., 2001, Loucks et al., 2006 and Stankiewicz et al., 2012). CtBP1
appeared on polyacrylamide gels as a single band of approximately 48 kDa and CtBP2
appeared as a doublet of approximately 48/50 kDa. In the initial PowerBlot™ analysis,
the expression of each of these proteins was significantly decreased by at least two-fold
in CGNs incubated for 24 h with toxin B (Fig. 4.1B). In a separate experiment using a
distinct preparation of primary CGN cultures, the toxin B-induced decrease in CtBP1 and
CtBP2 expression was confirmed (Fig. 4.1C).
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Figure 4.1 CtBP1 and CtBP2 are downregulated in CGNs exposed to Clostridium
difficile Toxin B, an inhibitor of Rho family GTPases. A. CGNs were incubated for
24 h in control medium containing 25 mM KCl and 10% FBS (Con) in the absence or
presence of Toxin B (Tox B; 40 ng/ml). Cells were then lysed and protein extracts were
subjected to PowerBlot™ analysis. Incubation with Tox B resulted in the downregulation
of both CtBP1 (indicated by the black arrows) and CtBP2 (a doublet indicated by the
asterisks). G protein-coupled receptor kinase-interacting protein-z-short (GITz-short;
white arrows) is shown to demonstrate equal protein loading of the PowerBlot™ gels. B.
Densitometric quantification of CtBP1 and CtBP2 protein expression in Con and Tox Btreated CGNs. Results shown are the mean ± range from duplicate PowerBlot™ gels and
are expressed as the fold change in CtBP expression between Tox B-treated cells and
Con. C. To confirm the results of the Powerblot™, CGNs obtained from a different
primary culture than those utilized in the PowerBlot™ analysis were incubated for 24 h
in either Con medium or medium containing Tox B. After incubation, CtBP1 and CtBP2
expression was analyzed by western blotting. Blots were then stripped and re-probed for
actin as a loading control. I acknowledge Emily Schroeder for assistance with generating
data for this figure.
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4.4.2 Multiple pro-death stimuli induce downregulation of CtBPs in CGNs
Next, we examined the effects of a number of diverse pro-death stimuli on the
expression of CtBPs in CGNs. Primary CGN cultures require serum-derived growth
factors and depolarizing extracellular potassium for their survival. Removal of
depolarizing potassium (i.e., 5K conditions) induces apoptosis of CGNs through an
intrinsic pathway (D'Mello et al., 1993 and Linseman et al., 2002). Upon removal of
serum and depolarizing potassium (5K conditions), the expression of both CtBP1 and
CtBP2 was significantly decreased (Fig. 4.2A). Similar reductions in CtBP expression
were observed when CGNs were incubated with the BH3 mimetic, HA14-1, the nitric
oxide donor, sodium nitroprusside (SNP), or the complex I inhibitor, 1-methyl-4phenylpyridinium (MPP +) (Fig. 4.2B). The expression of CtBP1 was also analyzed by
immunofluorescent staining under control, 5K, and MPP + treatment conditions. In
control CGNs, CtBP1 was localized almost exclusively to the nucleus (Fig. 4.2C, upper
panels). However, whether CGNs were exposed to either 5K or MPP +, two completely
distinct stressors, CtBP1 immunoreactivity essentially disappeared in cells that
demonstrated condensed and/or fragmented chromatin indicative of apoptotic
morphology (Fig. 4.2C, middle and lower panels). These results demonstrate the
downregulation of CtBP1 and CtBP2 in neurons undergoing apoptosis and further show
that CtBPs are downregulated in response to a number of mechanistically distinct prodeath stimuli.
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Figure 4.2 Multiple pro-death stimuli induce downregulation of CtBPs in CGNs. A.
CGNs were incubated for 24 h in either control medium containing 25 mM KCl and 10%
FBS (Con) or apoptotic medium containing only 5 mM KCl and lacking FBS (5K). Cells
were then lysed, proteins resolved by SDS-PAGE, and immunoblotted for CtBP1 and
CtBP2. Blots were subsequently stripped and re-probed for actin to show equal loading.
B. CGNs were incubated for 24 h in either Con medium alone or containing the Bcl-2
inhibitor HA14-1 (HA14; 15 µM), the nitric oxide donor sodium nitroprusside (SNP;
100 µM), or the complex I inhibitor 1-methyl-4-phenylpyridinium (MPP +; 150 µM).
After incubation, protein extracts were western blotted for CtBP1 and CtBP2. Blots were
also stripped and re-probed for actin as a loading control. C. CGNs were incubated for
24 h in either Con medium, 5K medium, or medium containing MPP +, as described
above in (A) and (B). Following incubation, cells were fixed with 4% paraformaldehyde
and their nuclei stained with DAPI. The microtubule network was stained with a
polyclonal antibody to β-tubulin and a Cy3-conjugated secondary antibody. CtBP1 was
detected using a monoclonal antibody to CtBP1 and a secondary antibody conjugated to
FITC. White arrows indicate cells with condensed and/or fragmented nuclei indicative of
apoptotic cell death. Note that regardless of the stimulus, CGNs with apoptotic nuclear
morphology displayed essentially no detectable CtBP1. Scale bar = 10 microns. I
acknowledge Emily Schroeder for assistance with generating data for this figure.
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4.4.3 Antisense oligonucleotides to CtBP1 induce CGN apoptosis
To determine if forced downregulation of CtBP1 is sufficient to trigger CGN
apoptosis, we transfected cells with morpholino-antisense oligonucleotides to rat CtBP1
using an EndoPorter delivery reagent. As negative controls, CGNs were transfected with
inverse morpholino oligonucleotides or were exposed to the EndoPorter reagent alone.
Transfections and subsequent 24 h incubations were performed in control medium
containing 25 mM KCl and 10% FBS. CGNs transfected with morpholino-antisense
oligonucleotides to rat CtBP1 underwent significant apoptosis characterized by nuclear
condensation and fragmentation (Fig. 4.3A and 4.3B). In contrast, CGNs exposed to the
EndoPorter reagent alone or transfected with inverse morpholino oligonucleotides
displayed a similar level of apoptosis to untreated control CGNs. Although the
morpholino-antisense oligonucleotides were fluorescently labeled with fluorescein, we
were unable to accurately assess the extent of CtBP1 downregulation within the
transfected cell population using immunofluorescent staining for CtBP1. This was
primarily because the cells that fluoresced positive for the morpholino-antisense
oligonucleotides were most often apoptotic and their nuclei were essentially devoid of
CtBP1 immunoreactivity. However, given that CtBP1 nuclear staining disappears in
apoptotic cells (see Fig. 4.2C), we cannot discern whether the CtBP1 staining is lost due
to the antisense treatment or due to the fact that the cell is undergoing apoptosis. Given
this limitation, our data suggest that antisense-mediated down-regulation of CtBP1 is
sufficient to induce significant CGN apoptosis.
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Figure 4.3 Morpholino-antisense oligonucleotides to CtBP1 induce CGN apoptosis.
A. CGNs were incubated for 24 h in Con medium alone or containing the vehicle
Endoporter (EP; 6 µl/ml), EP plus morpholino-antisense oligonucleotides to CtBP1 (Anti;
10 µM), or EP plus inverse control morpholino-oligonucleotides (Inv; 10 µM). Apoptosis
was quantified from 3 separate experiments each performed in triplicate. Antisense
treatment induced significant CGN apoptosis (*p < 0.05) when compared to Inv, EP, or
Con treatments. B. Representative images of CGNs following incubation with
morpholino-antisense oligonucleotides or appropriate controls, as described in (A). Cells
were fixed and nuclei stained with Hoechst. CGNs containing nuclei that were visibly
condensed and/or fragmented were scored as apoptotic. I acknowledge Emily Schroeder
for assistance with generating data for this figure.
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4.4.4 The CtBP inhibitor, 4-methylthio-2-oxobutyric acid (MTOB), induces actinomycin
D-sensitive apoptosis of CGNs
As an alternative means of knocking out CtBP function in CGNs, we next
incubated cells with the putative CtBP inhibitor, MTOB. This compound is a CtBP
dehydrogenase substrate which acts as a CtBP inhibitor and is toxic to cancer cells at
high (1–10 mM) concentrations (Straza et al., 2010). In agreement with this previous
study, incubation of CGNs with MTOB for 24 h revealed that significant apoptosis was
induced at a concentration of 5 mM (Fig. 4.4A). Moreover, the CGN apoptosis induced
by this concentration of MTOB was delayed and required 24 h of incubation (Fig. 4.4B).
In accordance with MTOB inducing apoptosis of CGNs, its toxic effects were completely
suppressed by blocking the transcription of new genes with actinomycin D (Fig. 4.4C and
D). Moreover, consistent with MTOB inhibiting the co-repressor function of CtBP,
incubation with this compound induced a late induction of the CtBP target, the BH3-only
protein Noxa, at 24 h post-treatment (Fig. 4.4E). Collectively, these results demonstrate
that inhibition of CtBP co-repressor function is capable of inducing actinomycin Dsensitive CGN apoptosis.
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Figure 4.4 The CtBP inhibitor, MTOB, induces CGN apoptosis. A. MTOB dose
response: CGNs were incubated for 24 h in Con medium containing increasing
concentrations of MTOB. Apoptosis was quantified as the percentage of cells with
condensed and/or fragmented nuclei. B. MTOB time course: CGNs were incubated for
increasing durations with 5 mM MTOB and apoptosis was quantified. C. Representative
fluorescence images of CGNs incubated for 24 h in Con medium alone or containing
5 mM MTOB ± actinomycin D (AD). D. Quantification of CGN apoptosis for the
experiment described in (C). E. CGNs were incubated for increasing durations with
5 mM MTOB. Cell lysates were prepared and western blotted for Noxa and actin. For
(A), (B), and (D); **p < 0.01 compared to Con, ††p < 0.01 compared to MTOB. The
results shown represent the means ± SEM of three independent experiments each
performed in duplicate.
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4.4.5 In addition to the recognized proteasome degradation pathway, CtBPs are also
downregulated through a novel caspase-dependent mechanism in CGNs
Several previous reports have demonstrated that CtBPs are downregulated via
proteasomal degradation during p53-independent apoptosis in non-neuronal cells (Paliwal
et al., 2006, Wang et al., 2006, Zhang et al., 2003 and Zhang et al., 2005). However, the
mechanism by which CtBPs are downregulated in neurons undergoing apoptosis has not
previously been explored. To address this question, we analyzed the effects of inhibitors
of the proteasome or caspases on the downregulation of CtBPs induced by various prodeath stimuli in CGNs. Downregulation of CtBP1 and CtBP2 induced under 5K apoptotic
conditions in CGNs was completely prevented by the pan-caspase inhibitor, BOC, but
was only partially attenuated by the proteasome inhibitor MG132 (Fig. 4.5A). In response
to apoptosis induced by toxin B or the related Clostridium sordellii lethal toxin which
also inhibits Rac GTPase (Just et al., 1996), the observed downregulation of CtBP1 and
CtBP2 was significantly blocked by caspase inhibition with BOC or zVAD but was
unaffected by proteasome inhibition with MG132 (Fig. 4.5B and 4.5C). In contrast to 5K
and the Clostridial toxins which are each known to activate caspases in CGNs, we have
previously shown that CGN death induced by MPP + occurs through a caspaseindependent mechanism (Harbison et al., 2011). In agreement with this, the
downregulation of CtBP1 and CtBP2 induced by MPP + in CGNs was unaltered by BOC
but was significantly inhibited by MG132 (Fig. 4.5D). These data indicate that distinct
pro-death stimuli act through a proteasome-dependent pathway and/or an alternative
caspase-dependent pathway to downregulate CtBPs in neurons. To our knowledge, this is
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the first demonstration of CtBP expression being regulated via a caspase-dependent
mechanism.
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Figure 4.5 Caspases and the proteasome contribute to CtBP downregulation in a
stimulus-specific manner and CtBPs are downregulated in an exclusively
proteasome-dependent manner following exposure to the complex I inhibitor
MPP +. A. CGNs were incubated for 24 h in Con medium or 5K medium ± the pancaspase inhibitor BOC (50 µM) or the proteasome inhibitor MG132 (10 µM). B. CGNs
were incubated for 24 h in Con medium alone or containing ToxB (40 ng/ml) ± either
BOC or MG132. C. CGNs were incubated for 24 h in Con medium alone or containing
Clostridium sordellii lethal toxin (400 µg/ml) ± the pan-caspase inhibitor zVAD (50 µM)
or MG132. Following incubation, cells were lysed, proteins resolved by SDS-PAGE and
transferred onto PVDF membranes. Blots were probed for CtBP1 and CtBP2 followed by
stripping and re-probing for actin to indicate equal loading. D. CGNs were incubated for
24 h in Con medium alone or containing MPP + (150 µM) ± BOC or MG132. Following
incubation, cells were lysed, proteins resolved by SDS-PAGE, and immunoblotted using
CtBP1 and CtBP2 antibodies. Blots were stripped and re-probed for actin to show equal
loading. I acknowledge Emily Schroeder for assistance with generating data for this
figure.
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4.4.6 6-hydroxydopamine (6-OHDA) induces caspase-dependent downregulation of
CtBPs in the dopaminergic N27 cell line
In order to establish that the novel caspase-dependent mechanism of CtBP
downregulation observed in CGNs undergoing apoptosis was not unique to this cell
system, we next investigated the mode of CtBP downregulation in an in vitro model
relevant to Parkinson's disease. The N27 cell line is a large T-antigen-immortalized,
mesencephalon-derived cell line with characteristics of dopaminergic neurons (Zhou et
al., 2000). Exposure of N27 cells to the neurotoxin, 6-OHDA, induces caspase-dependent
apoptosis (Latchoumycandane et al., 2011). Incubation of N27 cells with 6-OHDA
resulted in the downregulation of CtBP1 and CtBP2 in a dose-dependent manner
(Fig. 4.6A). In addition, the downregulation of CtBPs induced by 6-OHDA was largely
prevented by the pan-caspase inhibitor, BOC, but was actually accentuated by the
proteasome inhibitor MG132 (Fig. 4.6B). Thus, caspase-dependent downregulation of
CtBPs occurs in diverse neuronal cell systems and in response to multiple pro-apoptotic
stressors.
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Figure 4.6 Incubation of N27 dopaminergic cells with 6-OHDA induces
downregulation of CtBP1 and CtBP2 through a caspase-dependent mechanism. A.
N27 cells were incubated for 24 h in Con medium alone or containing either 25 µM or
50 µM concentrations of 6-OHDA. Because of cell detachment induced by 6-OHDA,
medium containing floating cells was obtained in a microcentrifuge tube and pelleted.
The supernatant was then discarded and cells remaining in the 6-well dish were lysed,
scraped, and added to the previously pelleted cells which had detached. Combined
contents in the microcentrifuge tube were then lysed, and proteins were resolved by SDSPAGE. Once transferred onto PVDF membranes, samples were immunoblotted with
antibodies to CtBP1 and CtBP2. Membranes were stripped and re-probed for actin to
show equal loading. B. N27 cells were incubated for 24 h in Con medium alone or
containing 6-OHDA (25 µM) ± BOC (50 µM) or MG132 (10 µM). Cells lysates were
immunoblotted as described in (A). I acknowledge Emily Schroeder for assistance with
generating data for this figure.
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4.4.7 CtBP downregulation induced by 5K apoptotic conditions in CGNs does not occur
through an enhanced rate of protein degradation
The downregulation of CtBP1 observed under 5K apoptotic conditions occurred
in a relatively protracted manner over the course of many hours (Fig. 4.7A). One
principal mechanism by which proteins are downregulated is by an enhanced rate of
degradation. Given that the downregulation of CtBPs under 5K apoptotic conditions was
sensitive to caspase inhibition, we utilized pulse-chase methodology to determine if
CtBPs were being actively degraded during CGN apoptosis. Quantification of a discrete
pool of

35

S-labeled CtBP1 (pulse) following incubation in either 25K or 5K serum-free

medium (chase) resulted in nearly identical t1/2 values for CtBP1 of approximately 10 h
(Fig. 4.7B and 4.7C). These data suggest that CtBP1 does not undergo an enhanced rate
of degradation during 5K-induced apoptosis in CGNs. Instead, the downregulation of
CtBPs under these conditions is likely due to decreased synthesis of new protein.
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Figure 4.7 Pulse-chase analysis of the kinetics of CtBP1 downregulation in CGNs
incubated in apoptotic (5K) medium. A. CGNs were incubated in 5K medium for
various times over the course of 56 h. CtBP1 protein levels were assessed by western
blotting and membranes were stripped and re-probed for actin to show equal loading. B.
CGNs were initially incubated for 4 h in cysteine-methionine-free medium containing
35
S-methionine. Following this “pulse” incubation, cells were washed and medium was
replaced with serum-free Con medium or 5K medium. At various time points during this
“chase” incubation, cells were lysed and CtBP1 was immunoprecipated using a
monoclonal antibody. Immunoprecipitated samples were resolved on a 10%
polyacrylamide gel, transferred onto a PVDF membrane, and exposed directly to film. C.
Quantification of 35S-CtBP1 densitometry from (B) was graphed to compare the kinetics
of loss of CtBP1 during the 24 h “chase” incubation period. Values are plotted as a
percentage of the time 0 band density. CtBP1 displayed a half-life of approximately 10 h
in CGNs incubated in either Con or 5K medium. I acknowledge Emily Schroeder for
assistance with generating data for this figure.
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4.4.8 CtBP1 is not directly cleaved by caspase-3 in vitro
Upon examination of the CtBP1 amino acid sequence, a consensus DXXD
caspase-3 cleavage motif was noted in human CtBP1 at residues
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DNID106. This

consensus caspase-3 cleavage site is highly conserved and is present in CtBP1 and CtBP2
proteins of human, mouse, and rat species (Fig. 4.8A). An identical DNID motif present
in the adenomatous polyposis coli protein was previously shown to be directly cleaved by
caspase-3 (Webb et al., 1999). To determine if this
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DNID106 site serves as a viable

caspase-3 cleavage site in CtBP1 we performed an in vitro proteolysis experiment with
recombinant caspase-3 and recombinant CtBP1. As a positive control for caspase-3
activity, we utilized poly(ADP-ribose) polymerase (PARP) which is cleaved by caspase-3
to generate an 85 kDa fragment (Tewari et al., 1995). As expected, recombinant caspase3 cleaved PARP to produce the 85 kDa fragment but it failed to cleave CtBP1 to any
appreciable extent (Fig. 4.8B). Thus, despite the presence of a consensus caspase-3
cleavage motif, CtBP1 is not a direct substrate of caspase-3. This result is in agreement
with the above data and further suggests that the downregulation of CtBPs observed in
CGNs undergoing apoptosis is not due to direct caspase-mediated degradation.
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Figure 4.8 Despite the presence of a highly conserved, consensus caspase-3 cleavage
site, CtBP1 is not directly cleaved by recombinant caspase-3 in vitro. A. CtBP1 and
CtBP2 sequences across numerous species indicate a highly conserved caspase-3
cleavage site (DXXD; shaded residues). B. Recombinant CtBP1 (1.5 µg) or recombinant
PARP (5 µg) were incubated in the absence or presence of recombinant caspase-3
(rCasp3; 100 U) for 4 h at 37 °C. Recombinant proteins were then run on 7.5%
polyacrylamide gels and western blotted with monoclonal antibodies to CtBP1 and
PARP. The full length CtBP1 and PARP proteins are indicated by “fl”. The expected
85 kDa PARP cleavage fragment produced by caspase-3-dependent proteolysis is
denoted as “clv”. I acknowledge Emily Schroeder for assistance with generating data for
this figure.
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4.4.9 CtBP transcript levels are not significantly decreased during 5K-induced apoptosis
in CGNs
If the downregulation of CtBPs under 5K apoptotic conditions is due to decreased
synthesis of new protein, then one possible point of regulation is at the level of CtBP
gene transcription. To determine if CtBP1 and CtBP2 mRNA levels are reduced when
CGNs are incubated in 5K apoptotic medium, we performed RT-PCR analysis.
Surprisingly, even after 24 h incubation in 5K medium, no significant decrease in either
CtBP1 or CtBP2 transcript expression was observed (Fig. 4.9A and 4.9B). Similar results
were also obtained using quantitative real-time PCR analysis (data not shown). These
results indicate that the downregulation of CtBPs observed during CGN apoptosis is not
due to decreased gene transcription.
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Figure 4.9 Incubation of CGNs in apoptotic (5K) medium has no significant effect
on CtBP1 or CtBP2 transcript expression. A. CGNs were incubated in either Con or
5K medium for 24 h. Total RNA was isolated and subjected to RT-PCR using primers
specific for CtBP1, CtBP2, and actin mRNA transcripts. Representative bands are shown.
B. Quantification of three independent experiments performed in duplicate as described
in (A). CtBP1 and CtBP2 transcript expression levels were divided by the corresponding
actin signals for normalization.
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4.4.10 CtBP1 undergoes caspase-dependent downregulation in staurosporine-treated,
wild type (WT) mouse embryonic stem cells (mESCs) but not DGCR8 knockout (KO)
mESCs
The above findings indicate that CtBP function is essential for CGN survival and
furthermore, during CGN apoptosis CtBPs undergo an indirect, caspase-dependent
downregulation that occurs via a post-transcriptional mechanism. Micro RNAs
(miRNAs) are small noncoding RNAs that act as negative post-transcriptional regulators
by binding to the 3′ UTRs of target mRNAs (Lai, 2002). Mature miRNAs are produced
by a series of tightly regulated processing events. First, the primary miRNA transcript
(pri-miRNA) is cleaved by the Microprocessor, a protein complex consisting of the
ribonuclease Drosha and its essential cofactor, DiGeorge Critical Region 8 (DGCR8)
(Gregory and Schiekhattar, 2005). Microprocessor cleavage of pri-miRNAs generates
intermediate precursor miRNAs (pre-miRNAs) which are in turn, processed by Dicer to
produce the mature miRNAs (Triboulet and Gregory, 2010). As a first step to determine
if the caspase inhibitor-sensitive downregulation of CtBPs induced during apoptosis
might be mediated via a miRNA-dependent pathway, we compared the expression of
CtBP1 in WT mESCs to DGCR8 KO mESCs which are deficient in miRNA biogenesis
(Wang et al., 2007). Incubation of WT mESCs with the classical apoptosis inducer,
staurosporine, caused a marked downregulation of CtBP1 that was prevented by the pancaspase inhibitor QVD (Fig. 4.10A, left blot). In contrast, incubation of DGCR8 KO
mESCs with staurosporine failed to have any significant effect on the expression of
CtBP1 (Fig. 4.10A, right blot). It is important to note that staurosporine treatment caused
significant cell death in both cell lines that was partially blunted by co-treatment with
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QVD (Fig. 4.10B). These data indicate that the caspase-dependent downregulation of
CtBP1 induced under apoptotic conditions requires intact miRNA processing and
biogenesis machinery.
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Figure 4.10 DGCR8 knockout mouse embryonic stem cells (mESCs) do not display
caspase-dependent downregulation of CtBP1 in response to staurosporine
treatment. A. Wild-type (WT) and DGCR8 knockout (KO) mESCs were incubated for
24 h in Con medium alone or containing staurosporine (STS; 100 nM) ± the pan-caspase
inhibitor QVD (20 µM). Following incubation, cell lysates were resolved by SDS-PAGE
and western blotted for CtBP1. Membranes were subsequently stripped and reprobed for
actin as a loading control. B. WT or KO mESCs were treated as described in (A).
Representative bright field images are shown following a 24 h treatment period. Scale
bar = 10 microns.
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4.5 Discussion
CtBPs act as transcriptional co-repressors of a number of pro-apoptotic genes
including the Bcl-2 family members Bax, Noxa, Bik, Bim, and Bmf (Bergman and
Blaydes, 2006, Grooteclaes et al., 2003 and Kovi et al., 2010). Therefore, it is not
surprising that CtBPs might be downregulated in cells undergoing apoptosis. However, to
our knowledge the present study is the first to document this effect during neuronal
apoptosis. Previous studies of CtBP function in the nervous system have been mostly
limited to the role of these proteins in development. For instance, the Drosophila CtBP
(dCtBP) significantly impacts development of the fly peripheral nervous system by
negatively regulating formation of mechanosensory bristles, perhaps by influencing extra
sensory organ precursor cell fate (Biryukova and Heitzler, 2008 and Stern et al., 2009).
CtBPs are expressed throughout the developing avian CNS, often in overlapping regions
but sometimes in unique localizations such as CtBP1 expression in dorsal root ganglia
and CtBP2 expression in emigrating neural crest cells (Van Hateren et al., 2006). The
functional significance of CtBP expression in the developing chick CNS is demonstrated
by the key role that these proteins play in regulating the transition of neural precursor
cells in the ventricular zone of the dorsal spinal cord from a proliferative to a
differentiated state (Xie et al., 2011). In a similar manner, CtBP1 and CtBP2 display both
duplicative and independent roles in mouse CNS development including maturation of
the forebrain and midbrain (Hildebrand and Soriano, 2002). Additional studies have
demonstrated interactions of CtBPs with a number of neuronal proteins including
neuronal nitric oxide synthase, actin-related protein alpha, and calsenilin, although the
physiological significance of these interactions is not well defined (Oma et al., 2003,
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Riefler and Firestein, 2001 and Zaidi et al., 2006). Finally, CtBPs have been loosely
associated with some types of CNS injury. For example, CtBP expression has been
shown to decline rapidly following spinal cord injury in the mouse (Cai et al., 2012). In
another study, the glycolytic inhibitor, 2-deoxy-D-glucose, suppressed seizure activity in
a rat kindling model of temporal lobe epilepsy via an NRSF/CtBP-dependent repression
of the BDNF gene promoter (Garriga-Canut et al., 2006). These studies demonstrate that
CtBPs are key factors in CNS and peripheral nervous system development; however, the
role of CtBPs in determining neuronal survival and death has not been explicitly
investigated.
In the present study, we have identified CtBPs as essential pro-survival proteins in
CGNs. The expression of CtBP1 and CtBP2 was significantly downregulated in CGNs
exposed to a number of pro-apoptotic stressors. Moreover, forced downregulation of
CtBP1 using morpholino-antisense oligonucleotides was sufficient to induce CGN
apoptosis. In a similar manner, incubation of CGNs with the CtBP inhibitor, MTOB,
induced the upregulation of pro-apoptotic Noxa and triggered actinomycin D-sensitive
CGN apoptosis. These results are consistent with CtBPs functioning in CGNs as prosurvival factors which are subject to downregulation during neuronal apoptosis. One may
consider the downregulation of CtBPs as a major factor in determining whether neurons
succumb to apoptosis since loss of CtBP function ultimately leads to the de-repression of
pro-apoptotic genes.
In non-neuronal cells, CtBPs have previously been shown to be targeted for
proteasomal degradation in response to pro-apoptotic stimuli that induce p53-independent
apoptosis (Paliwal et al., 2006, Wang et al., 2006, Zhang et al., 2003 and Zhang et al.,
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2005). In contrast, CGNs exposed to Rac GTPase-inhibitory Clostridial toxins displayed
downregulation of CtBP1 and CtBP2 that was insensitive to proteasome inhibition but
sensitive to caspase inhibition. This novel caspase-dependent downregulation of CtBPs
also predominated under 5K apoptotic conditions in CGNs and in N27 dopaminergic
cells exposed to 6-OHDA. In contrast, the downregulation of CtBPs induced in CGNs by
the complex I inhibitor, MPP +, was completely insensitive to caspase inhibition but was
significantly attenuated by proteasome inhibition. These results demonstrate that the
downregulation of CtBPs during neuronal apoptosis occurs via a stimulus-specific
mechanism with both proteasome-dependent and caspase-dependent modes of
downregulation.
Previous studies on the regulation of CtBP expression have focused largely on the
proteasome-dependent degradation of these transcriptional co-repressors. During p53independent apoptosis of non-neuronal cells, CtBPs are phosphorylated on Ser422 or Ser
428 (CtBP1 or CtBP2, respectively) by either homeodomain interacting protein kinase-2
or c-Jun NH2-terminal kinase, targeting these proteins for subsequent ubiquitinylation
and proteasomal degradation (Wang et al., 2006, Zhang et al., 2003 and Zhang et al.,
2005). Under some conditions, targeting of CtBP to the proteasome may require
interaction with additional proteins such as the tumor suppressor ARF (Paliwal et al.,
2006). Recently, additional pathways have been suggested to regulate CtBP expression
via the proteasome. For instance, Akt1 has recently been shown to cooperate with the
SUMO E3 ligase Pc2 to induce phosphorylation and ubiquitinylation of CtBP resulting in
its enhanced degradation (Merrill et al., 2010). Another pathway for CtBP degradation
involves its interaction with the X-linked inhibitor of apoptosis protein which directly
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ubiquitinylates CtBP and targets it for proteasomal degradation (Lee et al., 2012). On the
other hand, B-cell lymphoma-3 (Bcl-3) is a proto-oncogene that has recently been shown
to interact with and stabilize CtBP by preventing its ubiquitinylation and subsequent
proteasomal degradation (Choi et al., 2010). Interestingly, CtBP1 protein levels were
downregulated in HEK293T cells incubated with the apoptosis inducer etoposide, but this
effect was prevented by overexpression of Bcl-3. Thus, proteasome-dependent
degradation appears to be a dominant pathway for turnover of CtBPs in non-neuronal
cells undergoing apoptosis.
In marked contrast to these previous studies, we have identified a novel caspasedependent pathway for CtBP downregulation in neurons undergoing apoptosis. Despite
the presence of a conserved caspase-3 consensus cleavage site in the CtBP1 and CtBP2
proteins, CtBPs do not appear to be direct caspase-3 substrates in vitro. Although it
cannot be ruled out that other caspase family members may directly cleave CtBPs in
neurons undergoing apoptosis, the rate of degradation of CtBP1 in CGNs is not
significantly altered in 5K (apoptotic) medium suggesting that the downregulation of
CtBPs observed under these conditions is not due to enhanced proteolysis. Intriguingly,
CtBP1 and CtBP2 mRNA transcripts are not significantly decreased in CGNs subjected
to 5K apoptotic conditions indicating that the downregulation of CtBPs likely occurs via
a post-transcriptional mechanism. Consistent with this idea, the caspase-dependent
downregulation of CtBP1 observed in mESCs exposed to staurosporine does not occur in
DGCR8 KO cells that are deficient in miRNA biogenesis. Collectively, these data
suggest that the caspase-dependent downregulation of CtBPs observed in neurons
undergoing apoptosis may occur via a miRNA-dependent mechanism.
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Several recent studies add support to the hypothesis that CtBPs are subject to
significant post-transcriptional regulation by miRNAs. For instance, the expression of
miR-137 was found to inversely correlate with CtBP1 expression in melanoma cell lines.
Moreover, miR-137 suppressed CtBP1 3′ UTR luciferase-reporter activity and
overexpression of miR-137 decreased CtBP1 levels and caused a corresponding increase
in expression of the CtBP1 target Bax (Deng et al., 2011). Interestingly, the miR-137
gene is found on chromosome 1p22 which is a known susceptibility region for melanoma
and furthermore, miR-137 was found to be under expressed in a subset of patient-derived
melanomas (Bemis et al., 2008, Chan et al., 2011 and Walker et al., 2004). In a similar
manner, the miR-141-200c cluster was recently shown to downregulate the expression of
CtBP2 and its transcriptional repressor partner, ZEB, in PANC-1 human pancreatic
carcinoma cells (Sass et al., 2011). ZEB is a key inducer of the epithelial-tomesenchymal transition which is thought to promote malignant tumor progression,
particularly in pancreatic, colorectal, and breast cancer (Burk et al., 2008). These studies
indicate that specific miRNAs may act as tumor suppressors in part by targeting CtBPs
for translational repression. It is noteworthy that miR-137 has recently been shown to act
as a key regulator of embryonic neural stem cell fate (Sun et al., 2011). However,
whether miR-137 regulates CtBP expression in the CNS is presently unknown. In the
future, it will be important to determine if downregulation of CtBPs is associated with
particular neurodegenerative diseases, particularly those for which caspases are
implicated in the underlying pathogenesis.
Finally, elucidating the mechanism by which caspases indirectly influence CtBP
expression during neuronal apoptosis will require additional study. One possibility is that
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caspases degrade a protein that under healthy conditions acts as a suppressor of specific
miRNAs. Once this suppressor is degraded, miRNAs are induced and target CtBPs for
translational repression. This in turn, leads to the de-repression of a subset of CtBP target
pro-apoptotic genes that contribute to the execution of neuronal apoptosis. The existence
of “RNA silencing suppressor” (RSS) proteins is evidenced by the HIV-1 Tat and Rex
proteins which suppress specific siRNAs or miRNAs by competing for their binding with
Dicer or other proteins of the RNA-induced silencing complex (Houzet and Jeang,
2011 and Rawlings et al., 2011). Thus, it is reasonable to hypothesize that neurons may
possess intrinsic RSS proteins that are degraded by caspases during neuronal apoptosis.
Identification of these putative neuronal RSS proteins may be necessary to resolve the
mechanism underlying caspase-dependent CtBP downregulation during neuronal
apoptosis.

144

CHAPTER FIVE: DYSREGULATION OF RHO OR RAC ELICITS DEATH OF
MOTOR NEURONS AND ACTIVATION OF THESE GTPASES IS ALTERED IN
G93A MUTANT SOD1 MICE
5.1 Abstract
Numerous studies have demonstrated a critical function for Rho GTPase family
members (i.e., Rac, Rho, Cdc42) in neuronal survival. Although a pro-survival function
for Rac has been reported in several neuronal cell types, the antagonistic relationship
between Rac and Rho/ROCK signaling in neuronal survival remains poorly understood.
In the current study, we examined the effects of Rac GTPase inhibition on motor
neuronal survival. We demonstrate that treatment with NSC23766, a selective inhibitor of
the Rac-specific GEFs, Tiam1 and Trio, induces death of embryonic stem cell (ESC)derived motor neurons which is characterized by caspase-3 activation, dephosphorylation
of ERK5 and Akt, and nuclear translocation of the BH3-only protein Bad. We also
examined the effects of a constitutive activator of Rho, CN03, on motor neuronal survival
in vitro. In a manner similar to selective inhibition of Rac GTPase, treatment of ESCderived motor neurons with CN03 results in a marked loss of neurites and significant cell
death.

Furthermore, inclusion of either ROCK inhibitor, Fasudil or Y-27632,

significantly protects ESC-derived motor neurons against constitutive activation of Rho.
These data suggest that the balance between Rac and Rho signaling is critical for motor
neuron survival. Moreover, in the G93A mutant Cu,Zn-superoxide dismutase (SOD1)
mouse model of amyotrophic lateral sclerosis (ALS), active Rac1-GTP immunoreactivity
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is markedly decreased in choline acetyltransferase (ChAT)-positive motor neurons of the
lumbar spinal cord when compared to age-matched wild type (WT) littermates. In
addition, although total RhoB localizes principally to nuclei of ChAT-positive motor
neurons from WT mice, RhoB appears to redistribute to motor neuronal processes in endstage mice harboring the G93A SOD1 mutation. Collectively, our data demonstrate that
Rac and Rho are critical regulators of neuronal survival and as a result, disruptions in the
balance of their activities may contribute to the etiology of motor neurodegenerative
diseases such as ALS.
5.2 Introduction
ALS is a devastating and progressive neurodegenerative disease characterized by
severe muscle weakness and atrophy due to loss of motor neurons in the spinal cord,
brain stem, and motor cortex. Following diagnosis, ALS patients typically survive 2-5
years and succumb to death due to respiratory failure. Approximately 90% of ALS cases
are classified as sporadic while the remaining 10% appear to be caused by a genetic
component. In particular, mutations in SOD1 account for approximately 20% of all
familial cases of ALS. Currently, mice harboring G93A mutant SOD1 (mSOD1) are the
most extensively described rodent model of the disease (Pandya et al., 2013). Although
the mechanism of motor neuron loss underlying the etiology of ALS is presently unclear,
recent findings suggest that dysregulated Rho family GTPase activity may be a
contributing factor.
Rho family GTPases are monomeric G-proteins that belong to the Ras
superfamily of GTPases. Within the Rho GTPase family, RhoA, Rac1, and Cdc42 are the
best described members. Numerous studies in neurons have demonstrated that Rho
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GTPases are critical regulators of growth cone dynamics, dendritic spine morphogenesis,
and neuronal survival (Linseman and Loucks, 2008). Specifically, Rac GTPase elicits
neurite outgrowth and neuronal survival while Rho GTPase provokes neurite retraction
and neuronal apoptosis (Luo, 2000). Many studies suggest that this intricate balance
between Rho family GTPase activities is important for maintaining neuronal survival. For
example, we have previously shown in primary cerebellar granule neurons (CGNs) that
inhibition of Rac utilizing large Clostridial cytotoxins or overexpression of a dominant
negative Rac1 mutant induces mitochondrial-dependent apoptosis (Linseman et al., 2001;
Le et al., 2005; Loucks et al., 2006; Stankiewicz et al., 2012). Conversely, RhoA GTPase
activation in CGNs elicits apoptosis following glutamate-induced excitotoxity (Semenova
et al., 2007). These studies underscore the importance of maintaining tight regulation of
Rho family GTPase activity in order to promote neuronal survival.
More recent data have demonstrated that a disrupted balance between Rho family
GTPases, particularly diminished Rac activity and/or enhanced Rho activity, may
contribute to the pathogenesis of neurodegenerative diseases such as ALS. Indeed,
dominant negative Rac expression alone is sufficient to induce death of cultured motor
neurons (Jacquier et al., 2006). Moreover, expression of G93A mSOD1 induces redoxsensitive apoptosis of SH-SY5Y neuroblastoma cells that is dependent on inactivation of
Rac GTPase (Pesaresi et al., 2011). In addition to mutations in SOD1, the involvement of
Rac GTPase in maintaining motor neuron survival is underscored by the fact that loss-offunction mutations in a Rac guanine nucleotide exchange factor (GEF), alsin (ALS2), are
causative in juvenile-onset ALS (Yang et al., 2001; Yamanaka et al., 2003; Hadano et al.,
2007). Although alsin functions as a GEF for both Rac and Rab5 (Topp et al., 2004),
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overexpression of constitutively active Rac, but not Rab5, attenuates the cellular
apoptosis and reduced axonal growth observed following siRNA knockdown of alsin in
primary motor neurons (Jacquier et al., 2006). Furthermore, alsin has been specifically
demonstrated to antagonize mutant SOD1-induced NSC34 motor neuronal death via
activation of a Rac-dependent pro-survival signaling cascade (Kanekura et al., 2005).
Finally, a recent study identified that ARHGEF16, an upstream regulator of Rac GTPase
(Blanke and Jäckle, 2008), is hyper-methylated and downregulated in patients with
sporadic ALS (Figueroa-Romero et al., 2012). Collectively, these findings indicate that a
loss of Rac GTPase activity may be a common factor underlying the death of motor
neurons in both familial and sporadic forms of ALS.
In accordance with previous studies demonstrating a pro-apoptotic function for
Rho GTPase in neurons, expression of the Rho GTPase effector Rho kinase (ROCK) is
elevated 221% in the spinal cord of G93A mSOD1 mice when compared to WT mice,
suggesting a potential increase due to enhanced Rho GTPase activity (Hu et al., 2003).
These data indicate that in a manner similar to loss of Rac GTPase activity, gain of Rho
GTPase/ROCK signaling may contribute to the selective motor neuron death underlying
the etiology of ALS. This hypothesis is consistent with prior studies demonstrating
aberrant activation of the Rho/ROCK pathway in other animal models of
neurodegenerative disease (Mueller et al., 2005; Rikitake et al., 2005; Satoh et al., 2007;
Zhang et al., 2010; Rodriguez-Perez et al., 2013). Nonetheless, detailed studies
examining the activation status of Rac and Rho GTPases during ALS disease progression
have not previously been investigated.
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In the present study, we aimed to determine the effects of altered Rho family
GTPase activity on motor neuron survival in vitro and whether dysregulated activation of
Rho family GTPases may contribute to ALS disease progression in vivo in the G93A
mSOD1 mouse. We report that targeted inhibition of Rac GTPase via NSC23766
treatment or constitutive activation of Rho via CN03 treatment induced neurite retraction
and apoptosis of ESC-derived motor neurons in vitro. Moreover, in vivo, active Rac1GTP is significantly decreased in motor neurons from pre-symptomatic and end-stage
G93A mSOD1 mice when compared to age-matched WT mice. Finally, we demonstrate
that WT motor neurons express total RhoB in a diffuse distribution throughout the
nucleus and soma while motor neurons of end-stage G93A mSOD1 mice demonstrate a
significant redistribution of RhoB immunoreactivity to their axonal processes.
Collectively, these findings demonstrate that Rac and Rho are critical mediators of motor
neuronal survival. Consequently, diminished Rac GTPase activity or elevated Rho
GTPase activity may contribute to the selective motor neuron degeneration observed in
ALS.
5.3 Materials and Methods
5.3.1 Reagents
NSC23766, Fasudil, and the antibody used to detect ChAT were from EMD
Millipore (Billerica, MA). Alexafluor 647 used to detect ChAT staining was from Life
Technologies (Carlsbad, CA). CN03 and Y-27632 were purchased from Cytoskeleton
(Littleton, CO). The polyclonal antibody used to detect active caspase-3 by
immunocytochemistry was from Promega (Madison, WI). The polyclonal antibodies used
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for immunostaining phosphorylated Akt (pAkt; S473), phosphorylated ERK5 (pERK5;
T218/Y220), and Bad were from Cell Signaling Technology (Beverly, MA). The
monoclonal antibodies used to detect active Rac1-GTP and active RhoA-GTP were
purchased from NewEast Biosciences (King of Prussia, PA). The polyclonal antibodies
used to detect total RhoB and the vesicular acetylcholine transporter (VAChT) were
purchased from Santa Cruz Biotechnology (Dallas, Tx). 4,6-Diamidino-2-phenylindole
(DAPI) and retinoic acid were purchased from Sigma (St. Louis, MO). The antibody
utilized to detect CD11b was purchased from Abcam (Cambridge, MA). Anti-mouse
Cy3- or anti-rat FITC-conjugated secondary antibodies utilized for immunofluorescence
were from Jackson ImmunoResearch Laboratories (West Grove, PA). Sonic hedgehog
(SHH), recombinant human brain-derived neurotrophic factor (BDNF), recombinant rat
ciliary neurotrophic factor (CNTF), recombinant rat glial cell line-derived neurotrophic
factor (GDNF), and recombinant human neurotrophic-3 (NT3) were all purchased from
R&D Systems (Minneapolis, MN).
5.3.2 Hb9::GFP embryonic stem cell (ESC) culture
The Hb9 mouse embryonic stem cell (ESC) line was derived from a transgenic
mouse line expressing green fluorescent protein (Hb9::GFP) cDNA under the motor
neuron-specific Hb9 promoter and was kindly provided by Wichterle and colleagues.
Hb9::GFP ESCs were maintained in an undifferentiated state in culture and propagated as
previously described (Wichterle et al., 2002). Briefly, Hb9::GFP ESCs were grown on a
monolayer of mouse embryonic fibroblasts in ESC-grade DMEM medium containing
4500 mg/L glucose and 2250 mg/L Na-bicarbonate supplemented with 15% hyclone fetal
bovine serum (FBS), 2 mM L-glutamine, 1x Penicillin/Streptomycin, 1x non-essential
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amino acids, 1x nucleosides, 0.1 mM 2-mercaptoethanol, and 1000 U/mL leukemia
inhibitory factor (EMD Millipore).
5.3.3 Hb9::GFP ESC differentiation
ESC-derived motor neurons were differentiated as previously described
(Wichterle et al., 2002). Briefly, ESC cell colonies were partially dissociated and grown
in aggregate culture in ADFNK medium [DMEM/F12 differentiation medium containing
4500 mg/L glucose and supplemented 2 mM L-glutamine, 1x Penicillin/Streptomycin,
0.1

mM

2-mercaptoethanol,

1x

Insulin-Transferrin-Selenium

supplement

(Life

Technologies), and 10% Knockout Serum Replacement (Life Technologies)] to promote
the formation of embryoid bodies. After 2 days in culture, ADFNK medium was replaced
and supplemented with retinoic acid (2µM; Sigma) to induce the formation of neuronal
precursor cells. After 24 h, recombinant SHH and GDNF were added for an additional 4
days to promote the differentiation of neural precursor cells into spinal motor neurons.
Embryoid bodies were dissociated with papain (Worthington Bio, Lakewood, NJ) into
single cell suspensions and plated onto dishes coated with matrigel (BD Biosciences, San
Jose, CA). Differentiated ESC-derived motor neurons were cultured in DMEM/F12
medium containing 4500 mg/L glucose and 2250 mg/L Na-bicarbonate supplemented
with 5% horse serum, 1x Insulin-Transferrin-Selenium Supplement, 1x B27 Supplement,
and neurotrophic factors (BDNF, CNTF, GDNF, NT3; each at 10 ng/mL). Consistent
with the previously established protocol, typically 30% of the cells were EGFPexpressing motor neurons that could be maintained in culture for at least 7 days for
experiments (Wichterle et al., 2002; Fig. 5.1).
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5.3.4 Immunofluorescence microscopy
For green fluorescent images, live fluorescent images were captured using a 20×
air objective on an Olympus IX71 microscope with a Diagnostics Insight Spot 2 chargecoupled device (CCD) camera and a Diagnostics capture software analysis program for
digital deconvolution (Spot Imaging Solutions, Sterling Heights, MI).
For triple fluorescent images, motor neurons cultures were fixed in 4%
paraformaldehyde, washed once in PBS, and then permeabilized and blocked in PBS
containing 0.2% Triton X-100 and 5% BSA. Cell were incubated for 1 h in primary
antibodies diluted in 2% BSA and 0.2% Triton X-100 in PBS and subsequently washed
five times in PBS. Next, cells were incubated with DAPI and a Cy3-conjugated
secondary antibody diluted in 2% BSA and 0.2% Triton X-100. The cells were washed
five additional times with PBS before the addition of an antiquench solution composed of
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured
using a 63× water immersion objective on a Zeiss Axioplan 2 microscope with a Cooke
Sensicam deep cooled CCD camera and a Slidebook software analysis program for
digital deconvolution (Intelligent Imaging Innovations Inc., Denver, CO).
5.3.5 Quantification of cell death and neurite integrity
As NSC23766- and CN03-induced cell death resulted in detachment of EGFP+
ESC-derived motor neurons from the culture dish, as an indicator of cell death and
neurite integrity, the number of EGFP+ cells in ten randomly selected 20× fields was
counted as was the number of motor neurons with neurites greater than three times the
length of their soma. Typically, ~100-200 cells were quantified from each 22.73mm well.
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Final counts represent the data obtained from at least three independent experiments
performed in duplicate.
5.3.6 Animals
Wild type FVB (WT) and mice expressing G93A mutant human SOD1 (mSOD1)
on an FVB background were obtained from Jackson Laboratories (Bar Harbor, ME).
When two observers independently noted for two consecutive days that a mouse
displayed either hind limb trembling or failure to extend either hind limb fully when held
by its tail, the mouse was considered to display signs of disease onset (~90 days). Mice
unable to right themselves within 15 seconds after being placed on their side were
considered end-stage (~120 days). Male and female mice corresponding to pre-onset
(~60 days), onset (~90 days), and end-stage (~120 days) were sacrificed in an isofluorane
chamber followed by decapitation.

Lumbar spinal cord sections were identified by

vertebrae, isolated, and immediately preserved in OCT for immunohistochemical
analysis.
5.3.7 Immunohistochemistry
For immunohistochemical studies, 18 µM lumbar spinal cord tissue sections
obtained from paired animal sets (each G93A mSOD1 mouse and its WT littermate) were
fixed in 4% paraformaldehyde. Next, the sections were blocked in PBS containing 5%
BSA and 0.2% Triton X-100. Primary antibodies were diluted in PBS containing 2%
BSA and 0.2% Triton X-100 and sections were incubated in primary antibody overnight
at 4°C. Next, sections were washed five times in PBS. Sections were then incubated with
Hoescht dye and Alexafluor 647-, Cy3-, or FITC-conjugated secondary antibody diluted
in PBS containing 2% BSA and 0.2% Triton X-100. Sections were washed five
153

additional times with PBS before the addition of an antiquench solution composed of
0.1% p-phenylenediamine in 75% glycerol in PBS. Fluorescent images were captured
using a 40× air objective on a Zeiss Axioplan 2 microscope with a Cooke Sensicam deep
cooled CCD camera and a Slidebook software analysis program for digital deconvolution
(Intelligent Imaging Innovations Inc., Denver, CO).
5.3.8 Immunohistochemical Quantification
For paired sets of animals (each G93A mSOD1 mouse and its WT littermate),
identical exposure times were used to capture fluorescent fields containing a total of
approximately 100 ChAT-positive motor neurons per mouse. The DAPI and ChAT
signals were transposed onto a corresponding bright field image of the same field. To
select a specific motor neuron for quantitative analysis, only cells with large nuclei and
significant ChAT immunofluorescence were chosen. The bright field image was then
used to free hand draw an outline of the cell. The outline was then transposed onto the
triple fluorescent image. The Rac1-GTP or RhoA-GTP fluorescent signal (red) was then
measured within the outlined cell in relative units of average fluorescence intensity per
pixel using Adobe Photoshop CS. An average background red fluorescence signal was
also calculated for each individual field imaged by measuring the average fluorescence
intensity per pixel in regions of the field which were completely devoid of cell nuclei.
This background value was then subtracted from each of the individual cell fluorescence
values obtained from that specific field. Using this method, the Rac1-GTP and RhoAGTP fluorescence was quantified from approximately 100 ChAT-positive motor neurons
per mouse. Typically, images with high signal to noise ratios were most suitable for
quantitative analysis.
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5.3.9 Data Analysis
Results represent the mean ± S.E.M. for the number (n) of independent
experiments performed. Statistical differences between the means of unpaired sets of data
were evaluated by one-way analysis of variance with a post hoc Tukey's test or a
student’s t test. A p value of <0.05 was considered statistically significant. Images are
representative of at least three independent experiments.
5.4 Results
5.4.1 Generation and differentiation of ESC-derived motor neurons
To examine the involvement of Rho GTPases in regulating the survival of motor
neurons, we utilized the HBG3 mouse ESC cell line developed by Wichterle and Peljto
(Wichterle et al., 2002; Wichterle and Peljto, 2008). This ESC line was derived from a
transgenic mouse line expressing enhanced green fluorescent protein (EGFP) cDNA
under control of the mouse Hb9 promoter. The homeobox gene, Hb9, is expressed
selectively by postmitotic motor neurons and is a classical marker of mature motor
neuron identity (Arber et al., 1999). ESC colonies were partially dissociated and grown in
aggregate culture in differentiation medium to promote formation of embryoid bodies.
After 2 days in aggregate culture, retinoic acid was added to promote differentiation into
neural precursor cells (Fig. 5.1A; left panel). Following a 24 h exposure to retinoic acid,
recombinant sonic hedge hog (SHH) and glial cell line-derived neurotrophic factor
(GDNF) were added for an additional 4 days to promote differentiation and survival of
spinal motor neurons (Fig. 5.1A; right panel). Embryoid bodies containing differentiated
EGFP+ ESC-derived motor neurons (Fig. 5.1B; top image) were dissociated into single
cell suspensions (Fig. 5.1B; middle image) and plated onto dishes coated with matrigel
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(Fig. 5.1B; lower image and 5.1C). Following this protocol, approximately 30% of cells
terminally differentiated into EGFP expressing motor neurons (Fig. 5.1B; lower panel
and 5.1C). These EGFP+ motor neurons stain positively for Hb9, choline
acetyltransferase (ChAT), and β3-tubulin (data not shown).
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Figure 5.1 Generation and differentiation of ESC-derived motor neurons. A. HBG3
mouse ESCs harboring an EGFP transgene driven by the motor neuron-specific Hb9
promoter (Hb9::EGFP) were initially cultured on a monolayer of mouse embryonic
fibroblasts in medium containing serum and leukemia inhibitory factor to suppress
differentiation. After detachment with trypsin, ESCs were cultured in suspension with
differentiation medium containing retinoic acid to induce development of motor neuron
progenitors (left image). After 24 h of exposure to retinoic acid, sonic hedgehog (SHH)
and glial cell line-derived neurotrophic factor (GDNF) were added to further promote the
differentiation of neuronal precursor cells into spinal motor neurons (right image). After
48 h incubation with SHH, embryoid bodies typically were larger and contained more
EGFP+ motor neurons than those maintained in medium containing only retinoic acid
(compare right panels to left panels). Scale bar = 100 micron. B. Following the 48 h
incubation period with SHH and GDNF (top panel), embryoid bodies (EBs) were
collected and gently digested with papain to produce a single cell suspension (middle
panel). These cells were then plated onto matrigel-coated culture dishes (bottom panel).
After 24 h on matrigel, EGFP+ motor neurons appear healthy and extend long processes
as well as multiple shorter neurites (lower panel). Scale bar = 20 micron. C. 2x
magnification of bottom, right image from 1B. Scale bar = 20 micron.
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5.4.2 A selective inhibitor of the Rac-specific GEFs, Tiam1 and Trio (NSC23766; Rac
Inh), causes a marked loss of neurites and death of ESC-derived motor neurons
To establish the involvement of Rac-GTPase in maintaining survival of ESCderived motor neurons, motor neuronal cultures were treated with the Rac inhibitor
NSC23766.

This compound selectively and reversibly hinders GDP/GTP exchange

carried out by the Rac-specific GEFs, Tiam1 and Trio, which are significant regulators of
Rac in the central nervous system (Schmidt and Hall, 2002; Gao et al., 2004). In a
manner consistent with previous observations in CGNs (Chapter 3 of this thesis), ESCderived motor neuron cultures succumbed to cell death following exposure to targeted
Rac GTPase inhibition. Incubation with the Rac inhibitor for only 6 h caused significant
shrinkage of motor neuron soma and fragmentation of neuronal processes (Fig. 5.2A).
Following 24 h of Rac inhibition, these effects were even more pronounced with more
than 50% of the motor neurons detached from the culture dish and essentially none of the
remaining motor neurons exhibited significant neuronal processes (Fig. 5.2B).
Consistent with a critical pro-survival function for Rac GTPase, we also observed
activation of the death executioner caspase-3 in approximately 30% of the EGFP+ motor
neurons that remained attached to the culture dish after a 24 h exposure to the Rac
inhibitor (Fig. 5.4A). These results indicate that NSC23766-mediated inhibition of Rac
GTPase in ESC-derived motor neurons elicits cell death via a mechanism consistent with
both apoptosis and anoikis, a form of programmed cell death characterized by the
detachment of cells from the extracellular matrix.
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Figure 5.2 A selective inhibitor of the Rac-specific GEFs, Tiam1 and Trio
(NSC23766; Rac Inh), causes a marked loss of neurites and death of ESC-derived
motor neurons. A. ESC-derived motor neuron cultures were left untreated (Control) or
incubated with the Rac Inh (200 µM) for 6 h. Note that incubation with the Rac Inh
caused the motor neuron cell bodies to round up and induced marked fragmentation of
neuronal processes. Scale bar = 20 micron. B. ESC-derived motor neuron cultures were
left untreated (Con) or incubated with the Rac Inh (200 µM) for 24 h. After 24 h, the total
number of EGFP+ motor neurons was quantified as was the number of motor neurons
with neurites greater than three times the length of their soma. Results shown are the
mean ± SEM of 3 independent experiments performed on duplicate wells. *p<0.05,
**p<0.01 vs. Con.
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5.4.3 Inhibition of Rho Kinase (ROCK) only modestly protects ESC-derived motor
neurons subjected to selective Rac-GTPase inhibition
Recent evidence demonstrates that phenylalanine treatment of cortical neurons
results in a reduction of Rac expression and an induction of mitochondrial-dependent
apoptotic cell death in a RhoA/ROCK-dependent mechanism (Zhang et al., 2007; Zhang
et al., 2010). Therefore, we next examined whether inhibition of Rac GTPase induces
neurite retraction and subsequent cell death through unopposed Rho/ROCK signaling. In
ESC-derived motor neuron cultures treated with NSC23766, inclusion of either ROCK
inhibitor, Fasudil or Y-27632, showed a very modest attenuation of cell loss and neurite
fragmentation/retraction (Fig. 5.3A). However, quantification revealed that neither
ROCK inhibitor displayed a statistically significant protective effect against selective Rac
inhibition (Fig. 5.3B and 5.3C). These data suggest that the principal mechanism by
which ESC-derived motor neurons subjected to Rac inhibition undergo apoptosis is not
due to unopposed activation of pro-apoptotic Rho/ROCK signaling.
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Figure 5.3 Inhibition of ROCK only modestly protects ESC-derived motor neurons
subjected to selective Rac-GTPase inhibition. A. ESC-derived motor neuron cultures
were incubated in either control medium (Con), Con medium + Rac Inh (200 µM), Rac
Inh + Fasudil (10µM), or Rac Inh + Y-27632 (10µM) for 24 h. Images of EGFP+ cells
were captured at 24 h. Scale bar = 20 micron. B. ESC-derived motor neuron cultures
were treated as described in (A). After a 24 h incubation, the total number of EGFP+
motor neurons was quantified. C. ESC-derived motor neuron cultures were treated as
described in (A). After a 24 h incubation, the number of EGFP+ cells containing neurites
at least 3x the length of the soma was quantified. Results shown are the mean ± SEM of 3
independent experiments performed on duplicate wells. Values are expressed as a
percentage of the Con condition. **p<0.01, ***p<0.001 vs. Con.
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5.4.4 Selective inhibition of Rac GTPase in ESC-derived motor neurons induces
dephosphorylation of ERK5 and Akt and nuclear translocation of the BH3-only protein
Bad
The modest protection afforded by ROCK inhibitors indicates that other pathways
known to regulate cellular survival downstream of Rac GTPase may be altered in
NSC23766-treated ESC-derived motor neurons. In previous studies carried out in
primary CGNs, we have demonstrated that NSC23766-mediated Rac inhibition
deactivates a pro-survival signaling cascade involving MEK5/ERK5 and Akt, ultimately
leading to an induction, dephosphorylation, and mitochondrial localization of the proapoptotic BH3-only protein Bad (Chapter 3 of this thesis). As anticipated based on these
prior results, incubation with NSC23766 similarly induced dephosphorylation
(inactivation) of the pro-survival proteins ERK5 (T218/Y220) and Akt (S473) in ESCderived motor neurons (Fig. 5.4B and 5.4C). Remarkably, NSC23766 treatment evoked a
marked redistribution of the BH3-only protein Bad from a diffuse cytosolic pattern to an
exclusively nuclear localization (Fig. 5.4D). These findings indicate that inhibition of Rac
induces motor neuron death via a mechanism that involves inactivation of critical prosurvival ERK5- and Akt-dependent signaling pathways, in addition to a redistribution of
the BH3-only protein Bad from the cytosol to the nucleus.
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Figure 5.4 Selective inhibition of Rac GTPase in ESC-derived motor neurons
induces activation of caspase-3, dephosphorylation of ERK5 and Akt, and nuclear
translocation of the BH3-only protein Bad. ESC-derived motor neuron cultures were
left untreated (Control) or incubated with the Rac Inh (200µM) for 24 h. Cells were fixed
and signaling proteins were visualized with a Cy3-conjugated secondary antibody as
indicated (shown in red). Nuclei were stained with DAPI (shown in blue). Arrows
indicate EGFP+ motor neurons. A. Active (cleaved) form of caspase-3. B. pERK5
(T218/Y220). C. pAkt (S473). D. BH3-only protein Bad. Scale bar = 20 micron.
163

5.4.5 Constitutive activation of Rho via CN03 treatment induces a marked loss of neurites
and death of ESC-derived motor neurons
In a manner similar to loss of active Rac GTPase, previous studies have
demonstrated that activation of Rho GTPase is sufficient to provoke apoptosis in several
neuronal models (Bertrand et al., 2007; Semenova et al., 2007; Sanno et al., 2010;
Barberan et al., 2011). Thus, we examined whether a specific activator of Rho GTPase,
CN03, is toxic to ESC-derived motor neurons. CN03 is a fusion protein made up of the
catalytic domain of a bacterial cytotoxic necrotizing factor and a proprietary cell
penetration moiety. CN03 potently and selectively activates Rho GTPase by deamidating
glutamine 63 within the switch 2 region of the protein, thus locking it in an active
conformation (Flatau et al., 1997; Schmidt et al., 1997). Following a 24 h incubation
period with CN03, ESC-derived motor neuron cultures displayed an approximately 35%
reduction in EGFP+ motor neurons and a nearly 50% decrease in the number of EGFP+
motor neurons with neurites at least three times the length of their soma (Fig. 5.5A).
Quantification revealed that constitutive activation of Rho GTPase induces significant
cell death and neurite retraction (Fig. 5.5B). As anticipated, these data highlight that in a
manner similar to inhibition of Rac function, constitutive activation of Rho triggers motor
neuron death.
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Figure 5.5 Constitutive activation of Rho via CN03 treatment induces a marked loss
of neurites and death of ESC-derived motor neurons. A. ESC-derived motor neuron
cultures were left untreated (Control) or incubated with the CN03 (1µg/mL) for 24 h.
Scale bar = 20 micron. B. ESC-derived motor neuron cultures were left untreated (Con)
or incubated with CN03 (1 µg/mL) for 24 h After 24 h, the total number of EGFP+ motor
neurons was quantified as was the number of motor neurons with neurites greater than
three times the length of their soma. Results shown are the mean ± SEM of 3 independent
experiments performed on duplicate wells. *p<0.05, **p<0.01 vs. Con.
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5.4.6 Inhibition of ROCK significantly protects ESC-derived motor neurons subjected to
constitutive Rho GTPase activation
Recent evidence suggests a necessary role for ROCK in apoptosis induced by Rho
activation (Godin and Ferguson, 2010; Zhang et al., 2010). To definitively establish
whether downstream activation of ROCK is required to induce cell death in ESC-derived
motor neurons subjected to Rho activation, we evaluated whether co-incubation with
either ROCK inhibitor, Fasudil or Y-27632, exerted a protective effect against CN03
treatment. In ESC-derived motor neurons treated with CN03, co-incubation with either
Fasudil or Y-27632 protected against membrane blebbing and neurite retraction (Fig.
5.6A). Quantification of cell loss and neurite fragmentation/retraction in ESC-derived
motor neurons co-incubated with CN03 and Fasudil or Y-27632 revealed that inhibition
of ROCK conferred significant neuroprotection against Rho activation (Fig. 5.6B and
5.6C). These data support a model in which activation of Rho induces motor neurite
retraction, fragmentation, and cell loss that is dependent on activity of the downstream
effector ROCK.
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Figure 5.6 Inhibition of ROCK significantly protects ESC-derived motor neurons
subjected to constitutive Rho GTPase activation. A. ESC-derived motor neuron
cultures were incubated in either control medium (Con), Con medium + CN03 (1µg/mL),
CN03 + Fasudil (10µM), or CN03 + Y-27632 (10µM) for 24 h. At 24 h, images of
EGFP+ cells were captured. Scale bar = 20 micron. B. ESC-derived motor neuron
cultures were treated as described in (A). After the 24 h incubation, the total number of
EGFP+ motor neurons was quantified. C. ESC-derived motor neuron cultures were
treated as described in (A). After the 24 h incubation, the number of EGFP+ cells
containing neurites at least 3x the length of the soma was quantified. Results shown are
the mean ± SEM of 3 independent experiments performed on duplicate wells. Values are
expressed as a percentage of the Con condition. ***p<0.001 vs. Control, #p<0.05,
###p<0.001 vs. CN03.
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5.4.7 Rac1-GTP immunoreactivity is decreased in ChAT-labeled motor neurons from
G93A mSOD1 mice
Our data in ESC-derived motor neurons suggest that Rac GTPase activity is
essential to maintain motor neuronal survival. To begin to unravel the complex role of
Rac GTPase in ALS disease progression, lumbar spinal cord sections from end-stage
G93A mSOD1 mice (G93A) and their age-matched wild type (WT) littermates were
stained for DAPI, active Rac1-GTP, and ChAT. Quantification of Rac1-GTP intensity
revealed that there is markedly reduced Rac1-GTP immunoreactivity in ChAT-positive
motor neurons in the spinal cord of end-stage G93A mSOD1 mice when compared to WT
mice (Fig. 5.7A and 5.7B). Furthermore, a similar reduction in Rac1-GTP
immunoreactivity was observed at 90 days (disease onset) but not 60 days (presymptomatic; Fig 5.7B). To our knowledge, these findings are novel in that they are the
first to identify a substantial and progressive loss of active Rac1-GTP specifically in
spinal motor neurons of G93A mSOD1 mice.
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Figure 5.7 Rac1-GTP immunoreactivity is decreased in ChAT-labeled motor
neurons from G93A mSOD1 mice. A. Spinal cords from end-stage (~120 days) mice
harboring the G93A SOD1 mutation (G93A) or wild type (WT) littermates were
cryosectioned into 18µM sections. Sections were stained for DAPI, active Rac1-GTP
(red), and choline acetyltransferase (ChAT; to label motor neurons; green). Note that
Rac1-GTP immunoreactivity is consistently high in WT motor neurons but is
substantially decreased in ChAT-positive cells from G93A mutant mice. Arrows indicate
prominent ChAT-positive motor neurons. Scale bar = 10 micron. B. Lumbar spinal cord
tissue was stained as described in (A) and quantified for paired animal sets (each pair
consisting of an end-stage G93A mSOD1 mouse and its age-matched WT littermate) at
end-stage (~120 days), disease onset (~90 days), and pre-symptomatic (~60 days). The
graph shown represents the average fluorescence intensity (per pixel) per ChAT-positive
cell and is presented as the mean ± SEM for 4 paired sets of mice at each disease stage.
Values are expressed as a percentage of WT. *p<0.05 compared to WT by a paired t-test.
NS denotes not significant.
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5.4.8 Rac1-GTP immunoreactivity is enhanced in CD11b-positive microglia of end-stage
G93A mSOD1 mice when compared to WT littermates
Collectively, our data in mouse ESC-derived motor neurons indicate an essential
pro-survival function for Rac GTPase. Yet, previous studies have also shown that Rac1
activation within microglia can activate NADPH oxidase to enhance the production of
reactive oxygen species (ROS) and significantly contribute to the death of neighboring
neurons (Harraz et al., 2008). To determine whether increased activation of Rac1 in
microglia may contribute to the progression of disease in the G93A mSOD1 mouse
model of ALS, lumbar spinal cord sections were stained for DAPI, Rac1-GTP, and
CD11b. In agreement with aberrant Rac1 GTPase activity contributing to ALS disease
progression, we observed increased Rac1-GTP immunoreactivity in CD11b-labeled
microglia in the spinal cord of end-stage G93A mSOD1 mice (G93A) when compared to
WT mice (Fig. 5.8). Collectively, our data support a model in which aberrant Rac1
activity may contribute to ALS disease progression in a cell type-specific manner;
through loss of its pro-survival function in motor neurons and enhancement of its ROSgenerating function (via NADPH oxidase or Nox activity) in glial cells.
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Figure 5.8 Rac1-GTP immunoreactivity is enhanced in CD11b-positive microglia of
end-stage G93A mSOD1 mice when compared to WT littermates. Spinal cords from
end-stage (~120 days) mice harboring the G93A SOD1 mutation (G93A) or wild type
(WT) littermates were cryosectioned into 18µM sections. Sections were stained for
DAPI, active Rac1-GTP (red), and CD11b (to label microglia; green). Scale bar = 10
micron. Right image: 2.5X magnification of demarcated boxes from the upper image.
Note that Rac1-GTP immunoreactivity is essentially absent in WT microglia but is very
high in CD11b-positive cells from G93A mutant mice. Arrow indicates CD11b-labeled
microglia. Scale bar = 10 micron.
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5.4.9 RhoA-GTP immunoreactivity is not altered in ChAT-labeled motor neurons from
G93A mSOD1 mice
Given the antagonistic relationship between Rac GTPase and Rho GTPase
signaling in neurons, we predicted that diminished expression of active Rac1-GTP in
ChAT-positive motor neurons in the G93A mSOD1 mouse would correlate with
increased expression of active Rho GTPase. Although three isoforms of Rho GTPase
(RhoA, RhoB, and RhoC) have been identified, RhoA activity has been widely
demonstrated to provoke apoptosis in a variety of neuronal models (Dubreuil et al., 2006;
Semenova et al., 2007; Sanno et al., 2010). Thus, we stained lumbar spinal cord sections
from end-stage G93A mSOD1 mice (G93A) and their age-matched WT littermates for
DAPI, active RhoA-GTP, and ChAT. To our surprise, quantification of RhoA-GTP
staining revealed that there was no statistical difference between RhoA-GTP expression
in ChAT-positive motors neurons of end-stage G93A mSOD1 mice when compared to
WT mice (Fig. 5.9A). These results indicate that increased activation of RhoA GTPase
does not contribute to the motor neuronal cell death observed in the G93A mSOD1
mouse model of ALS.
5.4.10 RhoB immunoreactivity is enhanced in motor neuron axons of G93A mSOD1 mice
In addition to RhoA, enhanced RhoB activation has been demonstrated to be an
early marker of neuronal death in a murine stroke model (Trapp et al., 2001), and
cultured corticohippocampal neurons isolated from RhoB knockout mice are significantly
less sensitive than WT neurons to apoptosis induced by staurosporine (Barberan et al.,
2011). Therefore, we next stained lumbar spinal cord sections from end-stage G93A
mSOD1 mice (G93A) and their age-matched wild type littermates for DAPI, RhoB, and
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ChAT. Although the overall expression of RhoB did not appear to be enhanced in motor
neurons from end-stage ALS mice, the localization of RhoB was drastically altered. In
WT mice, ChAT-positive motor neurons expressed RhoB in a diffuse distribution
throughout the nucleus and soma; however, essentially no immunoreactivity was
observed in neuronal processes. In marked contrast, motor neurons of end-stage G93A
mSOD1 mice demonstrated significant RhoB immunoreactivity within their processes
(Fig. 5.9B and 5.9D). To definitively establish the axonal expression of RhoB in motor
neurons, spinal cord sections from end-stage G93A mSOD1 mice and WT mice were
stained for DAPI, RhoB and the vesicular acetylcholine transporter (VAChT). Our data
demonstrate that RhoB expression partially co-localizes with the VAChT in motor
neuron axons of end-stage G93A mSOD1, but not WT, mice (Fig. 5.9C). Interestingly,
RhoB redistribution appears to occur at a relatively late stage during disease progression
as RhoB was consistently localized to the nuclei and soma of both WT and G93A
mSOD1 motor neurons at disease onset (~90 days; compare Fig. 5.9D and 5.9E).
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Figure 5.9 RhoB immunoreactivity is enhanced in motor neuron axons of G93A
mSOD1 mice A. Spinal cords from end-stage mice (~120 days) harboring the G93A
SOD1 mutation (G93A) or wild type (WT) littermates were cryosectioned into 18µM
sections. Sections were stained for DAPI, active RhoA-GTP (red), and choline
acetyltransferase (ChAT; to label motor neurons). The graph shown represents the
average fluorescence intensity (per pixel) per ChAT-positive cell and is presented as the
mean ± SEM for 3 paired sets of mice (each pair consisting of an end-stage G93A
mSOD1 mouse and its age matched WT littermate). Values are expressed as a percentage
of WT. NS denotes not significant compared by a paired t-test. B. Spinal cords were
processed and cryosectioned as described in (A). Sections were stained for DAPI, RhoB
(red), and choline acetyltransferase (ChAT; to label motor neurons; green). Note that
RhoB immunoreactivity is not observed in neuronal processes of WT motor neurons but
brightly labels processes of ChAT-positive cells from G93A mutant mice. Scale bar = 5
micron. C. Spinal cords were cryosectioned as described in (A). Sections were stained for
DAPI, RhoB (red), and vesicular acetylcholine transporter (VAChT; to label motor
neuron axons; green). Note that RhoB immunoreactivity is not observed in neuronal
processes of WT motor neurons but brightly labels processes of VAChT-positive motor
neuron axons from G93A mSOD1 mice. Scale bar = 10 micron. D. Lumbar spinal cord
tissue was stained as described in (A) for 3 paired sets of end-stage mice (~120 days)
mice. Note that in each animal set RhoB immunoreactivity is not observed in neuronal
processes of WT motor neurons but brightly labels processes of ChAT-positive cells from
G93A mSOD1 mice. Arrows indicate RhoB expression in motor neuron processes. Scale
bar = 10 micron. E. Lumbar spinal cord tissue was stained as described in (A) for 3
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paired sets of disease onset mice (~90 days) mice. Note that in each 90 day animal set
RhoB expression principally localizes to the soma in both WT and G93A ChAT-positive
motor neurons. Scale bar = 10 micron.

175

5.4.11 Proposed model depicting the mechanisms by which dysregulated Rho family
GTPase activity may contribute to selective motor neuron degeneration in the G93A
mSOD1 mouse model of ALS
We propose in healthy spinal cords (Fig. 5.10A), microglia retain Rac1 in an
inactive GDP-bound state while motor neurons promote pro-survival signaling by
maintaining Rac1 in an active GTP-bound state. Furthermore, we propose that RhoB
localizes principally to the soma of healthy motor neurons. Conversely, in the diseased
spinal cords of G93A mSOD1 mice (Fig. 5.10B), we hypothesize that enhanced
activation of Rac1-GTP in microglia contributes to the activation of NADPH oxidase and
the release of toxic ROS from microglia. Furthermore, loss of Rac1-GTP pro-survival
signaling in G93A mSOD1 motor neurons leads to neurite retraction and motor neuron
death through deactivation of critical Rac1-dependent pro-survival signaling cascades.
Finally, we hypothesize that RhoB redistribution to axons of motor neurons leads to
axonal retraction and motor neuron death in G93A mSOD1 mice.
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Figure 5.10 Proposed model depicting the mechanism by which dysregulated Rho
family GTPase activity may contribute to selective motor neuron degeneration in
the G93A mSOD1 mouse model of ALS. A. In wild type spinal cords, active Rac1
(GTP-bound) transmits pro-survival signals in motor neurons. RhoB is localized to the
cytosol of motor neurons. In healthy microglia, Rac1 exists primarily in an inactive
(GDP-bound) state. B. In G93A mSOD1 spinal cords, decreased Rac1-GTP in motor
neurons promotes death via diminished pro-survival signals. The localization of RhoB
from the cytosol to motor neuron processes also promotes axonal retraction and motor
neuron death. Increased microglia in the spinal cord is indicative of microgliosis. Within
reactive microglia, increased Rac1-GTP leads to enhanced activation of NADPH oxidase
and the release of toxic reactive oxygen species (ROS). Red indicates increased
activation. Blue indicates decreased activation. Green indicates altered localization. I
acknowledge Aimee Winter for assistance with creating this figure.
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5.5 Discussion
It is well documented that the antagonistic relationship between Rac GTPase and
Rho GTPase is a determinant of neuronal survival. Therefore, it is perhaps not surprising
that inhibition of Rac GTPase or constitutive activation of Rho GTPase induces cell death
and neurite fragmentation/retraction of ESC-derived motor neurons. Indeed, inhibition of
Rac GTPase in embryonic rat spinal motor neurons is sufficient to cause suppression of
axon outgrowth and induce cell death (Jacquier et al., 2006). Moreover, in NSC34 motor
neuron-like cells, constitutively active Rac protects these cells from the toxic expression
of ALS-causing SOD1 mutants (Kanekura et al., 2005). Although the involvement of
Rho GTPase in regulating motor neuron survival is not as well established, RhoA is
activated in vulnerable brain regions following either traumatic brain injury or epileptic
insult (Dubreuil et al., 2006), and RhoB null cortical neurons are significantly less
sensitive to apoptotic stimuli than wild type neurons (Barberan et al., 2011). Thus, Rac
GTPase and Rho GTPase play key roles in a regulating neuronal survival.
Our data indicate that inhibition of Rac GTPase induces neurite fragmentation and
motor neuronal cell death through activation of the death executioner of apoptosis,
caspase-3, and via deactivation of essential pro-survival kinases, including ERK5 and
Akt. These results were anticipated based on our prior findings in primary CGNs
demonstrating that selective Rac inhibition with an inhibitor of Tiam1 and Trio induces
apoptosis through diminished pro-survival MEK5/ERK5 and Akt signaling (Chapter 3 of
this thesis). These findings are consistent with those of Kanekura et al. (2005) who
showed that a Rac/PI3K/Akt-dependent pro-survival signaling cascade attenuated mutant
SOD1-induced toxicity in the NSC34 motor neuron cell line. Furthermore, our findings in
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ESC-derived motor neurons substantiate the critical importance of Rac GTPase in
transmitting key pro-survival signaling cascades in terminally differentiated motor
neurons.
A critical pro-survival function of active pAkt (S473) is to phosphorylate the proapoptotic BH3-only protein Bad to sequester it to 14-3-3 cytosolic scaffolding proteins,
effectively diminishing its ability to induce apoptosis at the mitochondria (Zha et al.,
1996). Indeed, we have previously shown in NSC23766-treated CGNs that diminished
pAkt (S473) induces mitochondrial localization of Bad (Chapter 3 of this thesis).
Surprisingly, in the present study, we report that NSC23766 treatment evokes a marked
redistribution of the BH3-only protein Bad from a diffuse cytosolic pattern to an
exclusively nuclear localization in ESC-derived motor neurons. This result differs from
the mitochondrial translocation of Bad observed in CGNs exposed to the Rac inhibitor;
however, it is an intriguing finding since nuclear localization of Bad has been suggested
to stimulate entry of cells into the cell cycle (Chattopadhyay et al., 2001; Al-Bazz et al.,
2009), which is a known trigger of apoptosis in post-mitotic neurons (Folch et al., 2012).
Although our data indicate that inhibition of Rac GTPase induces neurite
fragmentation and motor neuronal death, it was surprising to reveal that inclusion of two
distinct ROCK inhibitors (i.e. Fasudil, Y-27632) did not significantly protect motor
neurons from loss of Rac GTPase activity.

Supporting crosstalk between Rac and

Rho/ROCK signaling, Rac GTPase has been shown to repress Rho/ROCK signaling in
HeLa cells through binding and activating the Rho GAP, p190RhoGAP (Wildenberg et
al., 2006). Furthermore, it has been previously demonstrated that Rho/ROCK signaling
can antagonize transmission of pro-survival Rac-dependent signaling pathways.
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In

particular, activation of Rho/ROCK enhances the phospholipid phosphatase activity of
PTEN which when coexpressed with RhoA, results in a synergistic reduction in active
Akt in human embryonic kidney cells (Li et al., 2005). Nonetheless, given that our data
do not support significant involvement of ROCK in mediating death of Rac-inhibited
ESC-derived motor neurons, it is possible that unopposed Rho GTPase activation may
induce neurite retraction and subsequent apoptosis through an alternative downstream
effector. Indeed, Semenova et al. (2007) previously demonstrated that ROCK activity
was dispensable in CGNs undergoing Rho-dependent glutamate excitotoxicity as
inclusion of Y-27632 did not attenuate nuclear fragmentation. Thus, our data do not
exclude the possibility that inhibition of Rac GTPase leads to unopposed pro-apoptotic
Rho GTPase signaling that occurs independent of ROCK activation in motor neurons.
Interestingly, although ROCK inhibitors were not protective against selective
inhibition of Rac GTPase in ESC-derived motor neurons, both Fasudil and Y-27632
protected against neurite loss and apoptosis elicited via constitutive activation of Rho
GTPase with CN03. These data highlight that activation of Rho GTPase may induce cell
death through downstream activation of a ROCK/PTEN pathway as PTEN indirectly
terminates Akt activation to induce neuronal death (Wu et al., 2012; Lai et al., 2014).
Furthermore, a recent report demonstrated that inhibition of ROCK utilizing a metabolite
of Fasudil, hydroxyfasudil, reduced G93A mSOD1-induced neurotoxicity in NSC34
motor neuronal-like cells in a manner that was dependent on reducing elevated PTEN
levels and restoring diminished levels of active Akt. Moreover, inhibition of Akt
abolished the neuroprotective effects afforded by hydroxyfasudil in G93A mSOD1transfected NSC34 cells (Takata et al., 2013). Collectively, these data predict that
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enhanced activation of Rho/ROCK signaling induces selective motor neuronal death
through activation of PTEN and subsequent deactivation of the pro-survival protein Akt.
To further investigate whether dysregulated Rho family GTPase activity
contributes to the etiology of ALS, we examined the expression of active Rac1 GTPase
and RhoA GTPase in the spinal cord of G93A mSOD1 mice. We report that active Rac1GTP immunoreactivity is significantly decreased in ChAT-positive motor neurons of
G93A mSOD1 mice when compared to age-matched littermates. Significant deficits in
active Rac1-GTP were observed in motor neurons of G93A mSOD1 mice at 120 days
(end-stage) and 90 days (onset), but not at 60 days (pre-symptomatic). This is consistent
with our findings demonstrating an essential role for Rac GTPase in maintaining ESCderived motor neuron survival and is further supported by studies reporting that
expression of Rac1 can antagonize cell death caused by mSOD1 expression in a variety
of neuronal models, including primary motor neurons (Kanekura et al., 2005; Jacquier et
al., 2006; Pesaresi et al., 2011). A potential mechanism by which G93A mSOD1 may
inactivate Rac1 GTPase in diseased motor neurons involves the growth factor adaptor
protein p66Shc. Upon oxidative stress, p66Shc is phosphorylated and translocates to the
mitochondria where it acts as an oxidoreductase to generate ROS (Giorgio et al., 2005;
Gertz and Steegborn, 2010). While G93A mSOD1 expression in SH-SY5Y cells induces
cell death consistent with decreased Rac1 GTPase activity, expression of an inactive
mutant of p66Shc abrogates this effect. The ability of p66Shc to regulate Rac1 activity
occurs via a redox-sensitive mechanism as treatment of SH-SY5Y cells with H2O2 led to
a proportionate decrease in Rac1 GTPase activity that was attenuated by expression of an
inactive p66Shc mutant (Pesaresi et al., 2011). While the precise mechanism by which
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active Rac1-GTP is downregulated in spinal motor neurons of G93A mSOD1 mice
remains to be determined, these findings highlight loss of Rac1 activity as a significant
factor in the selective motor neuron death observed in ALS.
Given the antagonistic relationship exerted between Rac GTPase and Rho GTPase
in conjunction with extensive evidence specifically implicating RhoA in neuronal
apoptosis, we predicted that decreased active Rac1-GTP immunoreactivity would
correlate with enhanced active RhoA-GTP expression in ChAT-positive motor neurons.
We were surprised to find that there was no significant difference between RhoA-GTP
expression in G93A mSOD1 and WT motor neurons. Instead, we found a marked
redistribution of total RhoB expression. While RhoB exclusively localizes to the soma in
WT motor neurons, RhoB significantly redistributed to neurites of spinal motor neurons
in end-stage, but not disease onset, ALS mice. This is an important finding given
substantial evidence demonstrating that RhoB can induce neurite retraction and
subsequent neuronal apoptosis (Trapp et al., 2001; Conrad et al., 2005; Barberan et al.,
2011). Indeed, in ALS mouse models, analysis of neuromuscular junctions reveals axonal
retraction and denervation prior to loss of alpha motor neuron cell bodies in the lumbar
spinal cord and associated development of clinical symptoms (Frey et al., 2000; Fischer
et al., 2004). However, collectively, our data suggest that loss of active Rac1-GTP may
underlie neurite retraction and motor neuron death in early disease stages (disease onset),
while RhoB redistribution may contribute to neurite retraction in later disease stages
(end-stage).
Contrary to the loss of active Rac1 GTPase observed in spinal cord motor
neurons, we show increased Rac1-GTP staining in CD11b-positive microglia of end183

stage G93A mSOD1 mice when compared to WT littermates. In agreement with these
findings, a previous report demonstrated that Rac1-GTP is actually upregulated in total
spinal cord lysates isolated from G93A mSOD1 mice (Harraz et al., 2008), lending to the
hypothesis that Rac1 activation plays a cell type-specific role in the progression of ALS.
Indeed, although selective motor neuron degeneration is a hallmark of ALS, several
reports indicate that death does not occur strictly via a cell-autonomous mechanism
(Ilieva et al., 2009). Importantly, in addition to its role in neuronal development and
survival, Rac1 is required to activate both Nox1 and Nox2, catalytic subunits of NADPH
oxidase, and activation of this complex may contribute to the death of neighboring motor
neurons through the generation of toxic superoxide (O2-) molecules (Wu et al., 2006; Raz
et al., 2010). Nox1, Nox2, and NADPH oxidase activity are upregulated in spinal cord
microglia from genetic mouse models of ALS and ALS patients (Wu et al., 2006).
Moreover, previous studies have demonstrated that either genetic deletion or chemical
inhibition of Nox1 or Nox2 can slow disease progression and improve survival in familial
ALS mice (Wu et al., 2006; Harraz et al., 2008). Further substantiating a role for
enhanced activation of Rac1 GTPase in microglia as a causative factor underlying the
progression of ALS, Harraz et al. (2008) demonstrated that mSOD1 stimulates Rac1dependent activation of NADPH oxidase in glial cells expressing ALS-causing forms of
mutant SOD1. Collectively, these studies indicate that aberrant Rac1 GTPase activation
in microglia may enhance NADPH oxidase activation and the release of toxic ROS to
elicit motor neuron death in this particular mouse model of ALS.
In addition to activation of NADPH oxidase, expression of G93A mSOD1 in
microglia leads to the Rac1-dependent secretion of pro-apoptotic TNFα and subsequent
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cell death of neighboring motor neurons in co-culture experiments (Li et al., 2011).
Intriguingly, a recent report by Tönges et al. (2014) demonstrated that inhibition of
ROCK via oral administration of Fasudil is protective against motor neuron loss in the
G93A mSOD1 mouse and this occurs at least partially via reduced secretion of TNFα
from microglia. Overall, these data support the notion that balanced signaling between
Rac and Rho/ROCK is ultimately disrupted in the spinal cord of G93A mSOD1 mice.
One potential mechanism by which G93A mSOD1 may activate Rac1 GTPase in
microglia is through the P2X7 receptor (Apolloni et al., 2013), which is responsible for
the release of pro-inflammatory factors from microglia, such as TNFα (Skaper et al.,
2010). Although the precise mechanism by which activation of Rac1 in microglia
enhances disease progression in the G93A mSOD1 mouse model of ALS requires further
investigation; collectively, these data suggest that Rac1 may contribute to
neurodegenerative disease in multiple cell type-specific ways; through loss of its prosurvival function in motor neurons and enhancement of its ROS-generating function in
glial cells.
Takata et al. (2013) recently administered Fasudil to G93A mSOD1 mice to
elucidate the involvement of ROCK activation on the integrity and viability of motor
neurons. Indeed, administration of Fasudil reduced motor neuronal loss, slowed disease
progression, and extended lifespan of G93A mSOD1 mice. Furthermore, this study
confirmed that ROCK inhibition attenuated elevated PTEN activation while restoring
diminished Akt activation that is typically observed in this particular familial mouse
model of ALS. It is interesting to note that in each study examining ROCK inhibition in
vivo, Fasudil was administered at a relatively early stage in disease progression (Takata et
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al., 2013; Tönges et al. 2014). In conjunction with our data implicating RhoB
redistribution to neuronal processes in end-stage mice as a potential causative factor
underlying disease progression, these data suggest that ROCK inhibition may prove to be
an effective treatment even after disease onset. However, it is important to note that the
antibody we utilized detected total RhoB expression as an antibody to active RhoB-GTP
is not yet commercially available. Nonetheless, given this limitation, our data aid in
clarifying the temporal and cell type-specific role that aberrant Rac1 GTPase and/or
RhoB GTPase activity may contribute to the underlying pathology in the G93A mSOD1
mouse model of ALS.
In summary, we show that selective inactivation of Rac GTPase or constitutive
activation of Rho GTPase is sufficient to evoke neurite retraction and subsequent cell
death of ESC-derived motor neurons. Further confirming the pro-survival role of Rac
GTPase in motor neurons, we report that Rac1-GTP is significantly reduced in ChATpositive spinal cord motor neurons of G93A mSOD1 mice, when compared to agematched WT littermates, at disease onset through end-stage. However, our data indicate
that the involvement of dysregulated Rac1 GTPase in contributing to the pathology of
ALS is much more complex as Rac1-GTP is upregulated in microglia from end-stage
mice harboring the G93A SOD1 mutation. Finally, we highlight that although RhoB
localizes principally to the soma of ChAT-positive motor neurons from WT mice, RhoB
redistributes to neuronal processes, including motor neuron axons, in end-stage mice
harboring the G93A SOD1 mutation. To our knowledge, these data are novel in that they
are the first to reveal the temporal and cell type-specific dysregulation of Rho family
GTPases in a familial mouse model of ALS.
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CHAPTER SIX: DISCUSSION
Accumulating evidence suggests an important and conserved role for Rho family
GTPases in mediating neuronal survival and death. Pivotal studies have demonstrated
that while Rac GTPase stimulates neurite outgrowth and neuronal survival, Rho GTPase
typically provokes neurite retraction and neuronal apoptosis. Nonetheless, the precise
pro-survival and pro-apoptotic signaling pathways mediated by Rho family GTPases in
neurons remains incompletely understood. We have previously shown that the Rho
family GTPase inhibitor ToxB induces CGN apoptosis primarily through deactivation of
Rac1 GTPase (Linseman et al., 2001; Le et al., 2005; Loucks et al., 2006). Thus, a
principal focus of this thesis was to examine the precise signaling pathways that are
regulated by Rac1 GTPase in primary CGNs. Furthermore, given recent evidence
suggesting that dysregulation of Rho GTPases may underlie the pathology of motor
neurodegenerative diseases such as ALS, an additional focus of this thesis was to
examine the effects of dysregulation of Rac GTPase or Rho GTPase in terminally
differentiated ESC-derived motor neurons and in an in vivo familial mouse model of
ALS.
6.1 Summary of Major Findings
We have previously shown that ToxB, a broad spectrum inhibitor of Rho, Rac,
and Cdc42, induces apoptosis of primary CGNs predominantly through deactivation of
Rac1 GTPase (Linseman et al., 2001; Le et al., 2005; Loucks et al., 2006). Indeed, in
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healthy CGNs, Rac GTPase promotes neuronal survival through activation of a prosurvival MEK1/2/ERK1/2 signaling cascade, acting downstream of PAK, that functions
to repress JNK/c-Jun activation of the BH3-only protein Bim, as well as, a pro-apoptotic
JAK/STAT signaling cascade (Linseman et al., 2001; Le et al., 2005; Loucks et al.,
2006). The aim of Chapter 2 of this thesis was to examine which particular member of
the STAT family induced CGN apoptosis downstream of Rac GTPase inhibition. In
CGNs treated with ToxB, STAT5 was upregulated, hyper-phosphorylated, and
translocated to nuclei to suppress transcription of the pro-survival protein Bcl-xL. These
data helped clarify a critical pro-apoptotic pathway that is activated in primary CGNs in
response to Rac GTPase inhibition.
Given that ToxB inhibits Rho, Rac, and Cdc42, the aim of Chapter 3 was to
examine the effects of a more targeted inhibitor of Rac GTPase in CGNs. NSC23766 is
an inhibitor of the Rac-specific GEFs, Tiam1 and Trio, and treatment with this compound
elicited apoptosis of CGNs via a mechanism that was distinct from ToxB. While ToxB
suppressed a pro-survival MEK1/2/ERK1/2 signaling cascade that led to reduced
degradation of the BH3-only protein Bim, the selective Rac inhibitor instead suppressed a
distinct pro-survival MEK5/ERK5 pathway that led to increased expression and
mitochondrial localization of the BH3-only protein Bad. These data demonstrate that
global inhibition of Rho GTPases versus selective inactivation of Rac GTPase induces
apoptosis through suppression of unique MAP kinase signaling pathways, which regulate
distinct pro-apoptotic members of the BH3-only subfamily of Bcl-2 family proteins.
An intriguing finding revealed in Chapter 4 of this thesis was that treatment of
CGNs with LTox or ToxB, which have overlapping specificity for inhibiting Rac
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GTPase, induced apoptosis concomitant with reduced expression of the transcriptional
corepressors, CtBPs. Thus, Chapter 4 of this thesis aimed to clarify the involvement of
CtBP downregulation in neuronal apoptosis. In CGNs undergoing apoptosis, CtBPs
appear to be regulated post-transcriptionally and in a mechanism dependent on both
caspase activation and intact miRNA biogenesis machinery. Furthermore, MTOBinduced inhibition of CtBPs induced apoptosis that was consistent with upregulation of
the CtBP target and BH3-only protein, Noxa. Although the exact mechanism by which
Rho GTPases regulate CtBP expression warrants further investigation, these data
demonstrate that CtBPs are essential pro-survival factors in CGNs.
Chapter 5 of this thesis aimed to extend our findings elucidating the involvement
of Rho GTPases in regulating CGN survival into an in vitro motor neuron model more
relevant to the etiology of ALS. Supporting an antagonistic relationship between Rac
GTPase and Rho GTPase, we report that inhibition of Rac GTPase or constitutive
activation of Rho GTPase was sufficient to induce apoptosis of ESC-derived motor
neurons.

Similar to our findings in CGNs, selective inhibition of Rac GTPase via

NSC23766 evoked apoptosis through suppression of pro-survival kinase pathways
involving ERK5 and Akt, as well as, nuclear translocation of the BH3-only protein Bad.
Furthermore, we report that Rac1-GTP is diminished in motor neurons and enhanced in
microglia in the spinal cords of mice harboring the G93A mSOD1 mutation, when
compared to age-matched WT littermates. Interestingly, we also demonstrated a marked
redistribution of RhoB from the cell soma of WT motor neurons to neuronal processes of
motor neurons in mice carrying the G93A SOD1 mutation. These data are the first to
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identify the cell type–specific and temporal dysregulation of Rho family GTPases in a
mouse model of familial ALS.
6.2 Elucidating the relationship between Rho GTPases and CtBPs
The downregulation of CtBP1 and CtBP2 in CGNs exposed to the small GTPase
inhibitors ToxB and LTox is a novel finding that warrants future investigation. As ToxB
(an inhibitor of Rac, Rho, and Cdc42) and LTox (an inhibitor of Rac, Ras, and Rap) have
overlapping specificity for inhibiting Rac GTPase, these findings suggests that Rac
GTPase may function upstream of CtBPs to regulate their expression and consequently,
the transcriptional repression of BH3-only pro-apoptotic proteins, such as Noxa. While
the precise mechanism by which CtBPs are downregulated in neurons exposed to small
GTPase inhibitors requires further investigation, recent studies have suggested a positive
correlation between the expression of CtBPs and the activity of Rho family GTPases in
non-neuronal cells. For example, overexpression of CtBP2 enhances Rac-dependent
migration of human non-small cell lung carcinoma cells consistent with both PTEN
inactivation and Akt activation (Paliwal et al., 2007).
Intriguingly, the CtBP-dependent activation of Rac requires the Rac-specific
GEF, Tiam1. Initial studies demonstrated that Tiam1 appears to be regulated by the CtBP
binding partner E1A. For instance, E1A expression led to the upregulation of Tiam1 and
the formation of Rac-dependent cadherin-based adhesions in mesenchymal V12Rastransformed Madin-Darby canine kidney II cells (Malliri et al., 2004). More recently, it
has been shown that CtBP2 occupies the Tiam1 promoter and enhances its transcription
in a Basic Kruppel-like factor (BKLF8)-dependent manner in HCT116 human colon
carcinoma cells (Paliwal et al., 2012). Indeed, although the recruitment of CtBPs to
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DNA-binding repressors (e.g. E1A, BKLF8) typically results in transcriptional
repression, more recent studies have demonstrated that CtBP may also activate
transcription in a gene-dependent manner. For instance, Drosophila CtBP activates
transcription of Wnt target genes following Wnt stimulation, while repressing other Wnt
target genes in the absence of Wnt (Fang et al., 2006).

Thus, CtBP may enhance

transcription of some genes (i.e. Tiam) while repressing others (i.e. PTEN, Noxa).
In conjunction with our own findings, these data suggest that CtBP1/CtBP2 and
Rac GTPase may function in a positive feedback loop to regulate the expression and
activities of one another (Fig. 6.1). Nonetheless, it is important to consider that our
studies demonstrating that CtBPs are regulated downstream of Rac GTPase were
conducted in primary neurons, while the CtBP2-dependent upregulation of Tiam1 and
subsequent activation of Rac GTPase was shown in H1299 cell lung and HCT116 colon
carcinoma cells. Thus, whether or not Rac GTPase lies upstream or downstream of
CtBP1 and CtBP2 may simply depend on the cell type. In future studies, it will be
important to determine whether CtBP2 similarly triggers Tiam1-dependent activation of
Rac GTPase in neurons. Indeed, the link between CtBPs and Rho family GTPases is only
recently being elucidated and future studies will be necessary to decipher the precise
relationship between CtBPs and Rho family GTPases.
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Figure 6.1 Proposed positive feedback loop between CtBPs and Rho GTPases.
Through a presently unknown mechanism, Rac GTPase enhances the expression of
CtBPs. CtBPs bind to DNA binding proteins (e.g. BKLF8) and occupy the promoter
region of the Rac-specific GEF Tiam1 to stimulate transcription. Increased levels of
Tiam1 result in enhanced activation of Rac-GTP.
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6.3 Inhibition of Rac1 GTPase as a novel in vivo model to study the pathology
of ALS
Collectively, the in vitro experiments presented in this thesis highlight a critical
function for Rac GTPase in regulating neuronal survival. While Chapter 2 and Chapter 3
demonstrate a crucial function for Rac GTPase in maintaining the survival of primary
CGNs; more recently, our work in Chapter 5 has identified a critical function for Rac
GTPase in maintaining the survival of terminally differentiated ESC-derived motor
neurons.

The importance of Rac GTPase in maintaining motor neuron survival is

substantiated by the fact that the Rac GEF alsin is mutated in juvenile onset forms of
ALS (Yang et al., 2001; Hadano et al., 2007). As previously discussed, alsin activates
Rac to maintain survival of embryonic rat spinal motor neurons (Jacquier et al., 2006)
and it has also been demonstrated that alsin can antagonize mSOD1-induced cell death of
NSC34 motor neuronal-like cells (Kanekura et al., 2005). However, the complexity of
whether or not Rac GTPase is responsible for motor neuron specific death associated
with alsin loss-of-function in in vivo rodent models is complicated by the fact that alsin
loss-of-function models do not fully recapitulate the aspects of the human disease.
Indeed, although four groups have independently generated different lines of ALS2
knockout (ALS2-/-) mice, each group found that the loss of alsin does not have a dramatic
effect on the survival or function of motor neurons in mice (Cai et al., 2005; Devon et al.,
2006; Hadano et al., 2006; Yamanaka et al., 2006). This could be due to the intrinsic
differences in organization of the human and mouse motor systems. In addition, the
paradox may be explained by compensatory mechanisms due to the fact that gene knock
out typically occurs prior to embryonic development (Hadano et al., 2006). Nonetheless,
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it is interesting to note that a cross between ALS2-/- mice and mice expressing G93A
mSOD1 did not exacerbate G93A mSOD1-associated disease symptoms such as body
weight loss and motor dysfunction (Hadano et al., 2010), underscoring the possibility that
Rac activity is already compromised in transgenic mice expressing G93A mSOD1.
Furthermore, while we and others have demonstrated that a loss of Rac GTPase
activity may contribute to the etiology of disease progression in the G93A mSOD1
mouse model of familial ALS, one caveat of these studies that must be considered is the
poor clinical relevance of this particular model to human cases of ALS (reviewed in
Wilkins et al., 2011). For instance, the only drug currently approved by the FDA for the
treatment of ALS, the anti-glutamateric compound Riluzole, demonstrates signs of
preserved motor neuron function and prolongs survival of the G93A mSOD1 mouse by
approximately two weeks (Gurney et al., 1996; 1998). Nonetheless, Riluzole has only a
minimal effect in human ALS progression and extends lifespan a mere three months
(Miller et al., 2007; Brooks, 2009). In addition to Riluzole, a number of compounds
targeting different facets of ALS disease progression (e.g. the antioxidant Vitamin E, the
antibiotic Minocycline, etc.) have shown no effect in the clinic after demonstrating
promising results in the G93A mSOD1 mouse (Wilkins et al., 2011). These data highlight
the necessity to develop new rodent models to study the pathogenesis of ALS.
A prominent field of research worthy of future investigation is the design of new
in vivo rodent models to study the underlying pathology and progression of ALS. Based
on the work presented in this thesis in conjunction with human studies demonstrating that
diminished Rac GTPase activity may be a causative factor in both familial and sporadic
forms of ALS (Yamanaka et al., 2003; Topp et al., 2004; Kanekura et al., 2005; Jacquier
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et al., 2006; Harraz et al., 2008; Figuera-Romero et al., 2013), development of a Rac
GTPase loss-of-function mouse expressing an inducible dominant negative mutant of
Rac1 under a motor neuron-specific promoter (e.g. ChAT, HB9) may aid in clarifying the
precise consequence that a of loss of Rac1 GTPase activity in motor neurons contributes
to motor neuron disease. In a similar manner, generation of a mouse model expressing
inducible constitutively active Rac1 under a microglia-specific promoter (e.g. CD11b)
may aid in clarifying the precise involvement that gain of Rac1 GTPase activity in
microglia contributes to the death of neighboring motor neurons. As it stands, while the
G93A mSOD1 mouse model of ALS has been helpful in clarifying the molecular
mechansims that underlie ALS disease progression, the fact that mSOD1 research has not
led to clinically applicable therapeutic advances indicates the necessity for more
therapeutically relevant models.
6.4 Mechanisms and consequences of dysregulated Rho GTPase activity in ALS
disease progression
6.4.1 Mechanisms and consequences of dysregulated Rac GTPase activity in ALS disease
progression
Supporting a pro-survival function for Rac GTPase, several studies have
substantiated an essential role for Rac GTPase in maintaining survival of various
different neuronal types, including motor neurons. These data lend to the hypothesis that
a loss of Rac GTPase function may underlie the selective motor neuronal death
associated with neurodegenerative disorders such as ALS. Nonetheless, this hypothesis
has been challenged by recent evidence demonstrating that active Rac1-GTP is actually
upregulated in total spinal cord homogenates isolated from mice expressing G93A
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mSOD1 when compared to age-matched littermates (Harraz et al., 2008). These findings
are not necessarily mutually exclusive and the data presented in this thesis aid in bridging
the gap in current research by demonstrating that Rac1 GTPase activity is diminished in
motor neurons and enhanced in microglia of mice harboring the G93A SOD1 mutation.
Given the large increase in microglia coincident with the death of substantial numbers of
motor neurons in the spinal cord of end-stage ALS mice, our data and those of Harraz et
al. seem to be compatible. Moreover, within the diseased spinal cord of transgenic mice
expressing G93A mSOD1, recent research indicates that mutant forms of SOD1 may
either increase or decrease the activity of Rac1 GTPase in a redox sensitive and cell-type
specific manner.
The ability of mutant forms of SOD1 to influence Rac1 GTPase in a redox
sensitive manner is particularly interesting given the proposed role of oxidative stress in
the disease progression of ALS. For example, several distinct mutant forms of SOD1
form aggregates in the mitochondria of motor neurons and cause a shift in the
mitochondrial redox state, ultimately resulting in a more oxidized environment (Ferri et
al., 2006). Consistent with our data demonstrating diminished Rac1-GTP expression in
motor neurons from G93A mSOD1 mice, a recent study has established the ability of
G93A mutant SOD1 to induce cell death via decreased expression of active Rac1 GTPase
in a redox sensitive manner in SH-SY5Y neuroblastoma cells. In this case, the growth
factor adaptor p66shc, a known regulator of mitochondrial-dependent oxidative balance,
diminishes the activity of Rac1 GTPase following adenoviral-driven expression of
mutant, but not wild type, SOD1. Intriguingly, p66Shc-mediated downregulation of Rac1
GTPase activity in SH-SY5Y cells expressing G93A mSOD1 appears to occur in a
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redox-sensitive manner as increasing concentrations of H2O2 results in a proportional
decrease in Rac1 GTPase activity and cell viability that is prevented by expression of an
inactive p66Shc mutant. The potential significance of p66shc-induced downregulation of
Rac1 GTPase activity is underscored by the fact that G93A mSOD1 mice crossed with
p66Shc-/- mice show improved motor performance, delayed disease onset, and increased
survival with respect to G93A mSOD1 mice (Pesaresi et al., 2011). While this previous
study was pivotal in demonstrating that G93A mSOD1 expression can cause a decrease
in Rac1 GTPase activity in SH-SY5Y cells, further studies will need to be conducted to
determine whether decreased expression of Rac1 GTPase occurs in a G93A mSOD1- and
p66Shc-dependent mechanism in motor neurons in particular.
In addition to G93A mSOD1-mediated downregulation of Rac1 GTPase activity
in motor neurons, it is also possible that Rac1 GTPase activity is decreased during the
progression of ALS due to alterations in the activity of Rac-specific GEFs. Indeed, as
previously discussed, loss-of-function mutations in the GEF alsin underlie early-onset
familial forms of ALS (Yang et al., 2001; Yamakana et al., 2003; Hadano et al., 2007).
Interestingly, recent evidence also suggests that epigenetic alterations of genes encoding
GEFs for Rac GTPase may underlie some sporadic forms of ALS. For example, the Rac
GEF, ARHGEF16, is hypermethylated and downregulated in postmortem sporadic ALS
spinal cord samples when compared to samples from neurologically normal controls
(Figueroa-Romero et al., 2012). These data indicate that loss of Rac activation due to
diminished GEF activity may also underlie motor neuron degeneration in both familial
and sporadic ALS disease progression.
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In a manner dissimilar to motor neurons, several studies indicate that mutant
forms of SOD1 associated with the pathology of ALS have an opposing function in
microglia, ultimately resulting in enhanced activation of Rac1 GTPase in a redoxsensitive manner. For example, Harraz et al. (2008) demonstrated WT SOD1 binds to
Rac1 and inhibits its intrinsic GTPase activity under reducing conditions, ultimately
increasing active Rac1 GTPase activity. In the presence of H2O2 (oxidizing conditions),
the interaction between WT SOD1 and Rac1 GTPase was uncoupled. Intriguingly, ALScausing mutations in SOD1 prevent the enzyme from redox uncoupling, resulting in
enhanced activation of Rac1 GTPase in microglia cells. Inevitably, aberrant Rac1
GTPase activity leads to increased activation of Nox2, a catalytic subunit of NADPH
oxidase, resulting in an overproduction of damaging ROS. Indeed, in agreement with
Rac1-dependent activation of NADPH oxidase as a contributing factor underlying motor
neuron degeneration in the G93A mSOD1 mouse, inhibition of or genetic deletion of
Nox2 improves disease progression and increases survival in this particular mouse model
of familial ALS (Wu et al., 2006; Marden et al,, 2007; Valdmanis et al., 2008).
Furthermore, Apolloni et al., (2013) recently identified extracellular ATP as a potential
mechanism by which Rac1 GTPase activity may be enhanced in microglia of G93A
mSOD1 mice. In primary microglia cells isolated from G93A mSOD1 mice, stimulation
of the P2X7 receptor by its agonist, 2’-3’-O-(benzoyl-benzoyl) ATP enhanced Nox2
activation and the production of ROS in a Rac1-dependent manner when compared to
microglia derived from non-transgenic animals. Thus, recent experimental evidence
suggests that G93A mSOD1 may stimulate Rac1 GTPase activation in a P2X7-dependent
mechanism to enhance the release of toxic ROS from microglia.
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6.4.2 Mechanisms and consequences of dysregulated Rho GTPase activity in ALS disease
progression
In contrast to a critical pro-survival role for Rac GTPase, many reports indicate
that Rho GTPase has an opposing function and leads to the transmission of pro-apoptotic
signals in neurons, including motor neurons. Although three isoforms of Rho GTPase
(RhoA, RhoB, and RhoC) have been identified, the involvement of RhoA and RhoB in
provoking neuronal apoptosis has been best described. While we predicted that a loss of
Rac1-GTP would correlate with increased active RhoA-GTP expression, we did not
detect a significant increase in active RhoA-GTP in motor neurons of G93A mSOD1
mice. However, we found a distinct redistribution of total RhoB in end-stage G93A mice
when compared to age-matched littermates. While RhoB principally localized to the
soma of WT motor neurons, it drastically redistributed to neuronal processes, including
motor neuron axons, of end-stage (~120 days), but not disease onset (~90 days), mice.
This is an important finding considering the involvement of RhoB GTPase in inducing
both neurite retraction and apoptosis (Conrad et al., 2005). Consistent with these
functions, we found that constitutive activation of Rho induced both neurite retraction
and membrane blebbing indicative of apoptosis in ESC-derived motor neurons. In future
studies, it will be important to discern whether RhoB redistribution leads to neurite
retraction and/or motor neuron apoptosis in the G93A mSOD1 mouse. Indeed, several
studies have highlighted that axonal retraction may occur independent of motor neuron
apoptosis in the familial mouse models of ALS. For example, studies indicate that in
early stages of the disease the nerve terminals and neuromuscular junctions are
disassembling while cell bodies in the spinal cord are relatively intact, leading to the
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notion that a “dying back” phenomenon underlies the pathology of ALS (Frey et al.,
2000; Fischer et al., 2004). This is somewhat conflicting with our finding that total RhoB
redistribution to axons occurs in end-stage, but not disease onset, G93A mSOD1 motor
neurons. Future studies will need to be performed to clarify the involvement of RhoB in
mediating neurite retraction and motor neuron death in rodent ALS models.
Alternatively, the loss of Rac1-GTP observed in motor neurons at disease onset may also
contribute to inhibition of axonal outgrowth in early disease stages of ALS progression.
Given the antagonistic relationship exerted between Rac GTPase and Rho GTPase, it is
likely that dysregulated activity of both GTPases contributes to axonal retraction and
motor neuron death observed during the progression of ALS.
6.5 Pharmacological targeting of Rho GTPase signaling pathways as a therapeutic
strategy for the treatment of ALS
6.5.1 Nox inhibitors to target aberrant Rac GTPase activation in microglia during ALS
disease progression
Collectively, the data presented in this thesis along with the work of others, has
suggested that increased Rac1 GTPase activity in microglia may contribute to the
activation of Nox2, the subsequent activation of NADPH oxidase, and generation of toxic
ROS.

Thus, one potential therapeutic target for the treatment of ALS may be

pharmacological inhibition of Nox. Indeed, Marden et al. (2007) reported that
homozygous knockout of Nox1 and Nox2 increased the lifespan of B6SJ G93A mSOD1
mice by 33 and 97 days, respectively. In a similar study, it was found that Nox2 deletion
extended the survival of C57BL/6J G93A mSOD1 mice by 15 days (Wu et al., 2006).
Pharmacological inhibition of Nox with high dose apocynin in B6SJL G93A mSOD1
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mice increased survival 113 days (Harraz et al., 2008). Recent efforts have also examined
whether diapocynin, the activated metabolite of apocynin, similarly extends survival of
G93A mSOD1 mice. While diapocynin and apocynin protected primary motor neurons
from nitric oxide-induced death in vitro, Trumbull et al. (2012) did not observe any
significant effect of these compounds on survival in B6SJL G93A mSOD1 expressing
mice. Although both of these studies treated mice harboring the G93A SOD1 mutation on
the same genetic background, the disparity in these reports may have occurred because
Trumbull et al. (2012) began apocynin and diapocynin treatment at 21 days of age, while
Harraz et al. (2008) began apocynin treatment at 14 days of age. Nonetheless, in the
Trumbull et al. (2012) study, mice treated with either apocynin or diapocynin did show a
trend toward increased survival. These conflicting studies underscore the need for
additional mouse models of ALS that are not related to mutations in SOD1 to futher
evaluate the potential use of Nox inhibitors as a treatment option for ALS patients.
Apocynin represents an attractive therapeutic compound for the treatment of ALS
due to its low toxicity and lack of side effects in humans (Van den Worm et al., 2001;
Stefanska and Pawliczak, 2008). Furthermore, diapocynin is also an attractive therapeutic
compound as it is predicted to be more permeable to the blood-brain barrier due to its
greater hydrophobicity. Indeed, in addition to rodent models of ALS, oral treatment with
apocynin is safe and effective in the MPTP marmoset model of Parkinson’s disease (PD).
During disease progression, apocynin relieved PD symptoms and increased the number of
surviving dopaminergic neurons compared to controls (Philippens et al., 2013). Thus,
these prior studies highlight the safety of apocynin for the treatment of devastating
neurodegerative disorders. Apocynin appears to be a relatively safe compound and it is
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worthy of consideration for future clinical trials in ALS patients. Nonetheless, further
examination is required to determine the safety of long-term use of Nox inhibitors in
humans.
6.5.2 ROCK inhibitors to target aberrant Rho GTPase activation in motor neurons
during ALS disease progression
The data presented in this thesis suggest that redistribution of RhoB to neuronal
processes and potential activation of the downstream effector ROCK may contribute to
axonal retraction and motor neuron death in the G93A mSOD1 mouse model of ALS.
Thus, inhibition of ROCK represents an attractive therapeutic target for examination in
preclinical trials using familial mouse models of ALS. Indeed, we recently conducted
preliminary experiments to determine whether treatment with the ROCK inhibitor Fasudil
was protective in the G93A mSOD1 mouse model. Mice were administered 100 mg/kg
of Fasudil in their drinking water beginning at 30 days of age. FVB G93A mSOD1 mice
administered Fasudil showed a delay in disease onset compared to untreated mutant mice
as measured by hind limb trembling or failure to extend either hind limb fully when held
by its tail (Fig. 6.3A). In addition, utilizing a paw grip endurance (PaGE) test that
measures the muscle strength of forelimbs and hindlimbs, G93A mSOD1 mice receiving
Fasudil treatment showed a delay in the decline in grip strength when compared to
untreated G93A mSOD1 mice (Fig. 6.2A). Fasudil treated mice also displayed a delay in
weight loss (Fig. 6.2B). Finally, we noted an increase in survival of G93A mSOD1 mice
treated with Fasudil when compared to untreated mutant mice (Fig. 6.3B). Although very
preliminary, these results suggest that inhibition of ROCK may prove to be an effective
treatment option for ALS patients.
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Figure 6.2 Administration of the ROCK inhibitor Fasudil delays latency to fall and
weight loss in the G93A mSOD1 mouse. Beginning at 60 days, mice were administered
100 mg/kg Fasudil daily in their drinking water. A. PaGE hanging wire test represented
as mean latency to fall at indicated ages. Note the delay in latency to fall in G93A
mSOD1 mice when compared to untreated mutant mice (n=2). B. Percent of peak body
weight at indicated ages. Note that the weight loss observed in untreated G93A mSOD1
is abrogated by Fasudil treatment (n=2). I would like to acknowledge Aimee Winter for
assistance in generating data for this figure.
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Figure 6.3 Administration of the ROCK inhibitor Fasudil delays onset and extends
survival in the G93A mSOD1 mouse. Beginning at 60 days, mice were administered
100 mg/kg Fasudil daily in their drinking water. A. Onset was determined when a mouse
displayed for two consecutive days either hind limb trembling or failure to extend either
limb fully when held by its tail (n=2). B. End-stage was determined when mice were
unable to right themselves within 15 seconds after being placed on their side (n=2). I
would like to acknowledge Aimee Winter for assistance in generating data for this figure.
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Consistent with non-cell autonomous death underlying the etiology of ALS, our
preliminary data is consistent with two recent reports examining the effect of Fasudil on
both microgliosis (Tönges et al., 2014) and motor neurons death (Takata et al., 2013) in
G93A mSOD1 mice on a BJSJL background. Tönges et al. (2014) demonstrated that
inhibition of ROCK preserved neuromuscular junctions and extended the survival of
G93A mSOD1 via a mechanism consistent with reduced microgliosis and decreased
release of pro-inflammatory cytokines and chemokines such as TNFα and IL-6. When
examining motor neuron death in G93A mSOD1 mice, Takata et al. (2013) demonstrated
that administration of Fasudil slowed disease progression and reduced motor neuron loss
by a mechanism consistent with reduced activation of ROCK and PTEN and restored
activation of the pro-survival kinase Akt. In future studies, it will be important to discern
whether the protection afforded by ROCK inhibitors correlates with reduced inhibition of
Rac1 GTPase in motor neurons of mice harboring mutations in SOD1. In conjunction
with our own work demonstrating that dysregulation of both Rac GTPase and Rho
GTPase may contribute to microglial activation and motor neuron death in G93A mutant
SOD1 mice, these studies serve to highlight that the intricate balance between Rho
GTPases is a critical determinant of motor neuronal survival and may be disrupted in
neurodegenerative disease such as ALS.
Collectively, these data highlight ROCK as a promising target for the treatment of
ALS patients. Currently, Fasudil is already in clinical use as a vasodilator agent (Zhao et
al., 2011) and inhibition of ROCK in patients with cerebral vasospasm does not appear to
cause any adverse side effects (Shibuya et al., 1992). Furthermore, Fasudil has not
shown any severe side effects or changes in blood pressure and heart rate in patients with
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angina or acute ischemic stroke (Shimokawa, 2002; Shibuya et al., 2005; Vicari et al.,
2005). Nonetheless, it is important to note that ROCKII knockout mice show embryonic
lethality whereas ROCKI knockout mice experience failure of eyelid closure and closure
of the ventral wall (Thumkeo et al., 2003; Shimizu et al., 2005), highlighting a critical
function for both ROCK isoforms in development. In addition, it was reported that
intracerebroventicular administration of the ROCK inhibitor Y-27632 increased anxietyrelated behavior in mice (Saitoh et al., 2006). Thus, while inhibition of ROCK offers a
promising therapeutic target for the treatment of ALS, further examination is required to
determine the safety of long-term use of nonselective inhibitors of ROCKI and ROCKII
(such as Fasudil and Y-27632) in humans.
Alternatively, the development of a safe ROCKII inhibitor may offer a viable
option for the clinical treatment of ALS. Although Fasudil targets both ROCKI and
ROCKII, ROCKII is preferentially expressed in brain and skeletal muscle tissue while
ROCKI shows more ubiquitous expression (Nakagawa et al., 1996). The expression
pattern of ROCKII is particularly interesting given that current research suggests that
motor neuron death in ALS appears to be consistent with a “dying back” mechanism in
which the neuromuscular junction (NMJ) begins to disassemble while the motor neuron
cell bodies in the spinal cord remain relatively intact (Dadon-Nachum et al., 2011). Given
that our data demonstrate a marked redistribution of RhoB to neuronal processes of endstage G93A mSOD1 mice, aberrant activation of ROCKII downstream of RhoB
activation in both motor neuron processes and skeletal muscle may underlie the selective
degeneration of NMJs during the progression of ALS. Indeed, Conti et al. (2014) recently
demonstrated that ROCKII expression is increased in the skeletal muscle of sporadic
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ALS patients. Thus, selective inhibition of ROCKII may prove to be a more direct and
effective target for the treatment of ALS.
Interestingly, recent data suggest that unopposed Rho/ROCK signaling may be a
common factor underlying additional neurodegenerative diseases. In fact, inhibition of
ROCK has been demonstrated to be an effective treatment option in other models of
neurodegenerative disease, including Parkinson’s disease (Tönges et al., 2012),
Alzheimer’s Disease (Song et al., 2013), and cerebral ischemia (Gibson et al., 2014).
Thus, ROCK inhibitors show promise for the treatment of ALS patients as well as those
diagnosed with other neurodegenerative diseases.
6.6 Conclusion
In conclusion, this thesis has elucidated the involvement of Rho family GTPases
in regulating neuronal survival. In particular, the work presented here has aided in
deciphering the precise signaling pathways that are regulated by Rac GTPase in primary
CGNs. Consistent with prior studies demonstrating an antagonistic relationship between
Rac GTPase and Rho GTPase, we have also demonstrated that inhibition of Rac GTPase
or activation of Rho GTPase induces neurite retraction and death of ESC-derived motor
neurons. In agreement with a pro-survival function, Rac1 GTPase activation is decreased
in spinal motor neurons of mice harboring the G93A mSOD1 mutation. Conversely,
RhoB GTPase appears to redistribute to motor neuronal processes in ALS mice. Thus,
while the pathology of ALS remains complex and multifaceted, the data presented in this
thesis highlight the potential involvement of dysregulated Rho GTPases as a causative
factor underlying the etiology of ALS. These data suggest that targeting Rho GTPase
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activity, or their downstream effectors, may have beneficial therapeutic effects for ALS
patients.

208

REFERENCES
Ahnert-Hilger, G., Holtje, M., Grosse, G., Pickert, G., Mucke, C., Nixdorf-Bergweiler,
B., Boquet, P., Hofmann, F. and Just, I. (2004) Differential effects of Rho
GTPases on axonal and dendritic development in hippocampal neurones. J
Neurochem, 90, 9-18.
Ahonen, T. J., Xie, J., LeBaron, M. J., Zhu, J., Nurmi, M., Alanen, K., Rui, H. and
Nevalainen, M. T. (2003) Inhibition of transcription factor Stat5 induces cell
death of human prostate cancer cells. J Biol Chem, 278, 27287-27292.
Al-Bazz, Y. O., Underwood, J. C., Brown, B. L. and Dobson, P. R. (2009) Prognostic
significance of Akt, phospho-Akt and BAD expression in primary breast cancer.
Eur J Cancer, 45, 694-704.
al-Shami, A., Bourgoin, S. G. and Naccache, P. H. (1997) Granulocyte-macrophage
colony-stimulating factor-activated signaling pathways in human neutrophils. I.
Tyrosine phosphorylation-dependent stimulation of phosphatidylinositol 3-kinase
and inhibition by phorbol esters. Blood, 89, 1035-1044.
Alberts, A. S. (2001) Identification of a carboxyl-terminal diaphanous-related formin
homology protein autoregulatory domain. J Biol Chem, 276, 2824-2830.
Amano, M., Chihara, K., Nakamura, N., Fukata, Y., Yano, T., Shibata, M., Ikebe, M. and
Kaibuchi, K. (1998) Myosin II activation promotes neurite retraction during the
action of Rho and Rho-kinase. Genes Cells, 3, 177-188.
Ang, L. H., Kim, J., Stepensky, V. and Hing, H. (2003) Dock and Pak regulate olfactory
axon pathfinding in Drosophila. Development, 130, 1307-1316.
Apolloni, S., Parisi, C., Pesaresi, M. G., Rossi, S., Carri, M. T., Cozzolino, M., Volonte,
C. and D'Ambrosi, N. (2013) The NADPH oxidase pathway is dysregulated by
the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral
sclerosis. J Immunol, 190, 5187-5195.
Arber, S., Han, B., Mendelsohn, M., Smith, M., Jessell, T. M. and Sockanathan, S. (1999)
Requirement for the homeobox gene Hb9 in the consolidation of motor neuron
identity. Neuron, 23, 659-674.
Bamburg, J. R., McGough, A. and Ono, S. (1999) Putting a new twist on actin:
ADF/cofilins modulate actin dynamics. Trends Cell Biol, 9, 364-370.
Barberan, S., McNair, K., Iqbal, K., Smith, N. C., Prendergast, G. C., Stone, T. W., Cobb,
S. R. and Morris, B. J. (2011) Altered apoptotic responses in neurons lacking
RhoB GTPase. Eur J Neurosci, 34, 1737-1746.
Bemis, L. T., Chen, R., Amato, C. M., Classen, E. H., Robinson, S. E., Coffey, D. G.,
Erickson, P. F., Shellman, Y. G. and Robinson, W. A. (2008) MicroRNA-137
targets microphthalmia-associated transcription factor in melanoma cell lines.
Cancer Res, 68, 1362-1368.
Bergman, L. M. and Blaydes, J. P. (2006) C-terminal binding proteins: emerging roles in
cell survival and tumorigenesis. Apoptosis, 11, 879-888.
Bertolotto, C., Maulon, L., Filippa, N., Baier, G. and Auberger, P. (2000) Protein kinase
C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation
and inactivation of BAD. J Biol Chem, 275, 37246-37250.
209

Bertrand, J., Di Polo, A. and McKerracher, L. (2007) Enhanced survival and regeneration
of axotomized retinal neurons by repeated delivery of cell-permeable C3-like Rho
antagonists. Neurobiol Dis, 25, 65-72.
Bingisser, R. M., Tilbrook, P. A., Holt, P. G. and Kees, U. R. (1998) Macrophage-derived
nitric oxide regulates T cell activation via reversible disruption of the
Jak3/STAT5 signaling pathway. J Immunol, 160, 5729-5734.
Biryukova, I. and Heitzler, P. (2008) Drosophila C-terminal binding protein, dCtBP is
required for sensory organ prepattern and sharpens proneural transcriptional
activity of the GATA factor Pnr. Dev Biol, 323, 64-75.
Blanke, S. and Jäckle, H. (2006) Novel guanine nucleotide exchange factor GEFmeso of
Drosophila melanogaster interacts with Ral and Rho GTPase Cdc42. FASEB J,
20, 683-691.
Blaskovich, M. A., Sun, J., Cantor, A., Turkson, J., Jove, R. and Sebti, S. M. (2003)
Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer
and activator of transcription 3 signaling pathway inhibitor with potent antitumor
activity against human and murine cancer cells in mice. Cancer Res, 63, 12701279.
Boise, L. H., Gonzalez-Garcia, M., Postema, C. E., Ding, L., Lindsten, T., Turka, L. A.,
Mao, X., Nunez, G. and Thompson, C. B. (1993) bcl-x, a bcl-2-related gene that
functions as a dominant regulator of apoptotic cell death. Cell, 74, 597-608.
Bokoch, G. M. (2003) Biology of the p21-activated kinases. Annu Rev Biochem, 72, 743781.
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A. and Greenberg, M. E.
(1999) Cell survival promoted by the Ras-MAPK signaling pathway by
transcription-dependent and -independent mechanisms. Science, 286, 1358-1362.
Borland, G., Bird, R. J., Palmer, T. M. and Yarwood, S. J. (2009) Activation of protein
kinase Calpha by EPAC1 is required for the ERK- and CCAAT/enhancer-binding
protein beta-dependent induction of the SOCS-3 gene by cyclic AMP in COS1
cells. J Biol Chem, 284, 17391-17403.
Brooks, B. R. (2009) Managing amyotrophic lateral sclerosis: slowing disease
progression and improving patient quality of life. Ann Neurol, 65 Suppl 1, S1723.
Buchwald, G., Hostinova, E., Rudolph, M. G., Kraemer, A., Sickmann, A., Meyer, H. E.,
Scheffzek, K. and Wittinghofer, A. (2001) Conformational switch and role of
phosphorylation in PAK activation. Mol Cell Biol, 21, 5179-5189.
Burk, U., Schubert, J., Wellner, U., Schmalhofer, O., Vincan, E., Spaderna, S. and
Brabletz, T. (2008) A reciprocal repression between ZEB1 and members of the
miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep, 9, 582589.
Butterworth, N. J., Williams, L., Bullock, J. Y., Love, D. R., Faull, R. L. and Dragunow,
M. (1998) Trinucleotide (CAG) repeat length is positively correlated with the
degree of DNA fragmentation in Huntington's disease striatum. Neuroscience, 87,
49-53.

210

Byts, N., Samoylenko, A., Fasshauer, T., Ivanisevic, M., Hennighausen, L., Ehrenreich,
H. and Siren, A. L. (2008) Essential role for Stat5 in the neurotrophic but not in
the neuroprotective effect of erythropoietin. Cell Death Differ, 15, 783-792.
Cai, H., Lin, X., Xie, C. et al. (2005) Loss of ALS2 function is insufficient to trigger
motor neuron degeneration in knock-out mice but predisposes neurons to
oxidative stress. J Neurosci, 25, 7567-7574.
Cai, Y., Li, J., Yang, S., Li, P., Zhang, X. and Liu, H. (2012) CIBZ, a novel BTB
domain-containing protein, is involved in mouse spinal cord injury via
mitochondrial pathway independent of p53 gene. PLoS One, 7, e33156.
Capitanio, D., Vasso, M., Ratti, A. et al. (2012) Molecular signatures of amyotrophic
lateral sclerosis disease progression in hind and forelimb muscles of an
SOD1(G93A) mouse model. Antioxid Redox Signal, 17, 1333-1350.
Cavalcanti, E., Gigante, M., Mancini, V. et al. (2010) JAK3/STAT5/6 pathway
alterations are associated with immune deviation in CD8 T cells in renal cell
carcinoma patients. J Biomed Biotechnol, 2010, 935764.
Cavanaugh, J. E., Jaumotte, J. D., Lakoski, J. M. and Zigmond, M. J. (2006)
Neuroprotective role of ERK1/2 and ERK5 in a dopaminergic cell line under
basal conditions and in response to oxidative stress. J Neurosci Res, 84, 13671375.
Chan, E., Patel, R., Nallur, S. et al. (2011) MicroRNA signatures differentiate melanoma
subtypes. Cell Cycle, 10, 1845-1852.
Chattopadhyay, A., Chiang, C. W. and Yang, E. (2001) BAD/BCL-[X(L)]
heterodimerization leads to bypass of G0/G1 arrest. Oncogene, 20, 4507-4518.
Cheng, J., Wang, Y., Liang, A., Jia, L. and Du, J. (2012) FSP-1 silencing in bone marrow
cells suppresses neointima formation in vein graft. Circ Res, 110, 230-240.
Cheung, Z. H., Chin, W. H., Chen, Y., Ng, Y. P. and Ip, N. Y. (2007) Cdk5 is involved in
BDNF-stimulated dendritic growth in hippocampal neurons. PLoS Biol, 5, e63.
Chinnadurai, G. (2002) CtBP, an unconventional transcriptional corepressor in
development and oncogenesis. Mol Cell, 9, 213-224.
Chipoy, C., Brounais, B., Trichet, V. et al. (2007) Sensitization of osteosarcoma cells to
apoptosis by oncostatin M depends on STAT5 and p53. Oncogene, 26, 66536664.
Choi, H.J., Lee, J.M., Kim, H. Nam, H.J., Shin, H.J., Kim, D., Ko, E., Noh, D.Y., Kim,
K.L., Kim, J.H., and Baek, S.H. (2010) Bcl3-dependent stabilization of CtBP1 is
crucial for the inhibition of apoptosis tumor progression in breast cancer. Biochem
Biophys Res Commun, 400, 396-402.
Choi, J. K., Kim, K. H., Park, H., Park, S. R. and Choi, B. H. (2011) Granulocyte
macrophage-colony stimulating factor shows anti-apoptotic activity in neural
progenitor cells via JAK/STAT5-Bcl-2 pathway. Apoptosis, 16, 127-134.
Chughtai, N., Schimchowitsch, S., Lebrun, J. J. and Ali, S. (2002) Prolactin induces SHP2 association with Stat5, nuclear translocation, and binding to the beta-casein
gene promoter in mammary cells. J Biol Chem, 277, 31107-31114.
Clark, E. A., King, W. G., Brugge, J. S., Symons, M. and Hynes, R. O. (1998) Integrinmediated signals regulated by members of the rho family of GTPases. J Cell Biol,
142, 573-586.
211

Colodner, K. J. and Feany, M. B. (2010) Glial fibrillary tangles and JAK/STAT-mediated
glial and neuronal cell death in a Drosophila model of glial tauopathy. J Neurosci,
30, 16102-16113.
Condorelli, F., Salomoni, P., Cotteret, S., Cesi, V., Srinivasula, S. M., Alnemri, E. S. and
Calabretta, B. (2001) Caspase cleavage enhances the apoptosis-inducing effects of
BAD. Mol Cell Biol, 21, 3025-3036.
Conrad, S., Schluesener, H. J., Trautmann, K., Joannin, N., Meyermann, R. and Schwab,
J. M. (2005) Prolonged lesional expression of RhoA and RhoB following spinal
cord injury. J Comp Neurol, 487, 166-175.
Contestabile, A. (2002) Cerebellar granule cells as a model to study mechanisms of
neuronal apoptosis or survival in vivo and in vitro. Cerebellum, 1, 41-55.
Conti, A., Riva, N., Pesca, M., Iannaccone, S., Cannistraci, C. V., Corbo, M., Previtali, S.
C., Quattrini, A. and Alessio, M. (2014) Increased expression of Myosin binding
protein H in the skeletal muscle of amyotrophic lateral sclerosis patients. Biochim
Biophys Acta, 1842, 99-106.
Cooney, R. N. (2002) Suppressors of cytokine signaling (SOCS): inhibitors of the
JAK/STAT pathway. Shock, 17, 83-90.
D'Mello, S. R., Galli, C., Ciotti, T. and Calissano, P. (1993) Induction of apoptosis in
cerebellar granule neurons by low potassium: inhibition of death by insulin-like
growth factor I and cAMP. Proc Natl Acad Sci U S A, 90, 10989-10993.
Dadon-Nachum, M., Melamed, E. and Offen, D. (2011) The "dying-back" phenomenon
of motor neurons in ALS. J Mol Neurosci, 43, 470-477.
Dan, C., Kelly, A., Bernard, O. and Minden, A. (2001) Cytoskeletal changes regulated by
the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J
Biol Chem, 276, 32115-32121.
Dan, C., Nath, N., Liberto, M. and Minden, A. (2002) PAK5, a new brain-specific kinase,
promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol, 22, 567-577.
Danial, N. N. and Korsmeyer, S. J. (2004) Cell death: critical control points. Cell, 116,
205-219.
Daniels, R. H., Hall, P. S. and Bokoch, G. M. (1998) Membrane targeting of p21activated kinase 1 (PAK1) induces neurite outgrowth from PC12 cells. EMBO J,
17, 754-764.
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y. and Greenberg, M. E.
(1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic
death machinery. Cell, 91, 231-241.
Dedoni, S., Olianas, M. C. and Onali, P. (2010) Interferon-beta induces apoptosis in
human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling
and down-regulation of PI3K/Akt pathway. J Neurochem, 115, 1421-1433.
del Peso, L., Gonzalez-Garcia, M., Page, C., Herrera, R. and Nunez, G. (1997)
Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.
Science, 278, 687-689.
Deng, Y., Deng, H., Bi, F., Liu, J., Bemis, L. T., Norris, D., Wang, X. J. and Zhang, Q.
(2011) MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma
cell lines. Int J Biol Sci, 7, 133-137.
212

Desagher, S., Severac, D., Lipkin, A., Bernis, C., Ritchie, W., Le Digarcher, A. and
Journot, L. (2005) Genes regulated in neurons undergoing transcription-dependent
apoptosis belong to signaling pathways rather than the apoptotic machinery. J
Biol Chem, 280, 5693-5702.
Devon, R. S., Orban, P. C., Gerrow, K. et al. (2006) Als2-deficient mice exhibit
disturbances in endosome trafficking associated with motor behavioral
abnormalities. Proc Natl Acad Sci U S A, 103, 9595-9600.
Didsbury, J. R., Uhing, R. J. and Snyderman, R. (1990) Isoprenylation of the low
molecular mass GTP-binding proteins rac 1 and rac 2: possible role in membrane
localization. Biochem Biophys Res Commun, 171, 804-812.
Dragunow, M., Faull, R. L., Lawlor, P., Beilharz, E. J., Singleton, K., Walker, E. B. and
Mee, E. (1995) In situ evidence for DNA fragmentation in Huntington's disease
striatum and Alzheimer's disease temporal lobes. Neuroreport, 6, 1053-1057.
Droppelmann, C. A., Keller, B. A., Campos-Melo, D., Volkening, K. and Strong, M. J.
(2013) Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing
factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis.
Neurobiol Aging, 34, 248-262.
Dubreuil, C. I., Marklund, N., Deschamps, K., McIntosh, T. K. and McKerracher, L.
(2006) Activation of Rho after traumatic brain injury and seizure in rats. Exp
Neurol, 198, 361-369.
Edamatsu, H., Gau, C. L., Nemoto, T., Guo, L. and Tamanoi, F. (2000) Cdk inhibitors,
roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to
induce efficient apoptosis of human cancer cell lines. Oncogene, 19, 3059-3068.
Eden, S., Rohatgi, R., Podtelejnikov, A. V., Mann, M. and Kirschner, M. W. (2002)
Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck.
Nature, 418, 790-793.
Edwards, D. C. and Gill, G. N. (1999) Structural features of LIM kinase that control
effects on the actin cytoskeleton. J Biol Chem, 274, 11352-11361.
Ekegren, T., Grundstrom, E., Lindholm, D. and Aquilonius, S. M. (1999) Upregulation of
Bax protein and increased DNA degradation in ALS spinal cord motor neurons.
Acta Neurol Scand, 100, 317-321.
English, J. M., Vanderbilt, C. A., Xu, S., Marcus, S. and Cobb, M. H. (1995) Isolation of
MEK5 and differential expression of alternatively spliced forms. J Biol Chem,
270, 28897-28902.
Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M. and Estrov, Z. (2003)
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces
antiapoptotic and proapoptotic signals in acute myeloid leukemia. Blood, 102,
630-637.
Fang, M., Li, J., Blauwkamp, T., Bhambhani, C., Campbell, N. and Cadigan, K. M.
(2006) C-terminal-binding protein directly activates and represses Wnt
transcriptional targets in Drosophila. EMBO J, 25, 2735-2745.
Fanger, G. R., Johnson, N. L. and Johnson, G. L. (1997) MEK kinases are regulated by
EGF and selectively interact with Rac/Cdc42. EMBO J, 16, 4961-4972.
Ferri, A., Cozzolino, M., Crosio, C., Nencini, M., Casciati, A., Gralla, E. B., Rotilio, G.,
Valentine, J. S. and Carri, M. T. (2006) Familial ALS-superoxide dismutases
213

associate with mitochondria and shift their redox potentials. Proc Natl Acad Sci U
S A, 103, 13860-13865.
Figueroa-Romero, C., Hur, J., Bender, D. E. et al. (2012) Identification of epigenetically
altered genes in sporadic amyotrophic lateral sclerosis. PLoS One, 7, e52672.
Finegan, K. G., Wang, X., Lee, E. J., Robinson, A. C. and Tournier, C. (2009) Regulation
of neuronal survival by the extracellular signal-regulated protein kinase 5. Cell
Death Differ, 16, 674-683.
Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez,
A., Khan, J., Polak, M. A. and Glass, J. D. (2004) Amyotrophic lateral sclerosis is
a distal axonopathy: evidence in mice and man. Exp Neurol, 185, 232-240.
Fjeld, C. C., Birdsong, W. T. and Goodman, R. H. (2003) Differential binding of NAD+
and NADH allows the transcriptional corepressor carboxyl-terminal binding
protein to serve as a metabolic sensor. Proc Natl Acad Sci U S A, 100, 9202-9207.
Flatau, G., Lemichez, E., Gauthier, M., Chardin, P., Paris, S., Fiorentini, C. and Boquet,
P. (1997) Toxin-induced activation of the G protein p21 Rho by deamidation of
glutamine. Nature, 387, 729-733.
Folch, J., Junyent, F., Verdaguer, E., Auladell, C., Pizarro, J. G., Beas-Zarate, C., Pallas,
M. and Camins, A. (2012) Role of cell cycle re-entry in neurons: a common
apoptotic mechanism of neuronal cell death. Neurotox Res, 22, 195-207.
Fournier, A. E., Takizawa, B. T. and Strittmatter, S. M. (2003) Rho kinase inhibition
enhances axonal regeneration in the injured CNS. J Neurosci, 23, 1416-1423.
Frey, D., Schneider, C., Xu, L., Borg, J., Spooren, W. and Caroni, P. (2000) Early and
selective loss of neuromuscular synapse subtypes with low sprouting competence
in motoneuron diseases. J Neurosci, 20, 2534-2542.
Fukata, M., Kuroda, S., Nakagawa, M. et al. (1999) Cdc42 and Rac1 regulate the
interaction of IQGAP1 with beta-catenin. J Biol Chem, 274, 26044-26050.
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J. and Zheng, Y. (2004) Rational design and
characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl
Acad Sci U S A, 101, 7618-7623.
Garriga-Canut, M., Schoenike, B., Qazi, R. et al. (2006) 2-Deoxy-D-glucose reduces
epilepsy progression by NRSF-CtBP-dependent metabolic regulation of
chromatin structure. Nat Neurosci, 9, 1382-1387.
Gertz, M. and Steegborn, C. (2010) The mitochondrial apoptosis pathway and p66Shc--a
regulatory redox enzyme or an adapter protein snuggling around? Cell Cycle, 9,
4425-4426.
Gibson, C. L., Srivastava, K., Sprigg, N., Bath, P. M. and Bayraktutan, U. (2014)
Inhibition of Rho-kinase protects cerebral barrier from ischaemia-evoked injury
through modulations of endothelial cell oxidative stress and tight junctions. J
Neurochem.
Ginham, R., Harrison, D. C., Facci, L., Skaper, S. and Philpott, K. L. (2001)
Upregulation of death pathway molecules in rat cerebellar granule neurons
undergoing apoptosis. Neurosci Lett, 302, 113-116.
Giorgio, M., Migliaccio, E., Orsini, F. et al. (2005) Electron transfer between cytochrome
c and p66Shc generates reactive oxygen species that trigger mitochondrial
apoptosis. Cell, 122, 221-33.
214

Giunta, B., Obregon, D., Hou, H. et al. (2006) EGCG mitigates neurotoxicity mediated
by HIV-1 proteins gp120 and Tat in the presence of IFN-gamma: role of
JAK/STAT1 signaling and implications for HIV-associated dementia. Brain Res,
1123, 216-225.
Godin, C. M. and Ferguson, S. S. (2010) The angiotensin II type 1 receptor induces
membrane blebbing by coupling to Rho A, Rho kinase, and myosin light chain
kinase. Mol Pharmacol, 77, 903-911.
Graness, A., Poli, V. and Goppelt-Struebe, M. (2006) STAT3-independent inhibition of
lysophosphatidic acid-mediated upregulation of connective tissue growth factor
(CTGF) by cucurbitacin I. Biochem Pharmacol, 72, 32-41.
Gregory, R. I. and Shiekhattar, R. (2005) MicroRNA biogenesis and cancer. Cancer Res,
65, 3509-3512.
Grimley, P. M., Dong, F. and Rui, H. (1999) Stat5a and Stat5b: fraternal twins of signal
transduction and transcriptional activation. Cytokine Growth Factor Rev, 10, 131157.
Grooteclaes, M., Deveraux, Q., Hildebrand, J., Zhang, Q., Goodman, R. H. and Frisch, S.
M. (2003) C-terminal-binding protein corepresses epithelial and proapoptotic
gene expression programs. Proc Natl Acad Sci U S A, 100, 4568-4573.
Grooteclaes, M. L. and Frisch, S. M. (2000) Evidence for a function of CtBP in epithelial
gene regulation and anoikis. Oncogene, 19, 3823-3828.
Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K. and Hall,
E. D. (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model
of familial amyotrophic lateral sclerosis. Ann Neurol, 39, 147-157.
Gurney, M. E., Fleck, T. J., Himes, C. S. and Hall, E. D. (1998) Riluzole preserves motor
function in a transgenic model of familial amyotrophic lateral sclerosis.
Neurology, 50, 62-66.
Ha, S. and Redmond, L. (2008) ERK mediates activity dependent neuronal complexity
via sustained activity and CREB-mediated signaling. Dev Neurobiol, 68, 15651579.
Hadano, S., Benn, S. C., Kakuta, S. et al. (2006) Mice deficient in the Rab5 guanine
nucleotide exchange factor ALS2/alsin exhibit age-dependent neurological
deficits and altered endosome trafficking. Hum Mol Genet, 15, 233-250.
Hadano, S., Kunita, R., Otomo, A., Suzuki-Utsunomiya, K., Ikeda, J.E. (2007) Molecular
and cellular function of ALS2/alsin: implication of membrane dynamics in
neuronal development and degeneration. Neurochem Int, 51, 74-84.
Hadano, S., Otomo, A., Kunita, R., et al. (2010) Loss of ALS2/alsin exacerbates motor
dysfunction in a SOD1 H46R-expressing ALS mouse model by disturbing
endolysosomal trafficking. PLoS One, 5, e9805.
Hakem, R., Hakem, A., Duncan, G. S. et al. (1998) Differential requirement for caspase 9
in apoptotic pathways in vivo. Cell, 94, 339-352.
Hakoshima, T., Shimizu, T. and Maesaki, R. (2003) Structural basis of the Rho GTPase
signaling. J Biochem, 134, 327-331.
Hall, A. (1998) Rho GTPases and the actin cytoskeleton. Science, 279, 509-514.
Harbison, R. A., Ryan, K. R., Wilkins, H. M., Schroeder, E. K., Loucks, F. A., Bouchard,
R. J. and Linseman, D. A. (2011) Calpain plays a central role in 1-methyl-4215

phenylpyridinium (MPP+)-induced neurotoxicity in cerebellar granule neurons.
Neurotox Res, 19, 374-388.
Harraz, M. M., Marden, J. J., Zhou, W. et al. (2008) SOD1 mutations disrupt redoxsensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin
Invest, 118, 659-670.
Heasman, S. J. and Ridley, A. J. (2008) Mammalian Rho GTPases: new insights into
their functions from in vivo studies. Nat Rev Mol Cell Biol, 9, 690-701.
Hildebrand, J. D. and Soriano, P. (2002) Overlapping and unique roles for C-terminal
binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol Cell Biol,
22, 5296-5307.
Hill, C. S., Wynne, J. and Treisman, R. (1995) The Rho family GTPases RhoA, Rac1,
and CDC42Hs regulate transcriptional activation by SRF. Cell, 81, 1159-1170.
Hing, H., Xiao, J., Harden, N., Lim, L. and Zipursky, S. L. (1999) Pak functions
downstream of Dock to regulate photoreceptor axon guidance in Drosophila. Cell,
97, 853-863.
Hirose, M., Ishizaki, T., Watanabe, N. et al. (1998) Molecular dissection of the Rhoassociated protein kinase (p160ROCK)-regulated neurite remodeling in
neuroblastoma N1E-115 cells. J Cell Biol, 141, 1625-1636.
Houzet, L. and Jeang, K. T. MicroRNAs and human retroviruses. (2011) Biochim
Biophys Acta, 1809, 686-693.
Hu, J. H., Chernoff, K., Pelech, S. and Krieger, C. (2003) Protein kinase and protein
phosphatase expression in the central nervous system of G93A mSOD overexpressing mice. J Neurochem, 85, 422-431.
Igaz, P., Toth, S. and Falus, A. (2001) Biological and clinical significance of the JAKSTAT pathway; lessons from knockout mice. Inflamm Res, 50, 435-441.
Ilieva, H., Polymenidou, M. and Cleveland, D. W. (2009) Non-cell autonomous toxicity
in neurodegenerative disorders: ALS and beyond. J Cell Biol, 187, 761-772.
Jacquier, A., Buhler, E., Schafer, M. K., Bohl, D., Blanchard, S., Beclin, C. and Haase,
G. (2006) Alsin/Rac1 signaling controls survival and growth of spinal
motoneurons. Ann Neurol, 60, 105-117.
Jank, T. and Aktories, K. (2008) Structure and mode of action of clostridial glucosylating
toxins: the ABCD model. Trends Microbiol, 16, 222-229.
Jeon, B. T., Jeong, E. A., Park, S. Y. et al. (2013) The Rho-kinase (ROCK) inhibitor Y27632 protects against excitotoxicity-induced neuronal death in vivo and in vitro.
Neurotox Res, 23, 238-248.
Jin, Z. and Strittmatter, S. M. (1997) Rac1 mediates collapsin-1-induced growth cone
collapse. J Neurosci, 17, 6256-6263.
Johnson, K. and D’Mello, S.R. (2005) p21-activated kinase-1 is necessary for
depolarization-mediated neuronal survival. J Neurosci Res, 79, 809-15.
Just, I., Selzer, J., Hofmann, F., Green, G. A. and Aktories, K. (1996) Inactivation of Ras
by Clostridium sordellii lethal toxin-catalyzed glucosylation. J Biol Chem, 271,
10149-10153.
Just, I., Selzer, J., Wilm, M., von Eichel-Streiber, C., Mann, M. and Aktories, K. (1995)
Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature, 375, 500503.
216

Kaganoi, J., Watanabe, G., Okabe, M., Nagatani, S., Kawabe, A., Shimada, Y., Imamura,
M. and Sakai, Y. (2007) STAT1 activation-induced apoptosis of esophageal
squamous cell carcinoma cells in vivo. Ann Surg Oncol, 14, 1405-1415.
Kanekura, K., Hashimoto, Y., Kita, Y., Sasabe, J., Aiso, S., Nishimoto, I. and Matsuoka,
M. (2005) A Rac1/phosphatidylinositol 3-kinase/Akt3 anti-apoptotic pathway,
triggered by AlsinLF, the product of the ALS2 gene, antagonizes Cu/Znsuperoxide dismutase (SOD1) mutant-induced motoneuronal cell death. J Biol
Chem, 280, 4532-4543.
Katoh, H., Aoki, J., Ichikawa, A. and Negishi, M. (1998a) p160 RhoA-binding kinase
ROKalpha induces neurite retraction. J Biol Chem, 273, 2489-2492.
Katoh, H., Aoki, J., Yamaguchi, Y., Kitano, Y., Ichikawa, A. and Negishi, M. (1998b)
Constitutively active Galpha12, Galpha13, and Galphaq induce Rho-dependent
neurite retraction through different signaling pathways. J Biol Chem, 273, 2870028707.
Kelekar, A., Chang, B. S., Harlan, J. E., Fesik, S. W. and Thompson, C. B. (1997) Bad is
a BH3 domain-containing protein that forms an inactivating dimer with Bcl-XL.
Mol Cell Biol, 17, 7040-7046.
Keller, B. A., Volkening, K., Droppelmann, C. A., Ang, L. C., Rademakers, R. and
Strong, M. J. (2012) Co-aggregation of RNA binding proteins in ALS spinal
motor neurons: evidence of a common pathogenic mechanism. Acta Neuropathol,
124, 733-747.
Kim, A. S., Kakalis, L. T., Abdul-Manan, N., Liu, G. A. and Rosen, M. K. (2000)
Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome
protein. Nature, 404, 151-158.
Kim, H., Rafiuddin-Shah, M., Tu, H. C., Jeffers, J. R., Zambetti, G. P., Hsieh, J. J. and
Cheng, E. H. (2006) Hierarchical regulation of mitochondrion-dependent
apoptosis by BCL-2 subfamilies. Nat Cell Biol, 8, 1348-1358.
Kim, J. H., Cho, E. J., Kim, S. T. and Youn, H. D. (2005) CtBP represses p300-mediated
transcriptional activation by direct association with its bromodomain. Nat Struct
Mol Biol, 12, 423-428.
Kim, W. H., Hong, F., Radaeva, S., Jaruga, B., Fan, S. and Gao, B. (2003) STAT1 plays
an essential role in LPS/D-galactosamine-induced liver apoptosis and injury. Am J
Physiol Gastrointest Liver Physiol, 285, G761-768.
Kimura, K., Ito, M., Amano, M. et al. (1996) Regulation of myosin phosphatase by Rho
and Rho-associated kinase (Rho-kinase). Science, 273, 245-248.
Kitada, S., Krajewska, M., Zhang, X. et al. (1998) Expression and location of proapoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines.
Am J Pathol, 152, 51-61.
Kjoller, L. and Hall, A. (1999) Signaling to Rho GTPases. Exp Cell Res, 253, 166-179.
Kobayashi, K., Takahashi, M., Matsushita, N., Miyazaki, J., Koike, M., Yaginuma, H.,
Osumi, N. and Kaibuchi, K. (2004) Survival of developing motor neurons
mediated by Rho GTPase signaling pathway through Rho-kinase. J Neurosci, 24,
3480-3488.

217

Koipally, J. and Georgopoulos, K. (2000) Ikaros interactions with CtBP reveal a
repression mechanism that is independent of histone deacetylase activity. J Biol
Chem, 275, 19594-19602.
Korsmeyer, S. J., Shutter, J. R., Veis, D. J., Merry, D. E. and Oltvai, Z. N. (1993) Bcl2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin
Cancer Biol, 4, 327-332.
Kovi, R. C., Paliwal, S., Pande, S. and Grossman, S. R. (2010) An ARF/CtBP2 complex
regulates BH3-only gene expression and p53-independent apoptosis. Cell Death
Differ, 17, 513-521.
Kozma, R., Sarner, S., Ahmed, S. and Lim, L. (1997) Rho family GTPases and neuronal
growth cone remodelling: relationship between increased complexity induced by
Cdc42Hs, Rac1, and acetylcholine and collapse induced by RhoA and
lysophosphatidic acid. Mol Cell Biol, 17, 1201-1211.
Kranenburg, O., Poland, M., Gebbink, M., Oomen, L. and Moolenaar, W. H. (1997)
Dissociation of LPA-induced cytoskeletal contraction from stress fiber formation
by differential localization of RhoA. J Cell Sci, 110 ( Pt 19), 2417-2427.
Krebs, D. L. and Hilton, D. J. (2001) SOCS proteins: negative regulators of cytokine
signaling. Stem Cells, 19, 378-387.
Kreis, P., Thevenot, E., Rousseau, V., Boda, B., Muller, D. and Barnier, J. V. (2007) The
p21-activated kinase 3 implicated in mental retardation regulates spine
morphogenesis through a Cdc42-dependent pathway. J Biol Chem, 282, 2149721506.
Kubo, T., Yamashita, T., Yamaguchi, A., Sumimoto, H., Hosokawa, K. and Tohyama, M.
(2002) A novel FERM domain including guanine nucleotide exchange factor is
involved in Rac signaling and regulates neurite remodeling. J Neurosci, 22, 85048513.
Kumar, V., Carlson, J. E., Ohgi, K. A., Edwards, T. A., Rose, D. W., Escalante, C. R.,
Rosenfeld, M. G. and Aggarwal, A. K. (2002) Transcription corepressor CtBP is
an NAD(+)-regulated dehydrogenase. Mol Cell, 10, 857-869.
Kunda, P., Craig, G., Dominguez, V. and Baum, B. (2003) Abi, Sra1, and Kette control
the stability and localization of SCAR/WAVE to regulate the formation of actinbased protrusions. Curr Biol, 13, 1867-1875.
Kuppuswamy, M., Vijayalingam, S., Zhao, L. J., Zhou, Y., Subramanian, T., Ryerse, J.
and Chinnadurai, G. (2008) Role of the PLDLS-binding cleft region of CtBP1 in
recruitment of core and auxiliary components of the corepressor complex. Mol
Cell Biol, 28, 269-281.
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R.
and Newmeyer, D. D. (2005) BH3 domains of BH3-only proteins differentially
regulate Bax-mediated mitochondrial membrane permeabilization both directly
and indirectly. Mol Cell, 17, 525-535.
Lai, E. C. (2002) Micro RNAs are complementary to 3' UTR sequence motifs that
mediate negative post-transcriptional regulation. Nat Genet, 30, 363-364.
Lai, T. W., Zhang, S. and Wang, Y. T. (2014) Excitotoxicity and stroke: Identifying
novel targets for neuroprotection. Prog Neurobiol, 115C, 157-188.
218

Latchoumycandane, C., Anantharam, V., Jin, H. and Kanthasamy, A. (2011)
Dopaminergic neurotoxicant 6-OHDA induces oxidative damage through
proteolytic activation of PKCdelta in cell culture and animal models of
Parkinson's disease. Toxicol Appl Pharmacol, 256, 314-323.
Le, S. S., Loucks, F. A., Udo, H. et al. (2005) Inhibition of Rac GTPase triggers a c-Junand Bim-dependent mitochondrial apoptotic cascade in cerebellar granule
neurons. J Neurochem, 94, 1025-1039.
Lee, J. S., Lee, S. K., Youn, H. D. and Yoo, S. J. (2012) C-terminal binding proteinmediated transcriptional repression is regulated by X-linked inhibitor of apoptosis
protein. Biochem Biophys Res Commun, 417, 175-181.
Lei, M., Lu., W., Meng, W., Parrini, M.C., Eck, M.J., Mayer, B.J., Harrison, S.C. (2000)
Structure of PAK1 in an autoinhibited conformation reveals a multistage
activation switch. Cell, 102, 387-97.
Lennartsson, J., Burovic, F., Witek, B., Jurek, A. and Heldin, C. H. (2010) Erk 5 is
necessary for sustained PDGF-induced Akt phosphorylation and inhibition of
apoptosis. Cell Signal, 22, 955-960.
Li, H., Zhu, H., Xu, C. J. and Yuan, J. (1998) Cleavage of BID by caspase 8 mediates the
mitochondrial damage in the Fas pathway of apoptosis. Cell, 94, 491-501.
Li, M., Linseman, D. A., Allen, M. P., Meintzer, M. K., Wang, X., Laessig, T., Wierman,
M. E. and Heidenreich, K. A. (2001) Myocyte enhancer factor 2A and 2D
undergo phosphorylation and caspase-mediated degradation during apoptosis of
rat cerebellar granule neurons. J Neurosci, 21, 6544-6552.
Li, Q., Spencer, N. Y., Pantazis, N. J. and Engelhardt, J. F. (2011) Alsin and
SOD1(G93A) proteins regulate endosomal reactive oxygen species production by
glial cells and proinflammatory pathways responsible for neurotoxicity. J Biol
Chem, 286, 40151-40162.
Li, X., Saint-Cyr-Proulx, E., Aktories, K. and Lamarche-Vane, N. (2002) Rac1 and
Cdc42 but not RhoA or Rho kinase activities are required for neurite outgrowth
induced by the Netrin-1 receptor DCC (deleted in colorectal cancer) in N1E-115
neuroblastoma cells. J Biol Chem, 277, 15207-15214.
Li, Z., Dong, X., Wang, Z. et al. (2005) Regulation of PTEN by Rho small GTPases. Nat
Cell Biol, 7, 399-404.
Linseman, D. A., Laessig, T., Meintzer, M. K., McClure, M., Barth, H., Aktories, K. and
Heidenreich, K. A. (2001) An essential role for Rac/Cdc42 GTPases in cerebellar
granule neuron survival. J Biol Chem, 276, 39123-39131.
Linseman, D. A. and Loucks, F. A. (2008) Diverse roles of Rho family GTPases in
neuronal development, survival, and death. Front Biosci, 13, 657-676.
Linseman, D. A., Phelps, R. A., Bouchard, R. J., Le, S. S., Laessig, T. A., McClure, M. L.
and Heidenreich, K. A. (2002) Insulin-like growth factor-I blocks Bcl-2
interacting mediator of cell death (Bim) induction and intrinsic death signaling in
cerebellar granule neurons. J Neurosci, 22, 9287-9297.
Loucks, F. A., Le, S. S., Zimmermann, A. K., Ryan, K. R., Barth, H., Aktories, K. and
Linseman, D. A. (2006) Rho family GTPase inhibition reveals opposing effects of
mitogen-activated protein kinase kinase/extracellular signal-regulated kinase and
219

Janus kinase/signal transducer and activator of transcription signaling cascades on
neuronal survival. J Neurochem, 97, 957-967.
Luo, L. (2000) Rho GTPases in neuronal morphogenesis. Nat Rev Neurosci, 1, 173-180.
Machesky, L. M. and Gould, K. L. (1999) The Arp2/3 complex: a multifunctional actin
organizer. Curr Opin Cell Biol, 11, 117-121.
Maekawa, M., Ishizaki, T., Boku, S. et al. (1999) Signaling from Rho to the actin
cytoskeleton through protein kinases ROCK and LIM-kinase. Science, 285, 895898.
Mäkelä, J., Koivuniemi, R., Korhonen, L. and Lindholm, D. (2010) Interferon-gamma
produced by microglia and the neuropeptide PACAP have opposite effects on the
viability of neural progenitor cells. PLoS One, 5, e11091.
Malliri, A., van Es, S., Huveneers, S. and Collard, J. G. (2004) The Rac exchange factor
Tiam1 is required for the establishment and maintenance of cadherin-based
adhesions. J Biol Chem, 279, 30092-30098.
Mani-Telang, P., Sutrias-Grau, M., Williams, G. and Arnosti, D. N. (2007) Role of NAD
binding and catalytic residues in the C-terminal binding protein corepressor.
FEBS Lett, 581, 5241-5246.
Marden, J. J., Harraz, M. M., Williams, A. J., Nelson, K., Luo, M., Paulson, H. and
Engelhardt, J. F. (2007) Redox modifier genes in amyotrophic lateral sclerosis in
mice. J Clin Invest, 117, 2913-2919.
Martin, L. J. (1999) Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible
contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol,
58, 459-471.
Martín, P., Gomez, M., Lamana, A., Cruz-Adalia, A., Ramirez-Huesca, M., Ursa, M. A.,
Yanez-Mo, M. and Sanchez-Madrid, F. (2010) CD69 association with Jak3/Stat5
proteins regulates Th17 cell differentiation. Mol Cell Biol, 30, 4877-4889.
Masliah, E., Mallory, M., Alford, M., Tanaka, S. and Hansen, L. A. (1998) Caspase
dependent DNA fragmentation might be associated with excitotoxicity in
Alzheimer disease. J Neuropathol Exp Neurol, 57, 1041-1052.
Masters, S. C., Yang, H., Datta, S. R., Greenberg, M. E. and Fu, H. (2001) 14-3-3 inhibits
Bad-induced cell death through interaction with serine-136. Mol Pharmacol, 60,
1325-1331.
Meloni, A. R., Smith, E. J. and Nevins, J. R. (1999) A mechanism for Rb/p130-mediated
transcription repression involving recruitment of the CtBP corepressor. Proc Natl
Acad Sci U S A, 96, 9574-9579.
Merrill, J. C., Kagey, M. H., Melhuish, T. A., Powers, S. E., Zerlanko, B. J. and Wotton,
D. (2010) Inhibition of CtBP1 activity by Akt-mediated phosphorylation. J Mol
Biol, 398, 657-671.
Miller, R. G., Mitchell, J. D., Lyon, M. and Moore, D. H. (2007) Riluzole for
amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane
Database Syst Rev, CD001447.
Mohapatra, S., Chu, B., Wei, S., Djeu, J., Epling-Burnette, P. K., Loughran, T., Jove, R.
and Pledger, W. J. (2003) Roscovitine inhibits STAT5 activity and induces
apoptosis in the human leukemia virus type 1-transformed cell line MT-2. Cancer
Res, 63, 8523-8530.
220

Moucadel, V. and Constantinescu, S. N. (2005) Differential STAT5 signaling by liganddependent and constitutively active cytokine receptors. J Biol Chem, 280, 1336413373.
Mu, X., He, J., Anderson, D. W., Trojanowski, J. Q. and Springer, J. E. (1996) Altered
expression of bcl-2 and bax mRNA in amyotrophic lateral sclerosis spinal cord
motor neurons. Ann Neurol, 40, 379-386.
Mueller, B. K., Mack, H. and Teusch, N. (2005) Rho kinase, a promising drug target for
neurological disorders. Nat Rev Drug Discov, 4, 387-398.
Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K. and Narumiya, S. (1996)
ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming
protein serine/threonine kinase in mice. FEBS Lett, 392, 189-193.
Nakamura, K. and Johnson, G. L. (2003) PB1 domains of MEKK2 and MEKK3 interact
with the MEK5 PB1 domain for activation of the ERK5 pathway. J Biol Chem,
278, 36989-36992.
Nelson, E. A., Walker, S. R., Alvarez, J. V. and Frank, D. A. (2004) Isolation of unique
STAT5 targets by chromatin immunoprecipitation-based gene identification. J
Biol Chem, 279, 54724-54730.
Newsome, T. P., Schmidt, S., Dietzl, G., Keleman, K., Asling, B., Debant, A. and
Dickson, B. J. (2000) Trio combines with dock to regulate Pak activity during
photoreceptor axon pathfinding in Drosophila. Cell, 101, 283-294.
Nikolic, M., Chou, M. M., Lu, W., Mayer, B. J. and Tsai, L. H. (1998) The p35/Cdk5
kinase is a neuron-specific Rac effector that inhibits Pak1 activity. Nature, 395,
194-198.
Ohashi, K., Nagata, K., Maekawa, M., Ishizaki, T., Narumiya, S. and Mizuno, K. (2000)
Rho-associated kinase ROCK activates LIM-kinase 1 by phosphorylation at
threonine 508 within the activation loop. J Biol Chem, 275, 3577-3582.
Olson, M. F., Ashworth, A. and Hall, A. (1995) An essential role for Rho, Rac, and
Cdc42 GTPases in cell cycle progression through G1. Science, 269, 1270-1272.
Oma, Y., Nishimori, K. and Harata, M. (2003) The brain-specific actin-related protein
ArpN alpha interacts with the transcriptional co-repressor CtBP. Biochem Biophys
Res Commun, 301, 521-528.
Ona, V. O., Li, M., Vonsattel, J. P. et al. (1999) Inhibition of caspase-1 slows disease
progression in a mouse model of Huntington's disease. Nature, 399, 263-267.
Paliwal, S., Ho, N., Parker, D. and Grossman, S. R. (2012) CtBP2 Promotes Human
Cancer Cell Migration by Transcriptional Activation of Tiam1. Genes Cancer, 3,
481-490.
Paliwal, S., Kovi, R. C., Nath, B., Chen, Y. W., Lewis, B. C. and Grossman, S. R. (2007)
The alternative reading frame tumor suppressor antagonizes hypoxia-induced
cancer cell migration via interaction with the COOH-terminal binding protein
corepressor. Cancer Res, 67, 9322-9329.
Paliwal, S., Pande, S., Kovi, R. C., Sharpless, N. E., Bardeesy, N. and Grossman, S. R.
(2006) Targeting of C-terminal binding protein (CtBP) by ARF results in p53independent apoptosis. Mol Cell Biol, 26, 2360-2372.

221

Pandya, R. S., Zhu, H., Li, W., Bowser, R., Friedlander, R. M. and Wang, X. (2013)
Therapeutic neuroprotective agents for amyotrophic lateral sclerosis. Cell Mol
Life Sci, 70, 4729-4745.
Park, E. M. and Cho, S. (2006) Enhanced ERK dependent CREB activation reduces
apoptosis in staurosporine-treated human neuroblastoma SK-N-BE(2)C cells.
Neurosci Lett, 402, 190-194.
Pesaresi, M. G., Amori, I., Giorgi, C. et al. (2011) Mitochondrial redox signalling by
p66Shc mediates ALS-like disease through Rac1 inactivation. Hum Mol Genet,
20, 4196-4208.
Philippens, I. H., Wubben, J. A., Finsen, B. and Hart, B. A. (2013) Oral treatment with
the NADPH oxidase antagonist apocynin mitigates clinical and pathological
features of parkinsonism in the MPTP marmoset model. J Neuroimmune
Pharmacol, 8, 715-726.
Porter, A. C., Fanger, G. R. and Vaillancourt, R. R. (1999) Signal transduction pathways
regulated by arsenate and arsenite. Oncogene, 18, 7794-7802.
Porter, A. G. and Jänicke, R. U. (1999) Emerging roles of caspase-3 in apoptosis. Cell
Death Differ, 6, 99-104.
Postigo, A. A. and Dean, D. C. (1999) ZEB represses transcription through interaction
with the corepressor CtBP. Proc Natl Acad Sci U S A, 96, 6683-6688.
Quinlan, K. G., Verger, A., Kwok, A., Lee, S. H., Perdomo, J., Nardini, M., Bolognesi,
M. and Crossley, M. (2006) Role of the C-terminal binding protein PXDLS motif
binding cleft in protein interactions and transcriptional repression. Mol Cell Biol,
26, 8202-8213.
Ranganathan, A., Pearson, G. W., Chrestensen, C. A., Sturgill, T. W. and Cobb, M. H.
(2006) The MAP kinase ERK5 binds to and phosphorylates p90 RSK. Arch
Biochem Biophys, 449, 8-16.
Rawlings, J. S., Rosler, K. M. and Harrison, D. A. (2004) The JAK/STAT signaling
pathway. J Cell Sci, 117, 1281-1283.
Rawlings, R. A., Krishnan, V. and Walter, N. G. (2011) Viral RNAi suppressor
reversibly binds siRNA to outcompete Dicer and RISC via multiple turnover. J
Mol Biol, 408, 262-276.
Raz, L., Zhang, Q. G., Zhou, C. F., Han, D., Gulati, P., Yang, L. C., Yang, F., Wang, R.
M. and Brann, D. W. (2010) Role of Rac1 GTPase in NADPH oxidase activation
and cognitive impairment following cerebral ischemia in the rat. PLoS One, 5,
e12606.
Riefler, G. M. and Firestein, B. L. (2001) Binding of neuronal nitric-oxide synthase
(nNOS) to carboxyl-terminal-binding protein (CtBP) changes the localization of
CtBP from the nucleus to the cytosol: a novel function for targeting by the PDZ
domain of nNOS. J Biol Chem, 276, 48262-48268.
Rigacci, S., Talini, D. and Berti, A. (2003) LMW-PTP associates and dephosphorylates
STAT5 interacting with its C-terminal domain. Biochem Biophys Res Commun,
312, 360-366.
Rikitake, Y., Kim, H. H., Huang, Z., Seto, M., Yano, K., Asano, T., Moskowitz, M. A.
and Liao, J. K. (2005) Inhibition of Rho kinase (ROCK) leads to increased
cerebral blood flow and stroke protection. Stroke, 36, 2251-2257.
222

Rocha-Viegas, L., Vicent, G.P., Barañao, J.L., Beato, M., and Pecci, A. (2006)
Glucocorticoids repress bcl-x expression in lymphoid cells by reducing STAT5B
to the P4 promoter. J Biol Chem, 281, 33959-70.
Rodriguez-Perez, A. I., Dominguez-Meijide, A., Lanciego, J. L., Guerra, M. J. and
Labandeira-Garcia, J. L. (2013) Inhibition of Rho kinase mediates the
neuroprotective effects of estrogen in the MPTP model of Parkinson's disease.
Neurobiol Dis, 58, 209-219.
Rosen, R. L., Winestock, K. D., Chen, G., Liu, X., Hennighausen, L. and Finbloom, D. S.
(1996) Granulocyte-macrophage colony-stimulating factor preferentially activates
the 94-kD STAT5A and an 80-kD STAT5A isoform in human peripheral blood
monocytes. Blood, 88, 1206-1214.
Rossman, K. L., Der, C. J. and Sondek, J. (2005) GEF means go: turning on RHO
GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol, 6,
167-180.
Sah, V. P., Seasholtz, T. M., Sagi, S. A. and Brown, J. H. (2000) The role of Rho in G
protein-coupled receptor signal transduction. Annu Rev Pharmacol Toxicol, 40,
459-489.
Sahni, M., Raz, R., Coffin, J. D., Levy, D. and Basilico, C. (2001) STAT1 mediates the
increased apoptosis and reduced chondrocyte proliferation in mice overexpressing
FGF2. Development, 128, 2119-2129.
Saitoh, A., Yamada, M., Kobayashi, S., Hirose, N., Honda, K. and Kamei, J. (2006)
ROCK inhibition produces anxiety-related behaviors in mice.
Psychopharmacology (Berl), 188, 1-11.
Sánchez, I., Xu, C. J., Juo, P., Kakizaka, A., Blenis, J. and Yuan, J. (1999) Caspase-8 is
required for cell death induced by expanded polyglutamine repeats. Neuron, 22,
623-633.
Sanders, L. C., Matsumura, F., Bokoch, G. M. and de Lanerolle, P. (1999) Inhibition of
myosin light chain kinase by p21-activated kinase. Science, 283, 2083-2085.
Sanno, H., Shen, X., Kuru, N. et al. (2010) Control of postnatal apoptosis in the
neocortex by RhoA-subfamily GTPases determines neuronal density. J Neurosci,
30, 4221-4231.
Sass, S., Dietmann, S., Burk, U. C. et al. (2011) MicroRNAs coordinately regulate
protein complexes. BMC Syst Biol, 5, 136.
Satoh, S., Toshima, Y., Ikegaki, I., Iwasaki, M. and Asano, T. (2007) Wide therapeutic
time window for fasudil neuroprotection against ischemia-induced delayed
neuronal death in gerbils. Brain Res, 1128, 175-180.
Sawa, A., Wiegand, G. W., Cooper, J., Margolis, R. L., Sharp, A. H., Lawler, J. F., Jr.,
Greenamyre, J. T., Snyder, S. H. and Ross, C. A. (1999) Increased apoptosis of
Huntington disease lymphoblasts associated with repeat length-dependent
mitochondrial depolarization. Nat Med, 5, 1194-1198.
Schaeper, U., Boyd, J. M., Verma, S., Uhlmann, E., Subramanian, T. and Chinnadurai, G.
(1995) Molecular cloning and characterization of a cellular phosphoprotein that
interacts with a conserved C-terminal domain of adenovirus E1A involved in
negative modulation of oncogenic transformation. Proc Natl Acad Sci U S A, 92,
10467-10471.
223

Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J. L. and Giangrande, A.
(2003) CYFIP/Sra-1 controls neuronal connectivity in Drosophila and links the
Rac1 GTPase pathway to the fragile X protein. Neuron, 38, 887-898.
Schmidt, A. and Hall, A. (2002) Guanine nucleotide exchange factors for Rho GTPases:
turning on the switch. Genes Dev, 16, 1587-1609.
Schmidt, G., Sehr, P., Wilm, M., Selzer, J., Mann, M. and Aktories, K. (1997) Gln 63 of
Rho is deamidated by Escherichia coli cytotoxic necrotizing factor-1. Nature,
387, 725-729.
Schürmann, A., Mooney, A. F., Sanders, L. C., Sells, M. A., Wang, H. G., Reed, J. C.
and Bokoch, G. M. (2000) p21-activated kinase 1 phosphorylates the death
agonist bad and protects cells from apoptosis. Mol Cell Biol, 20, 453-461.
Sebök, A., Nusser, N., Debreceni, B., Guo, Z., Santos, M. F., Szeberenyi, J. and Tigyi, G.
(1999) Different roles for RhoA during neurite initiation, elongation, and
regeneration in PC12 cells. J Neurochem, 73, 949-960.
Semenova, M. M., Maki-Hokkonen, A. M., Cao, J., Komarovski, V., Forsberg, K. M.,
Koistinaho, M., Coffey, E. T. and Courtney, M. J. (2007) Rho mediates calciumdependent activation of p38alpha and subsequent excitotoxic cell death. Nat
Neurosci, 10, 436-443.
Shi, Y., Sawada, J., Sui, G., Affar el, B., Whetstine, J. R., Lan, F., Ogawa, H., Luke, M.
P. and Nakatani, Y. (2003) Coordinated histone modifications mediated by a
CtBP co-repressor complex. Nature, 422, 735-738.
Shibuya, M., Hirai, S., Seto, M., Satoh, S. and Ohtomo, E. (2005) Effects of fasudil in
acute ischemic stroke: results of a prospective placebo-controlled double-blind
trial. J Neurol Sci, 238, 31-39.
Shibuya, M., Suzuki, Y., Sugita, K. et al. (1992) Effect of AT877 on cerebral vasospasm
after aneurysmal subarachnoid hemorrhage. Results of a prospective placebocontrolled double-blind trial. J Neurosurg, 76, 571-577.
Shimizu, Y., Thumkeo, D., Keel, J. et al. (2005) ROCK-I regulates closure of the eyelids
and ventral body wall by inducing assembly of actomyosin bundles. J Cell Biol,
168, 941-953.
Shimokawa, H. (2002) Rho-kinase as a novel therapeutic target in treatment of
cardiovascular diseases. J Cardiovasc Pharmacol, 39, 319-327.
Sironi, J. J. and Ouchi, T. (2004) STAT1-induced apoptosis is mediated by caspases 2, 3,
and 7. J Biol Chem, 279, 4066-4074.
Skaper, S. D., Debetto, P. and Giusti, P. (2010) The P2X7 purinergic receptor: from
physiology to neurological disorders. FASEB J, 24, 337-345.
Song, Y., Chen, X., Wang, L. Y., Gao, W. and Zhu, M. J. (2013) Rho kinase inhibitor
fasudil protects against beta-amyloid-induced hippocampal neurodegeneration in
rats. CNS Neurosci Ther, 19, 603-610.
Soond, S. M., Carroll, C., Townsend, P. A., Sayan, E., Melino, G., Behrmann, I., Knight,
R. A., Latchman, D. S. and Stephanou, A. (2007) STAT1 regulates p73-mediated
Bax gene expression. FEBS Lett, 581, 1217-1226.
Stankiewicz, T. R., Loucks, F. A., Schroeder, E. K., Nevalainen, M. T., Tyler, K. L.,
Aktories, K., Bouchard, R. J. and Linseman, D. A. (2012) Signal transducer and
224

activator of transcription-5 mediates neuronal apoptosis induced by inhibition of
Rac GTPase activity. J Biol Chem, 287, 16835-16848.
Stefanska, J. and Pawliczak, R. (2008) Apocynin: molecular aptitudes. Mediators
Inflamm, 2008, 106507.
Stephanou, A. and Latchman, D. S. (2003) STAT-1: a novel regulator of apoptosis. Int J
Exp Pathol, 84, 239-244.
Stern, M. D., Aihara, H., Roccaro, G. A., Cheung, L., Zhang, H., Negeri, D. and Nibu, Y.
(2009) CtBP is required for proper development of peripheral nervous system in
Drosophila. Mech Dev, 126, 68-79.
Storz, P., Doppler, H., Pfizenmaier, K. and Muller, G. (1999) Insulin selectively activates
STAT5b, but not STAT5a, via a JAK2-independent signalling pathway in Kym-1
rhabdomyosarcoma cells. FEBS Lett, 464, 159-163.
Straza, M. W., Paliwal, S., Kovi, R. C. et al. (2010) Therapeutic targeting of C-terminal
binding protein in human cancer. Cell Cycle, 9, 3740-3750.
Su, J. H., Anderson, A. J., Cummings, B. J. and Cotman, C. W. (1994)
Immunohistochemical evidence for apoptosis in Alzheimer's disease.
Neuroreport, 5, 2529-2533.
Sun, G., Ye, P., Murai, K. et al. (2011) miR-137 forms a regulatory loop with nuclear
receptor TLX and LSD1 in neural stem cells. Nat Commun, 2, 529.
Sun, W., Kesavan, K., Schaefer, B. C., Garrington, T. P., Ware, M., Johnson, N. L.,
Gelfand, E. W. and Johnson, G. L. (2001) MEKK2 associates with the adapter
protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway. J Biol Chem,
276, 5093-5100.
Takagi, Y., Harada, J., Chiarugi, A. and Moskowitz, M. A. (2002) STAT1 is activated in
neurons after ischemia and contributes to ischemic brain injury. J Cereb Blood
Flow Metab, 22, 1311-1318.
Takata, M., Tanaka, H., Kimura, M. et al. (2013) Fasudil, a rho kinase inhibitor, limits
motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J
Pharmacol, 170, 341-351.
Tan, Y., Ruan, H., Demeter, M. R. and Comb, M. J. (1999) p90(RSK) blocks badmediated cell death via a protein kinase C-dependent pathway. J Biol Chem, 274,
34859-34867.
Tanaka, T., Tatsuno, I., Uchida, D. et al. (2000) Geranylgeranyl-pyrophosphate, an
isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured
cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutarylCoA reductase inhibition. J Neurosci, 20, 2852-2859.
Terstegen, L., Gatsios, P., Bode, J. G., Schaper, F., Heinrich, P. C. and Graeve, L. (2000)
The inhibition of interleukin-6-dependent STAT activation by mitogen-activated
protein kinases depends on tyrosine 759 in the cytoplasmic tail of glycoprotein
130. J Biol Chem, 275, 18810-18817.
Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier,
G. G., Salvesen, G. S. and Dixit, V. M. (1995) Yama/CPP32 beta, a mammalian
homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death
substrate poly(ADP-ribose) polymerase. Cell, 81, 801-809.
225

Thomas, L. B., Gates, D. J., Richfield, E. K., O'Brien, T. F., Schweitzer, J. B. and
Steindler, D. A. (1995) DNA end labeling (TUNEL) in Huntington's disease and
other neuropathological conditions. Exp Neurol, 133, 265-272.
Thomas, M., Finnegan, C. E., Rogers, K. M., Purcell, J. W., Trimble, A., Johnston, P. G.
and Boland, M. P. (2004) STAT1: a modulator of chemotherapy-induced
apoptosis. Cancer Res, 64, 8357-8364.
Thumkeo, D., Keel, J., Ishizaki, T., Hirose, M., Nonomura, K., Oshima, H., Oshima, M.,
Taketo, M. M. and Narumiya, S. (2003) Targeted disruption of the mouse rhoassociated kinase 2 gene results in intrauterine growth retardation and fetal death.
Mol Cell Biol, 23, 5043-5055.
Tönges, L., Frank, T., Tatenhorst, L., Saal, K.A., Koch, J.C., Szego, E.M., Bähr, M.,
Weishaupt, J.H., Lingor, P. (2012) Inhibition of Rho kinase enhances survival of
dopaminergic neurons and attenuates axonal loss in a mouse model of parkinson’s
disease. Brain, 135, 3355-70.
Tönges, L., Gunther, R., Suhr, M. et al. (2014) Rho kinase inhibition modulates microglia
activation and improves survival in a model of amyotrophic lateral sclerosis. Glia,
62, 217-232.
Topp, J. D., Gray, N. W., Gerard, R. D. and Horazdovsky, B. F. (2004) Alsin is a Rab5
and Rac1 guanine nucleotide exchange factor. J Biol Chem, 279, 24612-24623.
Trapp, T., Olah, L., Holker, I., Besselmann, M., Tiesler, C., Maeda, K. and Hossmann, K.
A. (2001) GTPase RhoB: an early predictor of neuronal death after transient focal
ischemia in mice. Mol Cell Neurosci, 17, 883-894.
Triboulet, R. and Gregory, R. I. (2010) Autoregulatory mechanisms controlling the
Microprocessor. Adv Exp Med Biol, 700, 56-66.
Troncoso, J. C., Sukhov, R. R., Kawas, C. H. and Koliatsos, V. E. (1996) In situ labeling
of dying cortical neurons in normal aging and in Alzheimer's disease: correlations
with senile plaques and disease progression. J Neuropathol Exp Neurol, 55, 11341142.
Trumbull, K. A., McAllister, D., Gandelman, M. M. et al. (2012) Diapocynin and
apocynin administration fails to significantly extend survival in G93A SOD1 ALS
mice. Neurobiol Dis, 45, 137-144.
Tudor, E. L., Perkinton, M. S., Schmidt, A. et al. (2005) ALS2/Alsin regulates Rac-PAK
signaling and neurite outgrowth. J Biol Chem, 280, 34735-34740.
Turner, J. and Crossley, M. (1998) Cloning and characterization of mCtBP2, a corepressor that associates with basic Kruppel-like factor and other mammalian
transcriptional regulators. EMBO J, 17, 5129-5140.
Um, M. and Lodish, H. F. (2006) Antiapoptotic effects of erythropoietin in differentiated
neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT
signaling pathways. J Biol Chem, 281, 5648-5656.
Valdmanis, P. N., Kabashi, E., Dion, P. A. and Rouleau, G. A. (2008) ALS predisposition
modifiers: knock NOX, who's there? SOD1 mice still are. Eur J Hum Genet, 16,
140-142.
Van den Worm, E., Beukelman, C. J., Van den Berg, A. J., Kroes, B. H., Labadie, R. P.
and Van Dijk, H. (2001) Effects of methoxylation of apocynin and analogs on the
226

inhibition of reactive oxygen species production by stimulated human neutrophils.
Eur J Pharmacol, 433, 225-230.
Van Hateren, N., Shenton, T. and Borycki, A. G. (2006) Expression of avian C-terminal
binding proteins (Ctbp1 and Ctbp2) during embryonic development. Dev Dyn,
235, 490-495.
Västrik, I., Eickholt, B.J., Walsh, F.S., Ridley, A., and Doherty, P. (1999) Sema3Ainduced growth-cone collapse is mediated by Rac1 amino acids 17-32. Curr Biol.
23, 991-8.
Vaudry, D., Falluel-Morel, A., Basille, M., Pamantung, T. F., Fontaine, M., Fournier, A.,
Vaudry, H. and Gonzalez, B. J. (2003) Pituitary adenylate cyclase-activating
polypeptide prevents C2-ceramide-induced apoptosis of cerebellar granule cells. J
Neurosci Res, 72, 303-316.
Verger, A., Quinlan, K. G., Crofts, L. A., Spano, S., Corda, D., Kable, E. P., Braet, F. and
Crossley, M. (2006) Mechanisms directing the nuclear localization of the CtBP
family proteins. Mol Cell Biol, 26, 4882-4894.
Vicari, R. M., Chaitman, B., Keefe, D. et al. (2005) Efficacy and safety of fasudil in
patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am
Coll Cardiol, 46, 1803-1811.
Wahl, S., Barth, H., Ciossek, T., Aktories, K. and Mueller, B. K. (2000) Ephrin-A5
induces collapse of growth cones by activating Rho and Rho kinase. J Cell Biol,
149, 263-270.
Wakil, S. M., Ramzan, K., Abuthuraya, R. et al. (2014) Infantile-onset ascending
hereditary spastic paraplegia with bulbar involvement due to the novel ALS2
mutation c.2761C>T. Gene, 536, 217-220.
Walker, G. J., Indsto, J. O., Sood, R. et al. (2004) Deletion mapping suggests that the
1p22 melanoma susceptibility gene is a tumor suppressor localized to a 9-Mb
interval. Genes Chromosomes Cancer, 41, 56-64.
Wan, J., Fu, A. K., Ip, F. C. et al. (2010) Tyk2/STAT3 signaling mediates beta-amyloidinduced neuronal cell death: implications in Alzheimer's disease. J Neurosci, 30,
6873-6881.
Wang, D., Stravopodis, D., Teglund, S., Kitazawa, J. and Ihle, J. N. (1996) Naturally
occurring dominant negative variants of Stat5. Mol Cell Biol, 16, 6141-6148.
Wang, S. Y., Iordanov, M. and Zhang, Q. (2006) c-Jun NH2-terminal kinase promotes
apoptosis by down-regulating the transcriptional co-repressor CtBP. J Biol Chem,
281, 34810-34815.
Wang, Y., Medvid, R., Melton, C., Jaenisch, R. and Blelloch, R. (2007) DGCR8 is
essential for microRNA biogenesis and silencing of embryonic stem cell selfrenewal. Nat Genet, 39, 380-385.
Watanabe, T., Hosoya, H. and Yonemura, S. (2007) Regulation of myosin II dynamics by
phosphorylation and dephosphorylation of its light chain in epithelial cells. Mol
Biol Cell, 18, 605-616.
Watson, C. J. and Miller, W. R. (1995) Elevated levels of members of the STAT family
of transcription factors in breast carcinoma nuclear extracts. Br J Cancer, 71, 840844.
227

Watson, F. L., Heerssen, H. M., Bhattacharyya, A., Klesse, L., Lin, M. Z. and Segal, R.
A. (2001) Neurotrophins use the Erk5 pathway to mediate a retrograde survival
response. Nat Neurosci, 4, 981-988.
Webb, S. J., Nicholson, D., Bubb, V. J. and Wyllie, A. H. (1999) Caspase-mediated
cleavage of APC results in an amino-terminal fragment with an intact armadillo
repeat domain. FASEB J, 13, 339-346.
Wells, C. M. and Jones, G. E. (2010) The emerging importance of group II PAKs.
Biochem J, 425, 465-473.
Wichterle, H., Lieberam, I., Porter, J. A. and Jessell, T. M. (2002) Directed
differentiation of embryonic stem cells into motor neurons. Cell, 110, 385-397.
Wichterle, H. and Peljto, M. (2008) Differentiation of mouse embryonic stem cells to
spinal motor neurons. Curr Protoc Stem Cell Biol, Chapter 1, Unit 1H 1 1-1H 1
9.
Wildenberg, G. A., Dohn, M. R., Carnahan, R. H., Davis, M. A., Lobdell, N. A.,
Settleman, J. and Reynolds, A. B. (2006) p120-catenin and p190RhoGAP regulate
cell-cell adhesion by coordinating antagonism between Rac and Rho. Cell, 127,
1027-1039.
Wilkins, H.M., Bouchard, R.J., Lorenzon, N.M., and Linseman, D.A. (2011) Poor
correlation between drug efficacies in the mutant SOD1 mouse versus clinical
trials of ALS necessitates the development of novel animal models for sporadic
motor neuron disease. Nova Science Publishers, 5, 1-40.
Wu, D. C., Re, D. B., Nagai, M., Ischiropoulos, H. and Przedborski, S. (2006) The
inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in
amyotrophic lateral sclerosis mice. Proc Natl Acad Sci U S A, 103, 12132-12137.
Wu, J., Li, J., Hu, H., Liu, P., Fang, Y. and Wu, D. (2012) Rho-kinase inhibitor, fasudil,
prevents neuronal apoptosis via the Akt activation and PTEN inactivation in the
ischemic penumbra of rat brain. Cell Mol Neurobiol, 32, 1187-1197.
Xie, Z., Chen, Y., Li, Z. et al. (2011) Smad6 promotes neuronal differentiation in the
intermediate zone of the dorsal neural tube by inhibition of the Wnt/beta-catenin
pathway. Proc Natl Acad Sci U S A, 108, 12119-12124.
Xu, J., Chen, S., Chen, H., Xiao, Q., Hsu, C. Y., Michael, D. and Bao, J. (2009) STAT5
mediates antiapoptotic effects of methylprednisolone on oligodendrocytes. J
Neurosci, 29, 2022-2026.
Yamaguchi, Y., Katoh, H., Yasui, H., Mori, K. and Negishi, M. (2001) RhoA inhibits the
nerve growth factor-induced Rac1 activation through Rho-associated kinasedependent pathway. J Biol Chem, 276, 18977-18983.
Yamanaka, K., Miller, T. M., McAlonis-Downes, M., Chun, S. J. and Cleveland, D. W.
(2006) Progressive spinal axonal degeneration and slowness in ALS2-deficient
mice. Ann Neurol, 60, 95-104.
Yamanaka, K., Vande Velde, C., Eymard-Pierre, E., Bertini, E., Boespflug-Tanguy, O.
and Cleveland, D. W. (2003) Unstable mutants in the peripheral endosomal
membrane component ALS2 cause early-onset motor neuron disease. Proc Natl
Acad Sci USA, 100, 16041-16046.

228

Yamauchi-Takihara, K. and Kishimoto, T. (2000) Cytokines and their receptors in
cardiovascular diseases--role of gp130 signalling pathway in cardiac myocyte
growth and maintenance. Int J Exp Pathol, 81, 1-16.
Yang, N., Higuchi, O., Ohashi, K., Nagata, K., Wada, A., Kangawa, K., Nishida, E. and
Mizuno, K. (1998) Cofilin phosphorylation by LIM-kinase 1 and its role in Racmediated actin reorganization. Nature, 393, 809-812.
Yang, Y., Hentati, A., Deng, H. X. et al. (2001) The gene encoding alsin, a protein with
three guanine-nucleotide exchange factor domains, is mutated in a form of
recessive amyotrophic lateral sclerosis. Nat Genet, 29, 160-165.
Yin, X. M. (2006) Bid, a BH3-only multi-functional molecule, is at the cross road of life
and death. Gene, 369, 7-19.
Youle, R. J. and Strasser, A. (2008) The BCL-2 protein family: opposing activities that
mediate cell death. Nat Rev Mol Cell Biol, 9, 47-59.
Zaidi, N. F., Kuplast, K. G., Washicosky, K. J., Kajiwara, Y., Buxbaum, J. D. and Wasco,
W. (2006) Calsenilin interacts with transcriptional co-repressor C-terminal
binding protein(s). J Neurochem, 98, 1290-1301.
Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S. J. (1996) Serine
phosphorylation of death agonist BAD in response to survival factor results in
binding to 14-3-3 not BCL-X(L). Cell, 87, 619-628.
Zhang, J., Yamada, O., Kawagishi, K., Araki, H., Yamaoka, S., Hattori, T. and
Shimotohno, K. (2008) Human T-cell leukemia virus type 1 Tax modulates
interferon-alpha signal transduction through competitive usage of the coactivator
CBP/p300. Virology, 379, 306-313.
Zhang, Q., Nottke, A., and Goodman, R.H. (2005) Homeodomain-interacting protein
kinase-2 mediates CtBP phosphorylation and degradation in UV-triggered
apoptosis. Proc Natl Acad Sci USA, 102, 2802-7.
Zhang, Q., Piston, D. W. and Goodman, R. H. (2002) Regulation of corepressor function
by nuclear NADH. Science, 295, 1895-1897.
Zhang, Q., Yoshimatsu, Y., Hildebrand, J., Frisch, S. M. and Goodman, R. H. (2003)
Homeodomain interacting protein kinase 2 promotes apoptosis by downregulating
the transcriptional corepressor CtBP. Cell, 115, 177-186.
Zhang, Y., Zhang, H., Yuan, X. and Gu, X. (2007) Differential effects of phenylalanine
on Rac1, Cdc42, and RhoA expression and activity in cultured cortical neurons.
Pediatr Res, 62, 8-13.
Zhang, Y., Zhao, J., Wang, J. and Jiao, X. (2010) Brain-derived neurotrophic factor
inhibits phenylalanine-induced neuronal apoptosis by preventing RhoA pathway
activation. Neurochem Res, 35, 480-486.
Zhao, J., Zhou, D., Guo, J. et al. (2011) Efficacy and safety of fasudil in patients with
subarachnoid hemorrhage: final results of a randomized trial of fasudil versus
nimodipine. Neurol Med Chir (Tokyo), 51, 679-683.
Zheng, Y. (2001) Dbl family guanine nucleotide exchange factors. Trends Biochem Sci,
26, 724-32.
Zhou, G., Bao, Z. Q. and Dixon, J. E. (1995) Components of a new human protein kinase
signal transduction pathway. J Biol Chem, 270, 12665-12669.
229

Zhou, W., Hurlbert, M. S., Schaack, J., Prasad, K. N. and Freed, C. R. (2000)
Overexpression of human alpha-synuclein causes dopamine neuron death in rat
primary culture and immortalized mesencephalon-derived cells. Brain Res, 866,
33-43.
Zhu, M., John, S., Berg, M. and Leonard, W. J. (1999) Functional association of Nmi
with Stat5 and Stat1 in IL-2- and IFNgamma-mediated signaling. Cell, 96, 121130.
Zou, H., Li, Y., Liu, X. and Wang, X. (1999) An APAF-1.cytochrome c multimeric
complex is a functional apoptosome that activates procaspase-9. J Biol Chem,
274, 11549-11556.

230

APPENDIX A: ABBREVIATIONS
5K, 5K- apoptotic medium
6-OHDA, 6-hydroxydopamine
AD, actinomycin D
AD, Alzheimer’s disease
Ad; adenoviral
Ad-CA, adenoviral constitutively active
Ad-DN, adenoviral domiant negative
Ad-GFP, adenoviral green fluorescent protein
Ad-WT, adenoviral wild type
ALS, amyotrophic lateral sclerosis
ALS2, alsin
Anti, morpholino-antisense oligonucleotides
APAF-1, apoptotic protease-activating factor-1
Arp2/3, actin related protein 2/3
Bcl-2, B-cell lymphoma-2
Bcl-3, B-cell lymphoma-3
BDNF, brain-derived neurotrophic factor
BH3, Bcl-2 homology-3 domain
BKLF, basic krüppel-like factor
BKLF8, basic kruppel-like factor 8
BSA, bovine serum albumin
CBP, CREB binding protein
CCD, charge-coupled device
CD11b, cluster of differentiation 11b
CDK, cyclin-dependent kinase
CGN, cerebellar granule neuron
ChAT, choline acetyltransferase
ChIP, chromatin immunoprecipitation
CNTF, ciliary neurotrophic factor
Con, control
CREB, cAMP response-element binding protein
CRIB, Cdc42/Rac-interactive binding
Ct, cycle threshold
CtBP, C-terminal binding protein
CytC, cytochrome C
Cyto, cytosolic
DAPI, 4,6-diamidino-2-phenylindole
dCtBP, drosophila CtBP
DGCR8, DiGeorge critical region 8
DH, Dbl homology
Dia, Diaphanous formin
DISC, death-inducing signaling complex
DMEM, Dulbecco’s modified Eagle’s medium
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DN, dominant negative
DRG, dorsal root ganglion
EB, embryoid bodies
eGFP, enhanced GFP
EP, endoporter
ERK, extracellular signal-regulated kinase
ESC, embryonic stem cell
FADD, Fas-associated death domain
FBS, fetal bovine serum
GAP, GTPase activating protein
GDI, guanine dissociation inhibitor
GDNF, glial cell line-derived neurotrophic factor
GDP, guanine diphosphate
GEF, guanine nucleotide exchange factor
GITz-short G protein-coupled receptor kinase-interacting protein-z-short
GM-CSF, granulocyte-macrophage colony-stimulating factor
GR, glucocorticoid receptor
GTP, guanine triphosphate
HD, Huntington’s disease
HDAC, histone deactylases
IB, immunoblot
Inh Pep, inhibitory peptide
Inv, inverse
IP, immunoprecipitate
JAK, Janus kinase
JAK3 Inh, JAK3 Inhibitor
JNK Inh, SP60012
JNK, c- Jun N-terminal kinase
JSI, JSI-124
KO, knockout
LPA, lysophosphatidic acid
LTox, lethal toxin
MAPK, mitogen activated protein kinase
MEFs, murine embryonic fibroblasts
MEK, mitogen activated protein kinase kinase
MEKK , mitogen activated protein kinase kinase kinase
mESCs, mouse embryonic stem cells
miRNA, micro RNA
MLC, myosin II regulatory chain
MLCK, myosin light chain kinase
MLCPPase, myosin light chain phosphatase
MPP+, methyl-4-phenylpyridinium
mSOD1, mutant superoxide dismutase 1
MTOB, 4-methylthio-2-oxobutyric
NADH, nicotinamide adenine dinucleotide
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NGF, nerve growth factor
NMJ, neuromuscular junction
NS, not significant
NSC, NCS23766
NT-3, neurotrophic-3
NWASP, neuronal Wiskott-Aldrich-syndrome protein
O.D., optical density
PaGE, paw grip endurance
PAK, p21-activated kinase
pAkt, phosphorylated Akt
pan-JI, pan-JAK inhibitor
PARP, poly-(ADP-ribose) polymerase
pBAD, phosphorylated Bad
PBS, phosphate-buffered saline
PBS-T, PBS containing 0.1% Tween 20
PCR, polymerase chain reaction
pERK, phosphorylated ERK
PH, Pleckstrin homology
PI3K, phosphatidylinositol 3-kinase
pMEK, phosphorylated MEK
pP90rsk, phosphorylated p90rsk
pPAK, phosphorylated PAK
pri-miRNA, primary miRNA
pSTAT, phosphorylated STAT
PTEN, phosphatase and tension homolog
Purv, purvalanol A
PVDF, polyvinylidene difluoride
rCasp3, recombinant caspase-3
RGNEF, Rho guanine nucleotide exchange factor
ROCK, Rho kinase
ROS, reactive oxygen species
Rosc, roscovitine
RSS, RNA silencing suppressor
Rux, ruxolitinib
SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis
SHH, sonic hedgehog
SNP, sodium nitroprusside
SOCS, suppressors of cytokine signaling
SOD1, superoxide dismutase 1
STAT, signal transducer and activator of transcription
STS, staurosporine
tBid, truncated Bid
Tof, tofacitinib
ToxB, C. difficile toxin B
TUNEL, Tdt-mediated dUTP–biotin nick end labeling
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VAChT, vesicular acetylcholine transporter
WASP, Wiskott-Aldrich-syndrome protein
WCL, whole cell lysate
WT, wild type
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